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Abstract
The placenta is the interface between the mother and the fetus fulfilling
important roles such as nutrient transfer, hormone production and barrier func-
tions. Pathological conditions associated with maternal stress during pregnancy
can cause placental adaptations which possibly affect fetal health and might lead
to long-term effects in later life. The placenta contains an autonomous endocrine
system which consists of hormones such as corticotropin-releasing hormone (CRH)
and cortisol (the human glucocorticoid) controlling stress responses. Exposure of
the fetus and placenta to glucocorticoids (GCs) is finetuned by CRH. The presence
of a GC barrier also modulates GC availability. The main component of this GC
barrier is the enzyme 11β-HSD2 which catalyzes active cortisol into cortisone. Ex-
pression of this enzyme is decreased in placental diseases such as pre-eclampsia and
intrauterine growth restriction (IUGR). This might be associated with elevated lev-
els of trophoblast apoptosis and disturbances of trophoblast differentiation found in
pregnancy-related disorders. Very little is known about the specific role of this en-
zyme and related pathways in placental apoptosis, differentiation, endocrine capacity
and the expression of molecules involved in the stress response and glucocorticoid
action. These potential effects were investigated in this thesis by using the placental
explant culture and the choriocarcinoma BeWo cellular model. Furthermore, the
capacity of GCs to regulate transcriptional events in BeWo cells was explored.
My results show that CRH treatment and activation of TLR4 have modulating ef-
fects on placental hCG production in placental explants. Moreover, the enzyme
11β-HSD2 seems to be involved in the homeostasis of placental differentiation and
apoptotic processes, the maintenance of hCG and progesterone secretion and it
might limit overactivation of CRH receptors and CRH secretion. GC insensitivity
was identified in the BeWo cells and it appears that in these cells the cAMP pathway
is the predominant pathway in regulating GC-responsive genes. Through a series of
reporter-gene-assays my results suggest that transfection of exogenous GRα restores
the BeWo cell sensitivity to GCs without affecting BeWo cell turnover and hormone
secretion.
In conclusion, placental CRH and 11β-HSD2 expression appear to play an important
role in the maintenance of placental endocrine function. GCs on the other hand did
not have strong regulatory effects in the BeWo cells suggesting a unique mechanism
through which trophoblast cells become insensitive to local glucocorticoid action.
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Chapter 1
Introduction
1.1 Stress Response: CRH and Glucocorticoid Metabo-
lism and 11β-HSD2
Stress during pregnancy is now considered to play a major role in fetal health and
pregnancy outcomes. To investigate the effects of stress on tissues including the pla-
centa, the hormonal mediators of stress responses corticotropin-releasing hormone
(CRH) and cortisol (the human glucocorticoid) are of fundamental importance. This
chapter focuses on the physiological roles of these two hormones and also on the en-
zyme 11β-HSD2 which is a modulator of the cellular glucocorticoid availability and
which is highly expressed in the placenta.
1.1.1 HPA Axis
To maintain a homeostatic state and to be able to respond appropriately to physical,
emotional and immunological stressors, organisms have developed special endocrine
systems. The hypothalamic-pituitary-adrenal (HPA) axis regulates these responses
(Figure 1.1). The key regulator molecules of the HPA axis are corticotropin-releasing
hormone (CRH) and arginine-vasopressin (AVP) which are synthesized by neurons
located in the paraventricular nuclei of the hypothalamus [Swanson et al., 1983].
After reaching the anterior pituitary gland, CRH and AVP bind synergistically to
their receptors in the corticotroph cells which stimulates synthesis and secretion
of adrenocorticotropic hormone (ACTH) into the bloodstream [Orth et al., 1983;
Watanabe and Orth, 1987; Pecori Giraldi and Cavagnini, 1998]. In the zona fasci-
culata of the adrenal gland, ACTH triggers the synthesis and systemic secretion of
glucocorticoids which exert pleiotropic effects in many target tissues due to the ubiq-
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uitous expression of the glucocorticoid receptor (GR) [Kemppainen and Behrend,
1997]. The glucocorticoids act in a negative feedback loop on the level of the hip-
pocampus, hypothalamus and the pituitary inhibiting CRH and ACTH production
[Jacobson and Sapolsky, 1991; Mahmoud and Jones, 1977; Jones et al., 1977]. This
mechanism ensures a tight control and prevents a prolonged hyperactivation of the
HPA-axis.
Figure 1.1: Diagram of the HPA axis. Stressful stimuli trigger expression of
CRH and AVP in the hypothalamus. These two hormones provoke synthesis of
ACTH in the pituitary gland. ACTH then leads to glucocorticoid secretion in the
adrenal cortex. Glucocortiocoids exert various effects in target tissue and a negative
feedback effect on the hippocampus, hypothalamus and pituitary. Adapted from
Boonstra [2004].
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1.1.2 Corticotropin-Releasing Hormone (CRH)
In 1981, the 41 amino acid peptide CRH was isolated by Vale et al. [1981]. CRH
belongs to a family of related peptides, which also includes the mammalian pep-
tides Urocortin I (Ucn I), Ucn II and Ucn III, fish urotensin and frog sauvagine
[Vaughan et al., 1995; Reyes et al., 2001; Lewis et al., 2001; Lederis et al., 1982;
Montecucchi et al., 1980]. CRH is the main regulator of the stress response. In ad-
dition to the hypothalamus, CRH is also produced by various tissues including the
placenta. At inflammatory sites, CRH seems to be an important regulator [Scopa
et al., 1994; Mastorakos et al., 1995] and also in the reproductive tissues, CRH is
involved in inflammatory-like phenomena such as blastocyst implantation and early
immune tolerance [Makrigiannakis et al., 2001, 2004]. In case of hypersecretion,
CRH seems to be implicated in various diseases such as anxiety disorders, depres-
sion and metabolic syndrome [Holsboer, 1999]. A circulating binding protein, called
CRH-binding protein (CRH-BP), is produced by the liver and placenta and it can
inactivate CRH [Linton et al., 1988; Potter et al., 1991; Sehringer et al., 2004]. This
subchapter introduces the CRH modes of action and the regulatory effects of CRH
with a special focus on reproductive roles.
1.1.2.1 CRH Receptors and Signalling
CRH can bind to two CRH receptors, namely CRH-R1 and CRH-R2. These re-
ceptors belong to the family of seven transmembrane domain (7TMD) G-protein
coupled receptors (GPCR) [Chang et al., 1993] and they are encoded by two dif-
ferent genes located on chromosome 17 and 7, respectively [Vamvakopoulos and
Sioutopoulou, 1994; Meyer et al., 1997]. The homology between CRH-R1 and CRH-
R2 is 71% on amino acid level [Lovenberg et al., 1995]. Because of alternative
splicing, several receptor subtypes for both CRH receptors are expressed in various
tissues, namely CRH-R1α, -R1β, -R1c, -R1d, -R1e, -R1f, -R1g, -R1h, and CRH-
R2α, -R2β, -R2γ [Chen et al., 1993; Ross et al., 1994; Grammatopoulos et al., 1999;
Pisarchik and Slominski, 2001; Liaw et al., 1996; Valdenaire et al., 1997; Kostich
et al., 1998]. The N-terminus of the CRH receptors is involved in ligand binding
and selectivity [Perrin et al., 1998; Wille et al., 1999]. The peptides CRH, Ucn I,
urotension I and sauvagine bind to the CRH-R1 with equal affinity and the peptides
Ucn I, Ucn II, Ucn III, urotensin I and sauvagine bind to the CRH-R2 with a higher
affinity than CRH binds to this receptor [Grammatopoulos and Chrousos, 2002].
The CRH receptors preferentially couple to the Gs-adenylyl cyclase signalling
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pathway, but also exhibit alternative coupling to and activation of other G-proteins
such as Gi, Go, Gq, and Gz exists (Figure 1.2) [Chen et al., 1986; Grammatopoulos
et al., 2001]. Further downstream signalling molecules include the protein kinases
A (PKA), PKC, MAP kinases p38 and ERK1/2 and also signalling molecules such
as Ca2+ and nitric oxide synthase (NOS) [Ulisse et al., 1990; Brar et al., 2004;
Kiang, 1997; Cantarella et al., 2001]. The variety of CRH receptor splice variants
and possible signalling pathways allow CRH to evoke different responses in a tissue-
dependent manner. Interestingly, in the placenta no coupling of the CRH receptors
to the Gs protein is observed, even though Gs protein is expressed [Karteris et al.,
2000]. Instead, coupling of CRH receptors to Gq, Go, and Gz takes place in the
placenta [Karteris et al., 2000].
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Figure 1.2: Signalling of the CRH receptor. A variety of signalling pathways can
be activated upon CRH binding to its receptor in a tissue-dependent manner. AC
= adenylyl cyclase, GC = guanylyl cyclase, GDP = guanosine diphosphate, GTP
= guanosine triphosphate, MAPK = MAP kinase, NOS = nitric oxide synthase,
PKA = protein kinase A, PKC = protein kinase C, PLC = phospholipase C, sGC
= soluble GC. Adapted from Grammatopoulos and Chrousos [2002].
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1.1.2.2 CRH in Reproductive Tissues
Grino et al. [1987] showed that CRH is expressed by the human placenta and Jones
et al. [1989] further demonstrated that CRH is also expressed in amnion, chorion
and decidua. The placental localization of CRH was investigated by Riley et al.
[1991] who showed a CRH-immunoreactivity in the syncytiotrophoblast, but not in
cytotrophoblasts.
The placental CRH, which is identical with the hypothalamic CRH, is located
on chromosome 8 [Arbiser et al., 1988]. Interestingly, CRH expression exponentially
rises during pregnancy only in humans and higher primates such as rhesus monkeys
and gorillas [Robinson et al., 1989] suggesting a distinct and specific regulation of
pregnancy of these species by CRH. In contrast to hypothalamic CRH, the pla-
cental CRH production is not suppressed by glucocorticoids, in fact glucocorticoids
increase expression and secretion of placental CRH [Robinson et al., 1988]. That
suggests presence of a positive feedback loop between CRH and glucocorticoids in
the placenta. In addition to the glucocorticoid regulation of CRH secretion, cAMP
stimulators have been shown to increase CRH expression in primary trophoblast
cells [Cheng et al., 2000].
The concentration of CRH rises towards the end of pregnancy [Frim et al.,
1988]. Furthermore, the concentration of CRH-BP falls within the third trimester
of pregnancy which leads to higher concentrations of active CRH towards the end
of pregnancy [Linton et al., 1993]. In pregnancy-related disorders such as pre-
eclampsia, intrauterine growth restriction (IUGR), and pre-term labour, CRH levels
rise higher than during normal pregnancies [Laatikainen et al., 1991; Goland et al.,
1993; Warren et al., 1992].
Placental CRH appears to play several roles during pregnancy. By activating
nitric oxide synthase CRH leads to vasodilatation of uterine and placental vessels
which is important for maintaining the vascular tone in the feto-placental circulation
[Clifton et al., 1995]. Placental CRH plays a role in parturition as it stimulates the
secretion of prostaglandin F2α and E2 and modulates prostaglandin F2α activity
which leads to contraction of myometrial cells [Jones and Challis, 1989; Benedetto
et al., 1994]. Furthermore, placental CRH regulates parturition by increasing matrix
metalloproteinase-9 (MMP-9) activity which contributes to membrane rupture [Li
and Challis, 2005].
In the fetal adrenal zone of the adrenal gland, placental CRH leads to the pro-
duction of dehydroepiandrosterone and its sulfate (DHEA/DHEAS) [Smith et al.,
1998a]. The human fetal adrenal (HFA) and the placenta form the so-called feto-
placental unit. The DHEA/DHEAS produced by the HFA are supplied to the
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placenta as precursor molecules to promote the production of estrogens [Siiteri and
MacDonald, 1966; Sirianni et al., 2005a]. Moreover, CRH also induces cortisol pro-
duction in the fetal adrenal cells which then contributes to maturation of fetal organs
[Sirianni et al., 2005b].
McLean et al. [1995] suggested the concept that CRH acts as a placental
clock. They discovered that CRH concentration were higher in women delivering
pre-term and lower in women delivering post-term compared to normal pregnancies.
CRH is further expressed in endometrial cells and ovaries. In the endome-
trium, epithelial cells and decidualized stromal cells express CRH which plays an
important role in the implantation process [Makrigiannakis et al., 1995; Mastorakos
et al., 1996]. Ferrari et al. [1995] showed that CRH leads to the decidualization
of stromal cells which is a prerequisite for a successful implantation of the blasto-
cyste. The effect of progesterone, main inducer of decidualization, is modulated by
interleukin-1 and -6 (IL-1, IL-6) which in turn are shown to be influenced by CRH
[Zoumakis et al., 2000]. In this way, CRH may fine-tune the decidualization process.
During the early stages of the implantation of the blastocyst, a maternal im-
munological tolerance is established. CRH plays a role in this process by increasing
apoptosis of activated T lymphocytes [Makrigiannakis et al., 2001].
During the invasion of the extravillous trophoblast cells, CRH controls this in-
vasion by downregulating the carcinoembryonic antigen-related cell adhesion molecule
1 (CEACAM1) expression [Bamberger et al., 2006].
In the ovaries, CRH is expressed in the thecal cells surounding the ovarian
follicles and in luteinized cells of the stroma [Mastorakos et al., 1994]. More CRH
is detected in thecal cells of mature follicles than in small follicles which might
implicate a role of CRH in the follicular maturation [Asakura et al., 1997]. Regard-
ing steroidogenesis, CRH inhibits estradiol and progesterone production by human
granulosa cells [Ghizzoni et al., 1997].
1.1.3 Regulators of Glucocorticoid Action
1.1.3.1 Glucocorticoid Receptor
The ubiquitously expressed glucocorticoid receptor (GR) belongs to the steroid/thy-
roid/retinoic acid nuclear receptor family of ligand-dependent transcription factors.
The human (h) GR gene NR3C1 (nuclear receptor subfamily 3, group C, member
1) is located on chromosome 5, has nine exons and several mRNA isoforms are
transcribed because of alternative splicing [Enc´ıo and Detera-Wadleigh, 1991]. The
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hGR was first cloned by Hollenberg et al. [1985] identifying two homologous protein
isoforms, GRα and GRβ, which only differ in their exon 9 (Figure 1.3). In addition,
multiple other isoforms of GRα exist due to alternative translation initiation sites
[Lu and Cidlowski, 2005]. The protein structure of the two GR isoforms GRα and
GRβ consists of an N-terminal domain (NTD), a DNA-binding domain (DBD), a
hinge region, and a ligand-binding domain (LBD) [Gigue`re et al., 1986] (Figure 1.3).
The transactivation domain AF-1 is located in the NTD functioning in a hormone-
independent way, the DBD binds to DNA via zinc-finger motifs and is involved in
the dimerization of two GRα molecules, and the LBD binds the ligands and contains
a second transactivation domain, AF-2, which is hormone-dependent [Luisi et al.,
1991; Hollenberg and Evans, 1988]. The GRα form is the isoform which acts as
the ligand-activated transcription factor, whereas the GRβ isoform does not bind
agonists and can inhibit the transcriptional action of GRα [Bamberger et al., 1995].
Figure 1.3: Diagram of GR domains. The GRα and GRβ isoforms are produced
by alternative splicing of exon 9. The protein structure is divided into the NTD,
DBD, hinge region and LBD which are involved in different functions such as bind-
ing to heat shock proteins, transactivation of the GR, receptor dimerization, DNA
binding at glucocorticoid-response elements, and interaction with other transcrip-
tion factors. Post-translational modification sites of the GR are labelled with P,
SUMO and U. DBD = DNA-binding domain, HSP = heat shock protein, LBD =
ligand-binding domain, NTD = N-terminal domain, P = phosphorylation, SUMO
= sumoylation, U = ubitquitination. Adapted from McMaster and Ray [2008].
8
In the absence of ligand, the GRα is localized in the cytoplasm and forms a
hetero-oligomeric complex with several other proteins such as heat-shock proteins
(hsp) and immunophilins [Dalman et al., 1991; Tai et al., 1992; Pratt and Toft, 1997].
Hsp90 of this complex is of particular interest as it masks the nuclear localization
sequences (NLS) of the GRα and keeps the GRα in an inactive conformation that
allows ligand binding [Bresnick et al., 1989; Cadepond et al., 1991]. After binding
of ligand to the LBD, the conformation of the GRα changes, it dissociates from the
Hsp90 and the hetero-oligomeric complex and translocates to the nucleus [Picard and
Yamamoto, 1987]. Two GRα molecules homodimerize and bind to glucocorticoid-
responsive elements (GREs) in promoter regions of target genes and thereby lead
to activation or repression of these genes [Tsai et al., 1988; Wrange et al., 1989].
During transcriptional activity, GRα interacts, via its AF-1 and AF-2 do-
mains, with several coactivators (Figure 1.4) such as p300/CBP (=p300 and cAMP-
responsive element-binding protein (CREB)-binding protein), the p/CAF (=p300/-
CBP associated factor), the p160 family of coactivators which include the SRCs
(=steroid receptor coactivators), the SWI/SNF (=SWItch/sucrose non-fermenting)
complex, and the complex DRIP/TRAP (=vitamin-D-receptor interacting protein/-
thyroid receptor-associated protein) [Chakravarti et al., 1996; On˜ate et al., 1995; Li
et al., 2003; Hittelman et al., 1999]. The coactivators have chromatin remodeling
activity or facilitate the binding of the basal transcription machinery.
Figure 1.4: Diagram of GR with its coactivators. GR interacts with several
coactivators such as SRC1, p300, CBP, SWI/SNF and p/CAF. PRMT1 and CARM1
= histone methyltransferases, RHA = RNA helicase, TBP = TATA-box binding
protein. TFII = general transcription factor II, RNA Pol II = RNA polymerase II.
Adapted from Walsh et al. [2012].
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Also posttranslational modifications of the GRα such as phosphorylation,
acetylation, sumoylation and ubiquitination have an influence on the GR transcrip-
tional activity [Ismaili and Garabedian, 2004; Nader et al., 2009; Le Drean et al.,
2002; Kinyamu et al., 2005].
In addition to acting as a homodimer on GRE elements of target genes to in-
duce gene transcription, the GRα can also interact with other transcription factors
such NFκB, AP-1 and STATs and thereby regulating gene transcription via tran-
scriptional cross-talk (Figure 1.5 for the various possibilities of GR mechanisms)
[Scheinman et al., 1995; Karin and Chang, 2001; Rogatsky and Ivashkiv, 2006].
Figure 1.5: Diagram of GR genomic mechanisms. The ligand-bound GR ac-
tivates or represses transcription of target genes via several genomic mechanisms.
GR = glucocorticoid receptor, GRE = glucocorticoid response element, TF = tran-
scription factor. Adapted from Ratman et al. [2013].
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Non-genomic actions of GCs
Glucocorticoids can also exert effects via three different non-genomic mechanisms.
Glucocorticoids can intercalate into membranes which leads to changes in their
physicochemical properties and influences cation transport [Stahn and Buttgereit,
2008]. Rapid effects of glucocorticoids, which do not involve protein synthesis, might
be explained by this model. Furthermore, glucocorticoids can bind to membrane-
bound glucocorticoid receptors (= mGRs). There are two types of mGRs: the classic
GR localized in the membrane and a non-classic mGR. These mGRs evoke responses
via MAPK and cAMP signalling pathways [Mitre-Aguilar et al., 2015]. Also, after
binding of glucocorticoids to the cytosolic classic GR, proteins such as heat shock
proteins and cochaperones are released which can exert non-genomic signalling ef-
fects [Japiassu´ et al., 2009].
1.1.3.2 Mineralocorticoid Receptor
The MR belongs to the same steroid receptor superfamily as the GR and acts as
a ligand-activated transcription factor as well. The MR is encoded by the gene
NR3C2 and was cloned by Arriza et al. [1987]. The endogenous ligand of the MR is
aldosterone, but the MR has similar affinity to cortisol [Arriza et al., 1987]. Because
of this fact, effects of glucocorticoids can also be mediated by MR in addition to GR.
Like the GR, the MR has an N-terminal domain, a DNA-binding (DBD), a hinge
region and a ligand-binding domain. The DBD from the MR is 94% homolog to the
DBD from the GR and binds to GRE elements in target gene promotors [Lombe´s
et al., 1993].
The MR is expressed in mineralocorticoid-target tissue including kidney
and in other tissues such as colon, salivary glands, specific brain regions, vascu-
lar tissue, adipocytes and placenta [Lombe`s et al., 1990; Sasano et al., 1992; Agar-
wal et al., 1993; Hirasawa et al., 2000; Pascual-Le Tallec and Lombe`s, 2005]. In
mineralocorticoid-target tissue, the enzyme 11β-HSD2 is very important because it
inactivates cortisol to cortisone and thereby enhances the binding of aldosterone to
the MR (see chapter 1.1.5).
Similar to GR trafficking, the MR forms a heterocomplex with other proteins
such as Hsp90, Hsp70, p23 and immunophilins in the cytosol [Nemoto et al., 1993;
Gallo et al., 2007], but also some nuclear localization of the MR is detectable [Nishi
et al., 2001]. After ligand binding, the MR translocates to the nucleus, possibly
with Hsp90, and within the nucleus MR dimerizes and transcription of target genes
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can occur [Galigniana et al., 2010; Grossmann et al., 2012].
1.1.4 Placental and Fetal GC Action
Fetal cortisol partly stems from the mother’s circulation by reaching the fetus via
transplacental transfer and is also partly produced by the fetus itself, specifically it
is produced by the fetal zone (FZ) from the fetal adrenal gland. Fetal cortisol levels
increase from week 35 of pregnancy until term [Murphy, 1982] which leads to fetal
organ maturation preparing the fetus for extrauterine life.
Cortisol plays an important role on the placental development as it can reg-
ulate placental size and morphology as well as it is involved in the regulation of
placental transport and endocrine function [Fowden et al., 2009]. Furthermore, cor-
tisol might act as sensor important for initiating adaptive responses in the placenta
[Fowden and Forhead, 2004].
Also, cortisol plays an important role in fetal organ maturation to prepare
the fetus for extrauterine life. For example, cortisol is involved in lung maturation,
in detail it leads to stimulation of surfactant protein production which is required
for a successful extrauterine function of the lung [Liley et al., 1989]. A single dose
of synthetic glucocorticoid is the standard therapy for pregnant women with risk of
pre-term labor as it accelerates the fetal lung maturation and thereby reduces the
morbidity and mortality caused by infant respiratory distress syndrome [Roberts
and Dalziel, 2006]. Furthermore, cortisol is important for the induction of hepatic
gluconeogenesis enzymes, for cardiac development, and for establishing an indepen-
dent thermoregulation [Townsend et al., 1991; Fowden et al., 1998; Reynolds and
Walker, 2003]. Thus, cortisol is very important for the successful maturation of
the fetus, but an excess of cortisol on the other hand can have detrimental effects
on fetal development such as intrauterine growth restriction and can lead to fetal
programming (see chapter 1.3.3).
Figure 1.6 summarizes the CRH and glucocorticoid signalling in the mother,
placenta and fetus.
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Figure 1.6: Diagram of CRH and GC signalling between mother, placenta
and fetus. Maternal cortisol (human glucocorticoid) levels are increased after
activation of the maternal HPA axis. Cortisol molecules pass through the placenta
where they are being inactivated by the enzyme 11β-HSD2 to cortisone (see chapter
1.1.5 for detailed information about 11β-HSD2). However, also local glucocorticoid
action in placental tissue takes place, e.g. cortisol increases placental CRH levels
and cortisol regulates placental development. Placental CRH activates production of
fetal DHEA/DHEAS (precursor of E2 in the placenta) and fetal cortisol in the fetal
adrenal. Fetal and maternal cortisol are important for fetal organ maturation, but
excess cortisol levels in the fetus can lead to fetal programming and low birth weight
(see chapter 1.3.3 for detailed information about fetal programming). Adapted from
Reynolds [2013a].
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1.1.5 The Enzyme 11β-HSD2
The enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) is a modulator
of glucocorticoid availability in cells playing an important role in mineralocorticoid-
target tissues as well as in the placenta.
The isoform 11β-HSD2 was found and characterized by Brown et al. [1993]
and Rusvai and Na´ray-Fejes-To´th [1993] and cloned by Albiston et al. [1994]. 11β-
HSD2 catalyzes exclusively the conversion of cortisol and corticosterone to cortisone
and 11-dehydrocorticosterone, respectively (Figure 1.7). Thereby NAD+ is required
as a cofactor in this biochemical reaction. In contrast to that, the isoform 11β-HSD1
catalyzes mainly the conversion of cortisone to cortisol which requires NADPH as a
cofactor [Low et al., 1994]. However, this type I enzyme also has a dehydrogenase
activity, even though the reductase activity is predominant. Sequence homology
(amino acids) between 11β-HSD1 and 11β-HSD2 is only 14% [Albiston et al., 1994].
Figure 1.7: Biochemical reactions of 11β-HSD1 and 11β-HSD2.
11β-HSD2 catalyzes the inactivation of cortisol into cortisone and 11β-
HSD2 catalyzes the conversion of cortisone to cortisol. Adapted from
http://www.totalflexblog.com/articles/11b-hsd1-inhibition/ .
The enzyme 11β-HSD2 is expressed in classical aldosterone/mineralocorti-
coid-target tissues including kidney and colon as well as in the placenta [Krozowski
et al., 1995; Smith et al., 1996]. As mentioned above (see chapter 1.1.3.2) the MR
binds cortisol and aldosterone with equal affinity in vitro, but in vivo the MR selec-
tively binds aldosterone. This is because of the activity of 11β-HSD2 inactivating
cortisol and its colocalization with the MR [Edwards et al., 1988; Funder et al.,
1988; Hirasawa et al., 1997; Odermatt et al., 2001].
11β-HSD1 is expressed highest in liver [Tannin et al., 1991] where it is colo-
calized with the GR modulating cortisol access to this receptor [Low et al., 1994].
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Role of 11β-HSD2 in Placenta
Expression of a dehydrogenase (11β-ol dehydrogenase) in the placenta which con-
verts cortisol into cortisone was described by Osinski [1960]. The now called 11β-
HSD2 plays an important role as the placental glucocorticoid barrier enzyme, which
limits the maternal cortisol to reach the fetus by inactivating the active cortisol into
cortisone [Benediktsson et al., 1997]. This mechanism is extremely efficient as it
has been shown that the cortisol concentration in the maternal circulation is 5- to
10-fold higher than in the fetal compartment [Beitins et al., 1973; Campbell and
Murphy, 1977]. When excess glucocorticoids reach the fetus, for example due to
stress or a decreased 11β-HSD2 expression, it could lead to a reduced birth weight
and fetal programming (see chapter 1.3.3), i.e. the individuals have a higher risk in
developing diseases such as metabolic and anxiety-related diseases in their adult life
[Seckl and Holmes, 2007].
The enzyme 11β-HSD2 is highly expressed in the syncytiotrophoblast layer,
which is the maternal-fetal interface, and weakly expressed in the cytotrophoblast
cells [Krozowski et al., 1995; Driver et al., 2001]. The placental 11β-HSD2 expression
steadily increases towards the end of pregnancy, whereas during the last two weeks of
gestation the 11β-HSD2 activity decreases [Schoof et al., 2001b; Murphy and Clifton,
2003]. In placenta-related diseases such as pre-eclampsia and IUGR, expression
of 11β-HSD2 is reduced (see chapter 1.3.1) [Schoof et al., 2001a; Causevic and
Mohaupt, 2007; Shams et al., 1998; Dy et al., 2008; McTernan et al., 2001].
Regarding transcriptional regulation, upregulation of 11β-HSD2 during syn-
cytialization of the cytotrophoblast cells is due to an elevated expression of the
transcription factor Sp1 [Li et al., 2011a]. The MAP kinases p38 and ERK1/2 are
involved in the up- and downregulation of basal 11β-HSD2 expression, respectively
[Sharma et al., 2009; Guan et al., 2013]. Several other factors are able to modulate
the expression of 11β-HSD2 such as pro-inflammatory cytokines (IL-1β, IL-6, TNF-
α), nitric oxide, oxygen, prostaglandin and PPARδ agonists [Chisaka et al., 2005;
Kossintseva et al., 2006; Sun et al., 1997; Alfaidy et al., 2002; Homan et al., 2006;
Hardy et al., 1999; Julan et al., 2005].
In addition to its role as a limiting factor of glucocorticoid access to the
fetal circulation, 11β-HSD2 might also regulate the local steroid action within the
placenta itself. Driver et al. [2001, 2003] detected expression of a functional MR
and corticosteroid-induced expression of SGK via MR in trophoblast cells. There-
fore, placental 11β-HSD2 may limit the activation of MR by cortisol like it does in
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mineralocorticoid-target tissue.
1.1.6 ABC Transporter
The ATP-binding cassette (ABC) transporter molecules phospho-glycoprotein (P-
gp, a synonym is multidrug resistance protein 1 (MDR1)) and breast cancer resis-
tance protein (BCRP) were discovered by Kartner et al. [1983] and Doyle et al.
[1998] and they are shown to be involved in the exportation of substrates includ-
ing cortisol molecules back into the maternal circulation [Hahnova-Cygalova et al.,
2011; Iqbal et al., 2012]. P-gp and BCRP are encoded by the genes ABCB1 and
ABCG2, respectively, and both are expressed in several tissues such as kidney, liver,
pancreas, colon, lungs and placenta and they function as drug transporter molecules
[Thiebaut et al., 1987; Maliepaard et al., 2001]. In the placenta, both transporter
molecules are expressed in the syncytiotrophoblast layer [Kolwankar et al., 2005;
Sun et al., 2006]. During pregnancy, expression of P-gp decreases towards term,
whereas BCRP expression does not change [Gil et al., 2005; Mathias et al., 2005].
In the placenta, they protect the fetus against xenobiotics such as chemotherapeu-
tics and antibiotics, but also against various endogenous compounds [Zhou, 2008;
Polgar et al., 2008]. Mares-Sa´mano et al. [2009] showed in silico that steroids can
bind to both P-gp and BCRP and van Kalken et al. [1993] showed that P-gp can
export cortisol which suggests that these transporter molecules are parts of the pla-
cental glucocorticoid barrier. As the transporter molecules modulate the cellular
availability of cortisol, they are involved in the cortisol action inside of cells. In
placenta-related diseases such as IUGR, infection and in pre-term labor, the expres-
sion of P-gp and BCRP seems to be altered [Evseenko et al., 2007; Mason et al.,
2011; Meyer zu Schwabedissen et al., 2006].
Figure 1.8 shows the glucocortcoid barrier and molecules involved in the local
glucocorticoid action in the placenta.
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Figure 1.8: Diagram of the GC barrier and GC local action in the placenta.
Molecules involved in the GC local action in the placenta are the GC receptors GR
and MR as well as transporter molecules P-gp and BCRP which export cortisol
back into the maternal circulation. The enzyme 11β-HSD2 fulfills the role of the
glucocorticoid barrier in the placenta by converting active cortisol into cortisone.
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1.2 Human Placenta
The human placenta is the interface between the mother and the fetus, fulfill-
ing important roles such as nutrient transfer; hormone, cytokine, and signalling
molecule production; protection of the fetus against the maternal immune system
and pathogens; and other barrier functions. The placenta develops from the tro-
phoblast, whereas the embryoblast develops into the fetus. Important during the
trophoblast development is the differentiation of trophoblast cells into the fused syn-
cytium which is the site of feto-maternal exchange as well as into extravillous tro-
phoblast which are important for a successfull invasion into maternal tissue [Tarrade
et al., 2001]. This chapter describes the morphology, differentiation and functions
of the placenta.
1.2.1 Placental Morphology
The placenta consists of several different components such as the chorionic plate,
which is the surface of the placenta facing the fetus, the villous trees with the in-
tervillous space, and the basal plate, which is the side of the placenta facing the
maternal tissue (Figure 1.9) (Baergen [2011] and Strauss [1964]). The term pla-
centa can be separated into 10-40 so-called cotyledons, consisting of villous trees.
The villous tree itself consists of syncytiotrophoblast (ST), cytotrophoblast cells
(CT), connective tissue (= mesenchymal stromal cells), and fetal capillaries and
veins and its development is described in chapter 1.2.2. Between the villous trees
is the intervillous space, which is bathed with maternal blood. The extravillous
trophoblast cells (EVT) play an important role in the remodeling of the mater-
nal decidual vessels, which is described in chapter 1.2.4. The contact side of the
maternal circulation with fetal tissue is the ST and its differentiation is described
in chapter 1.2.5. The structure of the placenta with its close contact of maternal
and fetal circulation allows the successful exchange of nutrients and waste between
mother and fetus.
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Figure 1.9: Diagram of placenta. Cross section of the human pla-
centa. The chorionic plate is facing the fetus. The chorionic villi are cov-
ered by the syncytiotrophoblast which is in direct contact with the mater-
nal blood. Adapted from: http://www.ib.bioninja.com.au/higher-level/topic-11-
human-health-and/114-reproduction.html.
1.2.2 Villous Tree Development
After fertilization, the zygote divides and thereby develops into a blastocyst. This
blastocyst reaches the uterine cavity on day 6-7 post conception (p.c.) and the im-
plantation process begins [Aplin, 2000]. The blastocyst attaches at the endometrium
with the inner cell mass (ICM) oriented to that side. The ICM develops into the
embryo, whereas the trophoblast part of the blastocyste develops into the placenta.
The trophoblastic cells invade the endometrium and start dividing, thereby forming
an inner layer, the cytotrophoblast, and an outer layer, the syncytiotrophoblast.
The maternal facing syncytiotrophoblast is generated by fusion of cytotrophoblast
cells (see chapter 1.2.5). On day 8 p.c., vacuoles, called lacunae, develop within the
syncytiotrophoblast [Baergen, 2011]. Between day 8 and 12 p.c., the syncytiotro-
phoblast expands and then covers the entire blastocyst. This stage, day 8-12 p.c., is
called the lacunar phase. After that, the transformation from the lacunar system to
the villous system occurs between day 13-28 p.c. Cytotrophoblast cells invade the
areas between the lacunae, called trabeculae, from the chorionic plate to the ma-
ternal side [Baergen, 2011] and each of the invaded trabeculae will develop into one
villous tree. These primary villi consist of syncytiotrophoblast and cytotrophoblast
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cells. During the transformation to secondary villi, embryonic mesenchymal cells,
which cover the inner surface of the blastocyst cavity, invade the villi [Castellucci
et al., 1990]. Between day 18-20 p.c., some of the mesenchymal cells differentiate into
hemangioblastic progenitor cells, which then develop into fetal capillaries [Dempsey,
1972]. Presence of these fetal capillaries within the villous stroma marks the transi-
tion into tertiary villi. Hence, the processes involved in the villous tree development
are trophoblastic sprouting, mesenchymal invasion and local fetal angiogenesis. Be-
ginning with the second month of pregnancy, the mesenchymal tertiary villi undergo
differentiation and different villous types occur: immature intermediate villi, mature
intermediate villi, stem villi, and terminal villi [Huppertz, 2008].
1.2.3 Placental Vascularization
As mentioned above, placental vascularization starts with the development of the
tertiary villi: extra-embryonic mesenchymal cells differentiate into hemangiogenic
progenitor cells [Demir et al., 2007]. This process, taking place from day 21-32 p.c.,
is a vasculogenesis process leading to new vessels formation. Hematopoietic cells,
which are precursors of blood cells, and angioblastic cells, which later differentiate
into endothelial cells, evolve from differentiation of the hemangiogenic progenitor
cells. From day 32 p.c. until term, angiogenesis, which is the connection of pre-
formed vessels with each other, is observed [Kaufmann et al., 2004]. Several growths
factors such as vascular endothelial growth factor (VEGF), placental growth factor
(PlGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), and an-
giopoietins are involved in vasculogenesis and angiogenesis. In the beginning of
vascularization, villous trophoblast cells secrete VEGF, PlGF, and FGF, whereas
in later stages, the newly occurred smooth muscle cells produce VEGF, FGF, and
angiopoietins [Sharkey et al., 1993; Vuorela et al., 1997; Riddell et al., 2012]. After
midgestation, length of vessels and their volume grow exponentially to meet the
demands of the fetus.
1.2.4 Extravillous Trophoblast Differentiation
Also during early stages of the placentation, at the basal plate, which is the con-
tact side of syncytiotrophoblast and maternal tissue, extravillous trophoblast cells
(EVT) deeply invade the endometrium (Figure 1.10). In the beginning, the syncy-
tiotrophoblast is in contact with the endometrium, but after cytotrophoblast cells
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have reached the basal plate, the syncytiotrophoblast is disrupted at some locations.
In these areas, cytotrophoblast cells differentiate into the proliferative EVTs, which
are the stem cells of the EVTs [Bulmer et al., 1988; Genbacev et al., 1993]. This cell
population can either differentiate into interstitial EVTs, which infiltrate the uterine
wall, or into endovascular EVTs, which invade maternal spiral arteries. During the
invasion process, the endovascular EVTs infiltrate the vessel walls and replace the
endothelium and as a result the decidual vessels are converted into uteroplacental
vessels characterized by low resistance which increases the blood flow [Pijnenborg
et al., 1980; Thaler et al., 1990]. Fibrinoid is deposited, possibly by endovascular
and interstitial trophoblasts, in the spiral arteries [Pijnenborg et al., 2006].
Figure 1.10: Remodelling of the uterine spiral arteries by extravillous tro-
phoblast. The extravillous trophoblast cells invade the myometrium to remodel
the uterine spiral arteries into low resistance vessels. Black arrow = movement of
EVTs, red arrow = blood flow. Adapted from Pijnenborg et al. [2006].
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1.2.5 Syncytiotrophoblast Differentiation
The syncytiotrophoblast (ST) is the direct contact side between the mother and
the fetus. It is a multinucleated cell layer and it arises from fusion of underlying
cytotrophoblast cells. The membrane facing the fetal side is called basal membrane
(BM) and the membrane facing the maternal side is called microvillous membrane
(MVM). Fusion of cytotrophoblast cells by differentiating into ST and shedding of
syncytial knots at the MVM are parts of the normal trophoblast cell turnover (Fig-
ure 1.11) [Huppertz et al., 1998].
Figure 1.11: Trophoblast turnover. Cytotrophoblast cells (= cyt troph) prolif-
erate, then undergo differentiation and fuse with the syncytiotrophoblast (= syn
troph). Nuclei are accumulated in syncytial knots which are shed from the layer
while undergoing apoptosis. Adapted from Carter [2008].
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1.2.5.1 Formation of ST
The syncytiotrophoblast (ST) develops within the first days of implantation of the
blastocyst into the decidua (Figure 1.12). Notably, implantation does not take place
without the ST since this cell layer has penetrating capacity. The development of
this first ST is characterized by cell-cell-fusion of cytotrophoblast cells [Po¨tgens
et al., 2002]. The function of the ST changes over time and the penetrating capacity
is lost, instead the ST develops important transport and endocrine functions. After
the first period, the ST grows and is maintained by fusion of cytotrophblasts with
the ST layer. The cytotrophoblast cells undergo a differentiation process before they
eventually fuse with the ST [McKenzie et al., 1998]. This incorporation of cytotro-
phoblasts at the BM takes place throughout pregnancy and in order to maintain
ST homeostasis, material of the ST needs to be removed at the MVM. The nuclei
remain in the ST for around 3-4 weeks before they enrich in certain areas of the
MVM as syncytial knots [Jones and Fox, 1977], which are shed into the maternal
capillary system.
Figure 1.12: Blastocyst implantation with early syncytiotrophoblast.
Adapted from Huppertz [2008]
23
1.2.5.2 Characteristics of ST
The syncytiotrophoblast is a multinucleated cell layer covering the whole villous
tree system of the placenta. This layer is in a postmitotic state [Burton and Jones,
2009]. Furthermore, the ST shows only a low transcriptional activity demonstrated
with different methods (staining for active Pol-II and histone modifications, nucle-
oside incorporation assay) by Ellery et al. [2009]. Specifically, the nuclei within the
ST layer are at different ages and therefore differently active. Some of the nuclei
display transcriptional activity whereas other nuclei do not have this capacity any-
more [Ellery et al., 2009]. The size of the ST surface area grows from 0.8 m2 at
week 12 of gestation to 12-14 m2 at term [Boyd, 1984]. The ratio of nuclei of ST
to a cytotrophoblast nucleus remains constant throughout pregnancy and is about
9 [Simpson et al., 1992].
1.2.5.3 Molecules involved in ST Formation
Regulation of cytotrophoblast fusion is diverse and several factors and signalling
pathways are involved. For example, different factors such as growth factors (epider-
mal growth factor (EGF), vascular endothelial growth factor (VEGF)), stimulating
factors (colony-stimulating factor (CSF), granulocyte-macrophage-CSF (GM-CSF)),
and hormones (human chorionic gonadotropin (hCG)) can promote the syncytial-
ization process, whereas other molecules such as tumor necrosis factor-α (TNF-α)
and transforming growth factor-β (TGF-β) inhibit the syncytium formation [Mor-
rish et al., 1987; Crocker et al., 2001; Garcia-Lloret et al., 1994; Shi et al., 1993;
Leisser et al., 2006; Morrish et al., 1991].
Signaling pathways involved in the fusion process of cytotrophoblasts are the
MAPK pathways (namely the p38 and the ERK1/2 MAPK) which are shown to
promote syncytial fusion [Daoud et al., 2005; Delidaki et al., 2011] and the PKA
pathway regulating important factors such as Syncytin-1 which participates as a
fusogene in the syncytial fusion process [Knerr et al., 2005].
In addition to the fusogenes Syncytin-1 and Syncytin-2 (see below), also other
molecules such as galectin-3 and its receptor CD98, placental protein 13 (PP13),
connexin 43, caspase-8, and members of the ADAM (a disintegrin and a metallo-
proteinase domain) family are shown to be involved in the trophoblast fusion or
are candidate molecules which might play a role in this process [Kudo et al., 2003b;
Dalton et al., 2007; Than et al., 2004; Frendo et al., 2003; Black et al., 2004; Huovila
et al., 1996].
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Syncytin-1 and Syncytin-2
Syncytin-1 was discovered in 1999 and it is the envelope protein of the human
endogenous retrovirus-W (HERVW) [Blond et al., 1999; Mi et al., 2000]. Syncytin-1
is a membrane glycoprotein and has fusogenic capacity when binding to its receptor,
the RD114/mammalian type D retrovirus receptor (RDR, synonyms are ASCT2 and
ATB0) [Blond et al., 2000]. Frendo et al. [2003] showed that Syncytin-1 is directly
involved in fusion of trophoblasts. In other tissues, the promotor of Syncytin-1 is
methylated preventing its expression [Matouskova´ et al., 2006].
In 2003 Syncytin-2, envelope protein of the HERV-FRD gene, was discovered
[Blaise et al., 2003]. It is expressed in the placenta and binds to the receptor MFSD2
(major facilitator superfamily domain containing 2) [Malassine´ et al., 2007; Esnault
et al., 2008]. Syncytin-2 is involved in the fusion process of trophoblast cells and also
possesses immunosuppressive activity [Vargas et al., 2009; Mangeney et al., 2007].
Other HERV envelope proteins such as EnvP(b) and EnvV are expressed in
the placenta, but they do not play a role in the fusion process [Vargas et al., 2012].
1.2.6 Placenta and Apoptosis
1.2.6.1 General Description of Apoptosis
Apoptosis is the process of programmed cell death and the term ”‘apoptosis”’ was
first used by Kerr et al. [1972]. In contrast to necrosis, which is an unregulated
cell death process involving several cells (for example induced by tissue damage),
apoptosis is an energy-dependent and controlled process affecting single cells [Kerr
et al., 1972]. Apoptosis is of fundamental importance for the development of organ-
isms, for the maintenance of cell homeostasis and for the regulation of the immune
system. However, excess or too little apoptosis is involved in pathologies such as
autoimmune and neurodegenerative diseases and cancer [Elmore, 2007].
During apoptosis, at the cellular level, the apoptotic cell seperates from
neighbouring cells, cytoplasm and nucleus condenses and apoptotic bodies detach
from the cell and these are being phagocytosed by macrophages and other cells
[Kerr et al., 1972]. At the molecular level, many proteins are cleaved by enzymes
(caspases) and the DNA is fragmented by nucleases. The activation of the caspases
is triggered by two different pathways, the extrinsic and intrinsic pathway (Figure
1.13), which are described below.
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Extrinsic and Intrinsic Pathway
The transmembrane death receptors, which belong to the TNF receptor superfam-
ily, play a central role in the activation of the extrinsic pathway [Ashkenazi and
Dixit, 1998] (Figure 1.13). After ligand binding, the death receptors such as CD95
(=Fas) and TNFR1 oligomerize and intracellular adapter molecules such as FADD
and TRADD bind to the receptors [Chinnaiyan et al., 1995; Hsu et al., 1995]. Death
domains of the receptors and the adapter molecules are important for their interac-
tion. The procaspase-8 is being recruited to this DISC (=death-inducing signalling
complex) complex where it is cleaved to active caspase-8 [Kischkel et al., 1995].
Members of the Bcl-2 (=B-cell lymphoma-2) family such as Bcl-2, Bcl-XL and
Bax play a central role in the activation of the intrinsic pathway [Leibowitz and Yu,
2010] (Figure 1.13). These molecules can either act anti-apoptotic or pro-apoptotic
and they can be divided in three groups [Leibowitz and Yu, 2010]. Members of the
first group such as Bcl-2 and Bcl-XL are characterized by 4 BH (=Bcl-2 homology)
domains and they are anti-apoptotic. Members of the second group such as Bax and
Bak possess 3 BH domains and they are pro-apoptotic. Members of the BH3-only
group such as Bad and Bid are involved in the detection of apoptotic signals. The
key function of the Bcl-2 members is the regulation of the mitochondrial pore (mi-
tochondrial permeability transition pore = MPTP) formation [Vander Heiden and
Thompson, 1999; Crompton, 1999]. Homo- and heterooligomerization processes of
the Bcl-2 members are important for the pore formation and so the ratio of pro-
and anti-apoptotic Bcl-2 members is involved in the decision whether a cell becomes
apoptotic [Oltvai et al., 1993; Yin et al., 1994; Chittenden et al., 1995]. The for-
mation of the MPTP leads to destruction of the mitochondrial membrane potential
and to the release of pro-apoptotic factors and cytochrom-c from the intermembrane
space of the mitochondria into the cytosol [Vayssiere et al., 1994; Bossy-Wetzel et al.,
1998; van Loo et al., 2002]. In the presence of ATP, a complex called apoptosome
consisting of cytochrom-c molecules and apaf-1 (= apoptotic protease activating
factor-1) molecules is formed and the procaspase-9 is actived [Hill et al., 2004; Yu
et al., 2005].
26
Figure 1.13: Extrinsic and Intrinsic Pathway of Apoptosis. Apoptosis can
be activated by the intrinsic or extrinsic pathway. (Left) Intrinsic pathway: Mem-
bers of the Bcl-2 family sense death stimuli and are involved in the formation of
the mitochondrial pore (= MPTP) and in the release of cytochrom-c (= Cyt-c).
In the cytoplasm, the apoptosome is formed from Apaf-1 and Cyt-c molecules in
the presence of ATP. This complex activates the procaspase-9. (Right) Extrinsic
pathway: Death receptors oligomerize after ligand binding and adapter molecules
such as FADD and TRADD bind via death domains to the receptors. This DISC
complex activates the procaspase-8. Activation of the initiator caspases-8 and -9
lead to activation of the execution phase of apoptosis.
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Execution Phase of Apoptosis
Both actived (cleaved) caspase-8 and caspase-9 initiate the execution phase of the
apoptotic process which starts with the activation (cleavage) of the effector caspases
(e.g. caspase-3/7). Caspases (= cystein-dependent aspartate specific protease) be-
long to the family of the ICE/CED-3 cysteinproteases [Alnemri et al., 1996]. Cas-
pases are synthezised as procaspases which require to be cleaved to unfold their
catalytic activity [Orth et al., 1996]. All caspases cleave their substrates after the
amino acid aspartate within a recognizing sequence, for example, caspase-3 and
-7 cleave their substrates at the DEVD recognition sequence [Thornberry et al.,
1997; Nicholson, 1999]. Many morphological features of apoptosis can be explained
by the cleavage of the substrates from the effector caspases. PARP (= poly-(ADP-
ribose)-polymerase) and the inhibitor of the endonuclease CAD (= caspase-activated
DNase) are among the estimated 200 substrates of the caspases [Sakahira et al., 1998;
Nicholson, 1999].
1.2.6.2 Apoptosis in Placenta during Pregnancy
Apoptosis takes place in normal placental cell turnover, which includes prolifera-
tion of cytotrophoblast cells, their fusion into the syncytiotrophoblast layer and the
apoptotic event of syncytial shedding. This cycle guarantees maintenance of the
syncytiotrophoblast by balancing proliferation and apoptosis of trophoblast cells.
During the lifetime of a placenta, apoptotic processes are observed in placental tis-
sue and the frequency of apoptosis rises towards the end of pregnancy [Smith et al.,
1997b; Gruslin et al., 2001; Athapathu et al., 2003]. Interestingly, apoptotic pro-
cesses in the placenta are elevated throughout pregnancy in placental diseases [Sharp
et al., 2010].
1.2.6.3 Apoptosis during ST Differentiation
In addition to its role in placental cell turnover, apoptotic features develop dur-
ing cytotrophoblast differentiation into the syncytiotrophoblast layer. Hallmarks
of apoptosis such as the phosphatidylserine (PS)-flip, activation of caspase-8 and
changes in the expression of pro- and anti-apoptotic molecules (Chapter 1.2.6.1) are
detected in the placenta during the differentiation process.
During early apoptosis, PS is externalized from the inner to the outer leaflet
of the cell membrane. Lyden et al., 1993, showed that the PS-flip arises during dif-
ferentiation of BeWo cells (a placental cell line) and Huppertz et al., 1998, demon-
strated that the PS-flip also occurs in primary placental tissue. Furthermore, the
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PS-flip seems to be a prerequisite for the fusion process since PS-antibodies can
inhibit fusion (Adler et al., 1995).
In apoptosis, activation of caspase-8, an initiator caspase, is an early event
that results from activation of the extrinsic apoptotic pathway. Several studies re-
vealed that activated caspase-8 is primarily localized in cytotrophoblast cells (De
Falco et al., 2004, Gauster et al., 2009), suggesting that its presence is required for
the initiation of the differentiation process. Black et al., 2004, showed that inhibiting
caspase-8 function by antisense oligonucleotides or by a peptide inhibitor impairs
the fusion process, which supports the above mentioned hypothesis. Another inter-
esting aspect is that several caspases seem to be involved in differentiation processes
of different cell types. For example, caspase-3 plays a role in the differentiation of
keratinocytes (Weil et al., 1999) and caspase-8 is involved in the monocyte matura-
tion (Secchiero et al., 2002). These results suggest the possibility that caspases have
a non-apoptotic function in addition to their known role in the apoptotic process.
After cytotrophoblast cell fusion, the apoptotic cascade is stopped and no
further signs of apoptosis develop aside from the syncytial shedding. Pro- and
anti-apoptotic molecules belong to the Bcl-2 protein family, which are expressed
in trophoblast cells. The syncytiotrophoblast layer highly expresses Bcl-2, an anti-
apoptotic protein, and moreover, in a placental cell culture model, Bcl-2 expression
was increased after differentiation (Sakuragi et al., 1994). These observations sug-
gest that up-regulation of Bcl-2 might be a mechanism in placental cells to end the
apoptotic events.
1.2.7 Functions of the Placenta
1.2.7.1 Placental Nutrient Transport
One role of the placenta is to ensure sufficient nutrient transfer to the fetus. For
the majority of nutrients required by the fetus, the maternal circulation is the only
source. Some molecules like oxygen can pass through the placental membrane, but
others need to be transported by specific transport proteins. Thus, the placental
membrane expresses several transport proteins for glucose, amino acids and fatty
acids (Figure 1.14). Specifically, the syncytiotrophoblast is the primary barrier and
both the maternal facing membrane, the microvillous membrane (MVM), and the
fetal facing basal membrane (BM) express these transporters. Maternal malnutri-
tion or deregulation of transporter molecules can compromise fetal development by
leading to abnormal fetal growth [Lager and Powell, 2012].
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Figure 1.14: Transport in ST. Several different transporter molecules for glucose,
amino acid and fatty acid transport are expressed in the MVM (= microvillous
membrane) and BM (= basal membrane) of the syncytiotrophoblast. FABP =
fatty acid binding protein, FATP = fatty acid transport protein, GLUT = glucose
transporter. Adapted from Lager and Powell [2012].
Glucose Transport
As the fetus does not produce glucose [Kalhan and Parimi, 2000], the maternal cir-
culation is the source for glucose transfer from mother to fetus. Transport of glucose
is mediated via glucose transporters (GLUTs), of which GLUT1 is the main glucose
transporter in the syncytiotrophoblast [Jansson et al., 1993]. Glucose transport is
a facilitated diffusion process [Johnson and Smith, 1980], as it is dependent on the
glucose concentration gradient between mother, placenta, and fetus. Higher levels of
GLUT1 are expressed on the maternal-facing membrane of the syncytiotrophoblast
than on the membrane facing the fetus [Jansson et al., 1993]. The placenta itself
has a high demand in glucose for its metabolism (0.13-0.33 mmol/min/kg); around
one-third of the glucose taken up by the placenta is metabolized via glycolysis,
the pentose phosphate pathway, and non-triose phosphate pathways in the placenta
[Hay, 1995; Lager and Powell, 2012]. The fetus has a glucose consumption of 0.07
mmol/min/kg and needs glucose as the primary substrate for growth.
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Amino Acid Transport
Non-essential amino acids can be synthesized by the fetus, but essential amino acids
need to be transported from the maternal circulation to the fetus passing through
the placenta. As the amino acid concentration is higher in the fetal than in the
maternal circulation [Philipps et al., 1978], the transport of amino acids is active,
specifically it is a secondary active transport. Amino acid transporters in the pla-
centa belong to sodium-coupled transporters, exchangers, and non-exchange eﬄux
transporters and more than 20 different of these transporters are expressed in the
placenta [Jansson, 2001]. The uptake of amino acids can be regulated by cytokines
and hormones including insulin, IGF1, and leptin [Jansson et al., 2003]. In addition
to the transfer of amino acids, the placenta can also metabolize amino acids to pro-
duce new amino acids, other compounds or energy as well as use amino acids for
protein synthesis. IUGR fetuses show a lower amino acid concentration in umbil-
ical cord blood than normal fetuses and exhibit an impaired placental amino acid
transport system [Cetin et al., 1988; Jansson, 2001].
Fatty Acid Transport
Fatty acids derive from triglycerides, which are hydrolyzed at the maternal surface
of the MVM by lipoprotein lipases [Waterman et al., 1998; Lindegaard et al., 2005].
These fatty acids are then transported in the placenta by fatty acid transport pro-
teins (FATPs), of which FATP1 and 4 are expressed in the placenta [Larque´ et al.,
2006; Kazantzis and Stahl, 2012]. Fatty acid binding proteins (FABPs) traffic fatty
acids within the syncytiotrophoblast and several subtypes of FABPs are expressed
in the placenta [Campbell et al., 1998]. The fatty acids are either transported
to the fetus or are metabolized in the placenta by esterification or beta-oxidation
[Ramsay et al., 1991; Oey et al., 2006]. Clinically, IUGR placentae show a dysreg-
ulated expression of the lipoprotein lipase [Tabano et al., 2006; Gauster et al., 2007].
1.2.7.2 Placental Endocrine Function
Another role of the placenta is to produce several different hormones, specifically
the syncytiotrophoblast layer fulfills the endocrine function of the placenta. The
hormones are involved in many processes such as the establishment and mainte-
nance of pregnancy, regulation of vascular development, adaptation and regulation
of maternal metabolism to pregnancy, regulation of fetal growth and parturition,
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and placental adaptation to adverse environments.
The hormones human chorionic gonadotropin (hCG), progesterone (P4) and
estradiol (E2) are described in more detail below. Growth factor hormones such
as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF)
are involved in the regulation of vascular development [Burton et al., 2009]. Hu-
man placental lactogen (hPL) acts as a growth hormone in the placenta, i.e. hPL
stimulates maternal IGF production and it leads to a higher availability of amino
acids and glucose [Handwerger and Freemark, 2000]. Moreover, adipocytokines and
insulin-like growth factors (IGFs) regulate maternal metabolism as well as placental
and fetal growth [D’Ippolito et al., 2012; Hiden et al., 2009]. Leptin seems to be
involved in many regulating processes such as placental growth, angiogenesis and
immunmodulation as well as fetal organogenesis [Gambino et al., 2010]. Receptors
for these hormones are expressed in the neighboring tissues as well as in the placenta
itself [Fowden et al., 2015] and therefore, the hormones act in a paracrine as well
as autocrine manner suggesting effects both in maternal and fetal compartments
(Figure 1.15).
Figure 1.15: Cross-talk of maternal, fetal and placental hormones and their
effects on mother, fetus and placenta. DHEA = dihydroepiandrostenedione,
IGF = insulin-like growth factor, T3 = tri-iodothyronine, T4 = thyroxine. Adapted
from Fowden et al. [2015].
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hCG
hCG is a peptide hormone, which is secreted by the syncytiotrophoblast. It con-
sists of two subunits, an α- and a β-subunit, of which the β-subunit is specific for
hCG. The α-subunit is also a subunit of the luteinizing hormone (LH), the follicle-
stimulating hormone (FSH), and the thyroid-stimulating hormone (TSH). Landefeld
et al. [1976] identified in first trimester placentae the mRNA which encodes for the
α-subunit precursor, Daniels-McQueen et al. [1978] isolated both hCG subunit mR-
NAs, and in 1994 the crystal structure of hCG was revealed by Lapthorn et al.
[1994]. hCG and LH bind to the same hCG/LH receptor belonging to the GPCR
family [McFarland et al., 1989; Minegishi et al., 1990; Jia et al., 1991] and this recep-
tor is expressed by several tissues including myometrium, endometrium, placenta,
fetal membranes and decidua [Reshef et al., 1990].
The hCG concentration rises during pregnancy, reaching a maximum be-
tween week 9 and 10 of gestation, and then the concentration decreases and stays
at a low constant level until the end of the pregnancy [Cole, 2010]. As the high
hCG concentrations are characteristic for a pregnancy, detection of hCG is used in
pregnancy tests [Chard, 1992].
hCG has multiple functions on the fetoplacental unit. One very important
function of hCG is the stimulation of the corpus lutuem to produce progesterone
during the first seven to eight weeks of pregnancy [Schmitt et al., 1996]. Further,
hCG appears to be involved in implantation as several effects of hCG on the en-
dometrium such as upregulation of LIF, VEGF and MMP-9 could be demonstrated
[Licht et al., 2007]. Also, hCG is involved in the control of endometrial vascular-
ization and placentation as it can stimulate migration of endothelial cells as well as
induce neovascularization [Zygmunt et al., 2002]. Another role of hCG is the sup-
pression of an immune response against fetoplacental tissue by upregulating MIF
(= macrophage inhibitory factor) in endometrial stromal cells and by attracting
regulatory T cells to the uterus [Akoum et al., 2005; Schumacher et al., 2009]. hCG
is further involved in modulating the differentiation of cytotrophoblasts into syncy-
tiotrophoblast and the relaxation of myometrial contractions [Eta et al., 1994; Shi
et al., 1993]. Many of the mentioned processes are especially important during early
pregnancy which might explain the high expression of hCG during the first trimester
of pregnancy.
In addition to hCG, which is produced by the syncytiotrophoblast, three
other forms of hCG exist, namely the hyperglycosylated hCG produced by cytotro-
phoblasts, the sulphated hCG produced by the pituitary and the free β-subunit
produced by several non-trophoblastic malignancies [Cole, 2012].
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Progesterone
During the first seven to eight weeks of pregnancy, progesterone (P4) is secreted
by the corpus luteum of the ovary gland. Then the so-called luteo-placental shift
occurs and the P4 production is taken over by the placenta [Csapo, 1969].
Progesterone belongs to the steroid hormones and binds to nuclear receptors,
the progesterone receptors PR-A and -B, which are transcribed from the same gene
with alternate promoter usage, as well as to membrane-bound progesterone receptors
(mPRs) [Li et al., 2004]. P4 exerts effects via genomic actions through PR-A and
PR-B receptors, which act as nuclear transcription factors after hormone binding
whereby PR-A can repress the function of PR-B [Vegeto et al., 1993]. Additionally,
progesterone also exerts effects via non-genomic actions mediated by either binding
to PR-A and -B or to the mPRs [Kowalik et al., 2013]. PRs are expressed in the
human uterus [Mote et al., 1999] and in the placenta [Rossmanith et al., 1997;
Shanker and Rao, 1999]. Other isoforms of the PR and a changed ratio of PR-
A to PR-B might play roles in P4 withdrawal (see below) [Goldman and Shalev,
2007]. The mPRs are expressed in gestational tissues including the endometrium,
myometrium and placenta [Fernandes et al., 2005].
The secretion of progesterone is gradually rising towards the end of preg-
nancy [Albrecht and Pepe, 1990]. Functions of progesterone are important during
all phases of gestation. Even before that, progesterone prepares the uterus for im-
plantation during the implantation window to establish uterine receptivity [Li et al.,
2011b]. During gestation, it is important for maintaining a successful pregnancy by
preventing uterine contractions [Ruddock et al., 2008]. Furthermore, progesterone
has a regulatory function as it prevents excessive trophoblast migration by neg-
atively regulating MMPs (matrix metalloproteinases) which are important in the
extravillous trophoblast invasion process [Higuchi et al., 1995]. Also, P4 exerts
immunomodulatory functions during pregnancy. For example, P4 can modulate cy-
tokine production by macrophages and T cells shifting the cytokine production to a
Th2 response [Piccinni et al., 1995]. Near term, it is hypothesized that a functional
P4 withdrawal occurs to induce labour. In subprimate mammals, a progesterone
withdrawal leads to the onset of labour [Zakar and Hertelendy, 2007]. In contrast, in
humans, the progesterone concentration does not decline at the end of pregnancy,
but the expression of the PRs (altered ratio of PR-A to PR-B and possibly in-
volvement of PR-C) might explain a functional withdrawal [Merlino et al., 2007].
Progesterone is used as a therapeutic application in pregnancies with a risk of abor-
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tion, miscarriage and pre-term labour [Di Renzo et al., 2005].
Estrogen
Estradiol (E2) like progesterone is a steroid hormone, but the placenta is unable to
directly synthesize estradiol from progesterone because the enzyme cytochrome P450
17α-hydroxylase is not expressed. Instead the placenta requires DHEA or DHEAS
from maternal and fetal circulation which then is used as a precursor molecule for
E2 production [Baulieu and Dray, 1963; Siiteri and MacDonald, 1966; Branchaud
et al., 1983].
E2 binds to two nuclear receptors, ERα and ERβ, as well as to a membrane-
bound receptor GPR30 [Bjo¨rnstro¨m and Sjo¨berg, 2005; Prossnitz et al., 2008]. The
nuclear receptors are expressed in the placenta [Bukovsky et al., 2003]. After ligand
binding, they translocate to the nucleus and bind to ERE sequences which leads
to gene expression regulation. The GPR30 is expressed in the endometrium and
decidua and might play a role in the implantation process [Kolkova et al., 2010].
Through this membrane-bound receptor, signalling pathways are activated which
lead to phosphorylation processes.
Plasma E2 concentration during pregnancy is increasing towards term [Al-
brecht and Pepe, 1990]. E2 fulfills varies functions at the maternal-fetal interface
such as regulation of blastocyst development and implantation, regulation of differ-
entiation of cytotrophoblast into syncytiotrophoblast, remodeling of uterine arteries,
modulating the release of MIF which is involved in the immune response, modulat-
ing the Th1-type and Th2-type cells (inhibition of Th1 cytokine and stimulation
of Th2 cytokine production), and regulation of placental hormone production like
leptin which is an important factor in placentation and fetal growth [Seshagiri et al.,
2009; Cronier et al., 1999; Albrecht and Pepe, 2010; Ietta et al., 2010; Salem, 2004;
Gambino et al., 2010].
1.2.8 Immunological Processes during Pregnancy
Cytokines are mediator molecules in inflammatory processes, but in the feto-maternal
unit they also play important roles in regulating processes such as uterine receptivity,
implantation, placentation, fetal immunotolerance, uterine expansion and prepara-
tion for labour. Thus, cytokines not only play roles in inflammation, they are also
involved in regulating physiological processes [Blank et al., 2008]. Deregulation of
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cytokines is associated with several diseases such as miscarriage, pre-term labor and
pre-eclampsia [Orsi and Tribe, 2008].
Cytokines can be divided into two groups: (1) IL-1, IL-2, IL-6, IL-12, IL-15,
IL-18, IFN-γ and TNF-α which belong to the pro-inflammatory cytokines involved
in Th1 responses (cell-mediated immunity) and (2) IL-4, IL-5, IL-10, IL-13 and
GM-CSF (granulocyte-macrophage colony-stimulating factor) which belong to the
anti-inflammatory cytokines involved in Th2 responses (humoral immunity) [Chal-
lis et al., 2009]. During pregnancy cytokines are produced by the placenta [Bowen
et al., 2002]. Pregnancy is characterized by a predominance of Th2 cytokines (= Th2
phenomenon) which is important in preventing aberrant inflammation processes and
allograft rejection of the fetus [Wegmann et al., 1993]. Alterations in this Th2 shift
are associated with adverse pregnancy outcome and preterm delivery (Figure 1.16).
Figure 1.16: Th2 phenomenon during pregnancy. Balance of Th1 and Th2
cytokines during pregnancy is shifted towards a predominance of Th2 cytokines.
Adapted from Challis et al. [2009].
1.2.8.1 Cytokines involved in Pregnancy-related Processes
In the first trimester of pregnancy, EVTs invade the maternal spiral arteries (Chap-
ter 1.2.4). During this invasion, an extensive remodelling of maternal spiral arteries
occurs, a process in which the matrix-metalloproteinases (MMPs) play a key role
[Zhou et al., 2003]. Important in this process is the cytokine IL-1β as it increases
the trophoblast MMP-9 expression and activity [Librach et al., 1994]. Also, the cy-
tokines TNF-α, IL-1α, and M-CSF (macrophage colony-stimulating factor) increase
MMP-9, whereas TGF-β leads to its inhibition [Meisser et al., 1999].
At the end of pregnancy, the cervical ripening and initiation of myome-
trial contractions during the parturition process are also regulated by cytokines
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(Figure 1.17). Sennstro¨m et al. [2000] observed an increase in IL-6, IL-8 and G-
CSF (granulocyte-CSF) during the cervial ripening process. And IL-1 increases the
prostaglandin E2 (PGE2) expression in myometrial cells which is important for my-
ometrial contraction [Todd et al., 1996; Olson, 2003]. MMPs are also involved in
the parturition process as they are able to remodel the extracellular matrix. The
concentration of MMP-9 is elevated in placental and fetal membranes during labour
[Xu et al., 2002].
Figure 1.17: Involvement of cytokines in parturition. Stimulation of TLRs and
secretion of pro-inflammatory cytokines are involved in the onset of the parturition
process. Adapted from Challis et al. [2009].
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Functions of TNF-α during Pregnancy
The pro-inflammatory cytokine TNF-α has been observed in the syncytiotrophoblast,
decidual and epithelial cells in maternal tissue during the first trimester as well as
in syncytiotrophoblast, villous stromal cells and decidual cells in term placentas
[Chen et al., 1991]. During the first trimester TNF-α inhibits trophoblast migration
[Bauer et al., 2004; Otun et al., 2011]. Another role of TNF-α in the placenta is its
involvement in trophoblast turnover and renewal [Yui et al., 1994]. Diseases such as
spontanous abortion, pre-term labour and pre-eclampsia are associated with a shift
to Th1 cytokines including TNF-α [Shaarawy and Nagui, 1997; Sadowsky et al.,
2006; Sharma et al., 2007].
1.2.8.2 Fetal Immunotolerance
Several maternal immune cells are present in the pregnant uterus such as uterine
natural killer cells (uNKs), macrophages, dendritic cells (DCs) and regulatory T cells
(Tregs) [Bulmer et al., 2010]. Since the embryo and fetus are semiallogeneic tissues,
it is surprising that no rejection takes place. On the contrary, an active maternal
immunological response is observed which establishes a milieu in the uterus in which
the fetus is tolerated.
Important in this process of tolerance are several maternal immune cells.
Macrophages are the second most abundant group of immune cells in the decidua
[Bulmer and Johnson, 1984] and they are involved in phagocytosis of cell debris,
immunosuppression and preventing maternal T lymphocyte activation [Abrahams
et al., 2004; Nagamatsu and Schust, 2010; Heikkinen et al., 2003]. They also have
an immunosuppressive character producing the anti-inflammatory cytokine IL-10
[McIntire et al., 2008]. Furthermore, dendritic cells (DCs) at the interface between
mother and fetus are tolerogenic and instead of presenting antigens their function
is to expand a regulatory T cells subpopulation (Treg) [Blois et al., 2004, 2007;
Amodio et al., 2013; Carosella et al., 2011]. The Tregs (CD25+/CD4+/FoxP3+) are
extremely important in the maternal tolerance of the fetus and in the maintenance
of a successful pregnancy as a decreased number of Tregs has been observed in
miscarriages [Heikkinen et al., 2004; Saito et al., 2005; Jin et al., 2009; Winger
and Reed, 2011]. Furthermore important for the maternal immunotolerance is that
trophoblast cells do not express classical HLA class Ia and class II antigens on
their surface like other eukaryotic cells, instead they express HLA-G proteins which
contribute to the immunotolerance in several ways [Hunt et al., 2005].
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1.3 Stress during Pregnancy
A successful placentation process is very important for the optimal development of
the fetus. Stressors can disrupt the placentation processes of placental growth, dif-
ferentiation and adaptation. If components of the placentation process fail and lead
to placental insufficiency, development of the fetus can be impaired, for example
placenta-related diseases such as pre-eclampsia (Chapter 1.3.1.1) and intrauterine
growth restriction (IUGR) (Chapter 1.3.1.2) can occur. Stress, which can occur
in many different forms such as maternal malnutrition, maternal pre-conditions
(obesity, diabetes) (Chapter 1.3.2), placental infection as physical stress, but also
psychological stress can have adverse effects on the placentation process. Also glu-
cocorticoids are involved in placental pathologies and in the so-called process of fetal
programming (Chapter 1.3.3).
1.3.1 Placenta-related Diseases
1.3.1.1 Pre-eclampsia
Pre-eclampsia is a common complication with an incidence of 2-8% of pregnancies
[Steegers et al., 2010]. In 75% of the cases, the disease develops at the end of the
pregnancy with a mild phenotype. However, pre-eclampsia causes maternal and
perinatal morbidity and mortality, including maternal renal or liver failure, stroke,
fetal growth restriction, preterm delivery, hypoxic injury, and death [Duley, 2009].
The clinical criteria are new hypertension (diastolic blood pressure of ≥ 90 mm Hg)
and proteinurea (≥ 300 mg in 24 h) at or after 20 weeks of gestation [Milne et al.,
2005]. Pre-eclampsia can develop into the more severe forms of the HELLP (hemol-
ysis, elevated liver enzymes, and low platelets) syndrome and eclampsia [Aloizos
et al., 2013; Douglas and Redman, 1994].
In pre-term pre-eclampsia the placental weight is decreased, whereas in term
pre-eclampsia its weight shows inconsistent and variable changes (U-shaped distri-
bution) [Dahlstrøm et al., 2008]. In severe pre-eclampsia, placentas are characterized
by placental poor perfusion and insufficiency which can have detrimental effects on
fetal development. Specifically, the invasion of the extravillous trophoblasts (EVTs)
and the subsequent remodelling of the maternal spiral arteries is impaired resulting
in high resistance vessels with less blood supply [Meekins et al., 1994; Matijevic
and Johnston, 1999; Naicker et al., 2003]. Consequences of altered invasion and
blood flow are elevated levels of oxidative stress, hypoxia and endothelial dysfunc-
tion [Roberts et al., 1991a,b]. Further hallmarks of pre-eclamptic placentas are poor
trophoblastic differentiation, endothelial damage, necrosis and hypoxic lesions [Red-
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line and Patterson, 1995; Stanek and Weng, 2007]. Also involved in the pathology
of pre-eclampsia is an excessive maternal inflammatory response [Redman et al.,
1999].
At the molecular level, several abnormalities can be observed in maternal
circulation of pre-eclamptic patients and in pre-eclamptic placentas. The expression
of factors involved in angiogenesis have been shown to be altered in pre-eclampsia.
The proangiogenic placental growth factor (PlGF) is decreased in women with pre-
eclampsia, whereas antiangiogenic factors such as sVEGFR-1 (soluble vascular en-
dothelial growth factor receptor-1, synonym is sFlt-1) and sEng (soluble endoglin)
are increased [Koga et al., 2003; Levine et al., 2006; Romero et al., 2008; Gu et al.,
2008]. With regards to the maternal inflammatory response, an increased activa-
tion of NFκB and elevated levels of cytokines such as TNF-α have been observed in
women with pre-eclampsia [Luppi et al., 2006; Conrad et al., 1998]. TNF-α is of spe-
cial interest as it is known to be involved in endothelial activation and dysfunction
which is a hallmark of pre-eclampsia [Pober and Cotran, 1990]. Endothelial dysfunc-
tion is detected by higher levels of marker molecules of endothelial activation such
as thrombomodulin, PAI-1, von Willebrand factor, and fibronectin in pre-eclamptic
women [Deng et al., 1994; Shaarawy and Didy, 1996].
In the pre-eclamptic placenta, several ultrastructural changes can be ob-
served. A decreased expression of Syncytin-1 and -2 is shown by several groups
[Knerr et al., 2002; Chen et al., 2006; Langbein et al., 2008; Vargas et al., 2011].
Apoptosis is increased in trophoblasts from pre-eclamptic placentas, specifically an
increase in activated caspase-3, elevated M30 staining (detects cleaved cytokeratin-
18), and a decreased expression of the anti-apoptotic Bcl-2 have been shown in
pre-eclamptic placentas [Aban et al., 2004; Austgulen et al., 2004; Ishihara et al.,
2002; Longtine et al., 2012]. Furthermore, expression of placental 11β-HSD2 has
been shown to be reduced in pre-eclampsia [Causevic and Mohaupt, 2007].
1.3.1.2 Intrauterine Growth Restriction
Intrauterine growth restriction (IUGR) is a complication of pregnancy whereby the
fetus does not reach its genetically pre-determined growth potential due to a patho-
logical cause. IUGR is different from small-for-gestational age (SGA) whereby the
fetus’s weight is less than the 10th percentile for gestational age [Battaglia and
Lubchenco, 1967], but no obstetric complications are observed. A better predictor
for perinatal morbidity and mortality is a fetal weight less than the 3rd percentile
for their gestational age according to McIntire et al. [1999]. The incidence of IUGR
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is 3-7% [Romo et al., 2009]. In addition to the increased perinatal morbidity and
mortality in IUGR [Bernstein et al., 2000; Gilbert and Danielsen, 2003], the fetus is
predisposed for developing certain diseases in its adult life (see chapter 1.3.3).
IUGR can occur due to genetic causes such as aneuploidies or due to en-
vironmental causes such as viral infection, drugs including smoking, and placental
disorders such as pre-eclampsia [Maulik, 2006; Longo et al., 2014; Mund et al., 2013].
The placenta from IUGR pregnancies is characterized by a decreased weight,
a greater thickness, ischemic thrombotic lesions, and excessive tissue injury such
as fibrinoid depositions [Teasdale, 1984; Nordenvall et al., 1991; Krebs et al., 1996;
Macara et al., 1996]. Furthermore, a decrease in vascularization and in syncytiotro-
phoblast surface area is observed in IUGR placentas [Chen et al., 2002; Junaid et al.,
2014; Teasdale and Jean-Jacques, 1988]. As in pre-eclampsia, a placental malperfu-
sion because of an inadequate spiral arterie remodeling by trophoblasts is observed
in IUGR [Lyall et al., 2013]. This leads to the phenomena of hypoxia, re-oxygenation
and oxidative stress within the placental tissue [Takagi et al., 2004; Kimura et al.,
2013].
At the molecular level, abnormalities in placentas from IUGR pregnancies
have been identified. Defects in placental transport function in IUGR have been
observed, namely a decreased activity of the System A amino acid transporter and
the taurine transporter as well as a decreased placental transport of leucin and lysin
which leads to nutrient restriction of the fetus [Norberg et al., 1998; Roos et al.,
2004; Jansson et al., 1998]. Potentially because of ER stress placental translation is
inhibited and the AKT-mTOR (Protein kinase B-mammalian target of rapamycin)
pathway, which is involved in the proliferation and cell growth regulation, is impaired
in IUGR placentas [Yung et al., 2008; Roos et al., 2007]. Possibly the insulin-like
growth factor (IGF) axis is also involved in the pathogenesis of IUGR as a reduced
expression of IGFs has been detected in IUGR placentas [Randhawa, 2008]. Re-
garding cell turnover, enhanced apoptosis appears to be present in IUGR placentas
[Smith et al., 1997a; Ishihara et al., 2002; Crocker et al., 2003]. For example, Levy
et al. [2002] detected an elevated expression of the pro-apoptotic molecule p53 in
growth-restricted placentas and Endo et al. [2005] observed an increased expression
of caspase-3 in IUGR placentas. Also the differentiation process of cytotrophoblasts
might be impaired as Ruebner et al. [2010] showed a decreased expression of the
fusogenes Syncytin-1 and -2 and of the MFSD2 receptor (receptor for Syncytin-2)
in IUGR placentas. Moreover, placental 11β-HSD2 expression has been shown to
be decreased in IUGR [Shams et al., 1998; McTernan et al., 2001; Dy et al., 2008;
Bo¨rzso¨nyi et al., 2012].
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1.3.2 Effects of Maternal Pathologies on Placentation
1.3.2.1 Diabetes
Diabetes during pregnancy can be pre-existing (diabetes mellitus type 1 and 2
(T1DM and T2DM) = pregestational diabetes (PGD)) or can be newly developed as
gestational diabetes mellitus (GDM). Diabetes can cause several complications dur-
ing pregnancy, especially when it is not well treated. Abnormalities in the placenta
are observed as well as programming effects on the offspring can occur (Chapter
1.3.3) [Daskalakis et al., 2008; Dabelea et al., 2000; Boney et al., 2005; Yogev and
Visser, 2009]. Furthermore, fetal outcomes tend to be characterized by macrosomia
(birth weight above the 90th percentile) and excessive fetal fat accumulation and
PGD leads to a higher risk of pre-term delivery (depending on the level of glycemic
control, prepregnancy BMI, weight gain during pregnancy and the presence of pre-
eclampsia) [He et al., 2015; Desoye and van Poppel, 2015; Melamed et al., 2008].
Diabetes leads to a hyperglycemic environment which is different from the
maternal and fetal environment during normal healthy pregnancy [Taricco et al.,
2009]. Also the pro-inflammatory nature of diabetes might alter placental and fetal
development [Radaelli et al., 2003]. In case of PGD, the altered environment is
present from the start of the pregnancy, which might already affect early stages of
placental development, whereas GDM is developing during pregnancy and therefore
might affect placental growth and function to later time points. Both types of
diabetes lead to a hyperglycemic-induced hyperinsulinemia in the placental and
fetal environment [Desoye and van Poppel, 2015].
The placenta in diabetes is characterized by an increase in weight, an enlarge-
ment of the surface, increased cytotrophoblast number, more blood vessels, larger
calibre of blood vessels and a thicker basement membrane [Taricco et al., 2003;
Jirkovska´ et al., 2002, 2012; Younes et al., 1996]. The hypervascularization and
placental capillary dilatation might be evoked by fetal hypoxia. The oxygen supply
from the mother to the fetus is reduced because of the maternal hyperglycemia and
an elevated level of HbA1c which has a higher oxygen affinity and this leads to fetal
hypoxia [Madazli et al., 2008; Teramo, 2010]. Additionally, the fetus in diabetes
has a higher oxygen demand because of the hyperglycemia-induced higher aerobic
metabolism which results ultimately in fetal hypoxia. Further, oxidative and nitra-
tive stress is elevated in diabetic placentas [Scho¨nfelder et al., 1996; Coughlan et al.,
2004; Lappas et al., 2011].
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1.3.2.2 Obesity
The prevalence of obesity has increased over the past years and an association be-
tween maternal overweight/obesity and adverse pregnancy outcomes has been ob-
served [Ogden et al., 2006; Yogev and Visser, 2009]. Fetal outcomes of obese moth-
ers show complications such as large-for-gestational-age (LGA) newborns, stillbirths
and also programming effects for developing obesity, diabetes and the metabolic syn-
drome in later life [Baeten et al., 2001; Jensen et al., 2003; Ehrenberg et al., 2004;
Cnattingius et al., 1998; Nohr et al., 2005; Salihu et al., 2007; Aune et al., 2014;
Boney et al., 2005]. Also the obese mothers are at higher risk for developing hyper-
tension, pre-eclampsia, and gestational diabetes during pregnancy [Galtier-Dereure
et al., 2000; Roberts et al., 2011a; Stupin and Arabin, 2014].
Obesity is characterized by a chronic systemic low-grade inflammatory milieu
(= increased levels of pro-inflammatory cytokines such IL-6, TNF-α and C-reactive
protein in the circulation and infiltration of macrophages into white adipose tis-
sue) [Cancello and Cle´ment, 2006; Clement and Langin, 2007]. Also the placenta
is exposed to an environment characterized by increased systemic pro-inflammatory
cytokines (IL-6, C-reactive protein) and extensive placental macrophage accumu-
lation with local production of pro-inflammatory cytokines (IL-6, TNF-α, IL-1) in
obese mothers [Ramsay et al., 2002; Challier et al., 2008]. The placenta expresses
elevated levels of IL-1β, IL-8 and MCP-1 (monocyte chemoattractant protein-1) in
maternal obesity [Roberts et al., 2011b].
Alterations in placental phenotype from overweight/obese mothers have not
been extensively studied yet. However, some interesting placental alterations on
molecular level such as impairment of mitochondrial function leading to increased
ROS and decreased ATP levels have been observed in placentae from obese mothers
which might compromise placental function [Mele et al., 2014]. Maternal obesity
is associated with activation of p38-MAPK and STAT3 signalling pathways in the
placenta possible evoked by the increased pro-inflammatory milieu [Aye et al., 2014].
The increased levels of IL-1β in placentae from obese mothers might cause impaired
placental insulin signalling [Aye et al., 2013] which could then possibly affect placen-
tal hormone production and transport of amino acids [Ren and Braunstein, 1991;
Aye et al., 2013]. Moreover, Saben et al. [2014] identified different mRNA expres-
sion of genes which are involved in hormone and cytokine activity, lipid metabolism
and angiogenesis in the placenta from obese mothers (gene ontology analysis). They
further detected activation of the inflammatory NFκB pathway in placentae from
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obese mothers [Saben et al., 2014], whereas this NFκB activation in placentae from
obese mothers was not confirmed in a study by Aye et al. [2014].
1.3.3 Fetal Programming
Fetal programming is the process of fetal adaptive metabolic changes during fetal
development which results in lifelong effects, i.e. these individuals are predisposed
to develop metabolic and cardiovascular diseases (for example, obesity, diabetes,
hypertension) as well as anxiety-related disorders [Reynolds, 2013b]. Figure 1.18
shows a summary of the fetal programming which demonstrates the central role of
glucocorticoids (cortisol in humans) in this process. There are mainly two causes
for fetal overexposure to glucocorticoids: activation of the maternal HPA axis by
nutritional or other stressful stimuli or a reduced placental 11β-HSD2 activity. Also,
administration of synthetic glucocorticoids (by risk of pre-term delivery [Smrcek
et al., 2005]) can lead to fetal overexposure to glucocorticoids.
Undernutrition plays an important role in fetal programming demonstrated
by studies of the Dutch famine in 1944/1945 [Ravelli et al., 1998; Roseboom et al.,
2000, 2001, 2006]. The concept that malnutrition is the cause of fetal program-
ming is known as the Barker Hypothesis [Barker, 1998]. Possibly, this hypothesis is
linked with the hypothesis that fetal overexposure to glucocorticoids underlie fetal
programming [Edwards et al., 1993] as Gardner et al. [1997] and Langley-Evans
[1997] showed that maternal glucocorticoids are involved in the low protein diet-
induced programming effects. Also other stressful stimuli including psychological
stress are associated with low birth weight and neurodevelopmental alterations in
the offspring [Buitelaar et al., 2003; Lipkind et al., 2010; Entringer et al., 2010].
Also, the enzyme 11β-HSD2 plays an important role in the fetal programming
process. It has been discovered by Benediktsson et al. [1993] that low birth weight
is associated with a reduced activity of 11β-HSD2 in rat. Many further studies in
humans and animals confirmed the correlation between birth weight and 11β-HSD2
activity and could demonstrate that a reduced expression of 11β-HSD2 leads to a
predisposition for developing various diseases in later life [McTernan et al., 2001;
Cottrell and Seckl, 2009].
There is also the possibility of an indirect effect of glucocorticoids on fetal
development and programming. Excess glucocorticoids within the placental tissue
might alter placental growth and function which then causes or contributes to fetal
growth and programming [Braun et al., 2013].
Cortisol is important during fetal development because it is involved in the
preparation of the fetus from intra- to extrauterine life, specifically it is involved
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in the maturation of lung, liver, kidney and gut [Fowden et al., 1998]. However,
excess cortisol levels alter fetal tissue maturation and gene transcription and likely
epigenetic modification of genes take place in the programming process [Moisiadis
and Matthews, 2014]. Also, during fetal development, excess glucocorticoids have
been shown to cause alterations of the fetal HPA axis which persists throughout
life and this is involved in the increased susceptibility of the individuals to develop
metabolic, cardiovascular and psychiatric disorders in later life [Reynolds, 2013a].
Figure 1.18: Diagram of Fetal Programming. Fetal overexposure to glucocorti-
coids due to higher maternal cortisol levels or to a reduction of placental 11β-HSD2
activity can result in fetal programming which leads to a predisposition of the indi-
viduals to develop metabolic, cardiovascular and anxiety-related disorders in later
life. Adapted from Reynolds [2013b].
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1.4 Thesis Aims
In this thesis, I wanted to investigate trophoblast molecular and cellular responses
(placental cell turnover, differentiation, apoptosis, hormone production and expres-
sion of molecules involved in the stress response and glucocorticoid action molecular
machinery) to hormones and mechanisms controlling placental adaptation processes
and stress responses (CRH, glucocorticoids and the enzyme 11β-HSD2).
In detail, aims of this study were:
1. Characterization of the placental explant tissue model to study CRH effects
on placenta biology processes such as proliferation, apoptosis and hormone
production
2. Elucidation of the BeWo trophoblast differentiation process and effects on cell
fusion and endocrine capacity, cell viability and apoptosis, as well as expression
of molecules involved in the cellular stress response and local glucocorticoid
action such as CRH and its receptors, gluco- and mineralocorticoid receptor
and the enzyme 11β-HSD2
3. Characterization of potential novel roles of the placental enzyme 11β-HSD2 in
BeWo cell biology besides its role in cortisol inactivation
4. Investigation of BeWo cell glucocorticoid responsiveness
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Chapter 2
Material and Methods
2.1 Cell Culture
2.1.1 Placental Explant Culture
Medium for Placental Explant Culture
CMRL-1066 (10X, Gibco, Life Technologies) was supplemented as follows to make
1 L of complete CMRL-1066 medium: 100 mL of 10X CMRL-1066 concentrate
was diluted with 800 mL of MilliQ water. 2.2 g NaHCO3 (Sigma-Aldrich), 100 mg
streptomycin sulphate (Sigma-Aldrich), 60 mg Penicillin G (1000000 units, Sigma-
ALdrich), 100 µg hydrocortisone (Sigma-Aldrich), 1 mg insulin (Sigma-Aldrich),
100 µg retinol acetate (Sigma-Aldrich), 100 mg L-glutamine (Sigma-Aldrich), and
50 mL FBS were added. Medium was filled up with MilliQ water to 1 L, pH was
adjusted to 7.4, and medium was sterile filtered. For end concentrations, see table
2.1.
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Ingredient End concentration
Streptomycin Sulphate 100 µg/mL
Penicillin G 100 IU/mL
Hydrocortisone 0.1 µg/mL
Insulin 1 µg/mL
Retinol Acetate 0.1 µg/mL
L-Glutamine 100 µg/mL
FBS 5%
Table 2.1: End concentrations of supplements added to CMRL-1066 cell
culture medium for placental explant culture.
Placental Explant Culture
Placentae were obtained from healthy individuals by caesarean section after written
consent and the project had ethical approval by local LREC. Demographic data of
the study subjects were not collected as our study design did not require these data.
The design of the study was to conduct different treatments (CRH, LPS) on placental
explants from healthy individuals to test whether these different treatments evoke
different responses by the explant tissue. This is similar to studies from Audette
et al. [2010], Cindrova-Davies et al. [2007], Novembri et al. [2011], Polliotti et al.
[1990] and Sima´n et al. [2001] in which no demographics are presented. (In contrast
to this are studies that compare placental explants from healthy patients to placental
explants from patients with pregnancy-related pathologies such as pre-eclampsia or
IUGR and in these studies demographics of the study subjects are provided [Crocker
et al., 2004; Matos et al., 2014; Smith et al., 1998b; Unek et al., 2014].)
Placentae were washed 8-10 times with sterile PBS to remove maternal blood.
Chunks were cut out and washed again once in PBS, and twice in complete CMRL-
1066 medium. In a Petri dish containing complete CMRL-1066 medium, small
fragments (around 3 mm) were cut and 3 of these fragments were cultured in one well
of a 12-well Netwell plate (15 mm Netwells, membrane mesh size 74 µm, Corning,
Appleton Woods). Wells were filled with 1.5 mL complete CMRL-1066 medium (see
above 2.1.1 for details). In all experiments, medium with the appropriate stimuli
was replaced every 24 h. Placental explants were cultured for up to 6 days in an
incubator (37◦C, 5% CO2, 20% O2).
For hormone measurement experiments, hormone concentrations were deter-
mined (Chapter 2.6 for ELISA details) every 24 h in the cell culture supernatant. On
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the last day, placental fragments were washed with PBS, then frozen at -80◦C and
protein concentration was determined at a later time point. After thawing, explant
fragments were centrifuged at maximum speed for 20 s to remove PBS residue. 50
µL 0.3 M sodium hydroxide was added and incubated for 5 min in a 70◦C heating
block, vortexing several times. The protein concentration was determined using the
BCA assay (Chapter 2.4.2 for details) after adding 450 µL H2O.
For immunohistochemistry (IHC) experiments, on the last day placental ex-
plants were washed with PBS and put into formalin (Chapter 2.5.2 for immunohis-
tochemistry protocol). Figure 2.1 shows an example of an IHC of placental explant
cultured for five days and stained with haematoxylin.
Figure 2.1: IHC of placental explant. Haematoxylin staining of placental ex-
plant. Blank arrows show the syncytiotrophoblast and red arrows show the cytotro-
phoblast cells.
For mRNA expression experiments, on the last day placental explants were
washed with PBS, then snap frozen at -80◦C and mRNA was isolated at a later time
point. For mRNA isolation, explants were homogenized using an autoclaved plastic
pestle before 500 µL mRNA lysis buffer from GenElute Mammalian Total RNA
Miniprep Kit (Sigma-Aldrich) was added and the protocol from the kit manufacturer
was followed. See Chapter 2.3 for details of mRNA quantification.
For protein expression experiments, on the last day placental explants were
washed with PBS, then snap frozen at -80◦C and protein lysates were prepared at
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a later time point. For lysate preparation, explants were homogenized using an
autoclaved plastic pestle and 500 µL RIPA buffer (Santa Cruz) was added before
protein concentration was determined using the BCA assay (Thermo Scientific) and
Western blot was performed (see Chapter 2.4 for details for protein quantification).
2.1.2 Cell Line Culture
Medium for Cell Line Culture
BeWo cells were cultured in Ham’s F12K (Kaighn’s) medium (Life Technologies)
supplemented with 10% heat-inactivated BenchMark
TM
FBS (Triple 0.1 µm Sterile-
Filtered, Gemini Bio-Products) and 1% Penicillin Streptomycin (5000 U/mL Peni-
cillin, 5000 µg/mL Streptomycin, Life Technologies) (= complete F12K medium).
HeLa and HEK-293 cells were cultured in DMEM high glucose medium (Life
Technologies) supplemented with 10% heat-inactivated BenchMark
TM
FBS (Triple
0.1 µm Sterile-Filtered, Gemini Bio-Products) and 1% Penicillin Streptomycin (5000
U/mL Penicillin, 5000 µg/mL Streptomycin, Life Technologies) (= complete DMEM
medium).
BeWo Cell Culture
BeWo cells (ATCC R© CCL-98TM) were removed from liquid nitrogen, warmed in a
water bath for 2-3 min until thawed, diluted with fresh complete F12K medium,
transferred in a cell culture flask, and incubated in an incubator (37◦C, 5% CO2,
20% O2) for 24 h. Then, the medium was changed and the cells were incubated
further for 3-4 additional days before splitting.
To split BeWo cells, medium was aspirated and the cells were washed once
with PBS before incubating them with 0.05% Trypsin-EDTA (Gibco R©, Life Tech-
nologies) for 1-2 min in the incubator. Fresh complete F12K medium was added
to the trypsinized cells and 1/6 of the cell suspension was transferred in a new cell
culture flask. The cells were split every 3-4 days and experiments were performed
with cells of less than 30 passages.
For cell freezing, cells were centrifuged after trypsinization for 5 min at 125g.
Medium was aspirated, cells were diluted in 5-10% DMSO in complete F12K medium
and placed in a cryofreezing container (Fisher Scientific) in -80◦C for 24 h before
storing them in liquid nitrogen.
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HEK-293 and HeLa Cell Culture
HEK-293 (ATCC R© CRL-1573TM) and HeLa (ATCC R© CCL-2TM) cells were taken
out of liquid nitrogen, warmed in a water bath for 2-3 min until thawed, diluted
with 10 mL fresh complete DMEM, and centrifuged for 5 min at 125g. Supernatant
was aspirated, cell pellet was resuspended in fresh complete DMEM, cells were
transferred in a new cell culture flask, and incubated in an incubator (37◦C, 5%
CO2, 20% O2) for 3-4 days before splitting.
To split the HEK-293 and HeLa cells, medium was aspirated and the cells
were washed once with PBS before incubating them with 0.05% Trypsin-EDTA
(Gibco R©, Life Technologies) for 1 min at room temperature (HEK-293) or 2 min
in the incubator (HeLa). Ten mL of fresh complete DMEM medium was added to
the trypsinized cells and they were centrifuged for 5 min at 125g. The supernatant
was aspirated, the cell pellet was resuspended in fresh complete DMEM, 1/6 of
the cell suspension was transferred in a new cell culture flask, and incubated in a
CO2 incubator (37
◦C, 5% CO2, 20% O2). The cells were split every 3-4 days and
experiments were performed with cells of less than 30 passages.
For cell freezing, cells were centrifuged after trypsinization for 5 min at 125g.
Medium was aspirated, cells were diluted in 5-10% DMSO in complete DMEM
medium and placed in a cryofreezing container (Fisher Scientific) in -80◦C for 24 h
before storing them in liquid nitrogen.
2.2 Treatments
2.2.1 Preparation of Stock Solutions and End Concentrations
CRH Treatment
CRH (Bachem or Calbiochem) was dissolved in 10% acetic acid to make a stock
solution of 1 mM. BeWo cells and placental explants were treated with 0.1 or 1
µM CRH for various time points depending on the experimental protocol. These
concentrations were chosen because of successful experiments performed with these
concentrations by members of our group.
LPS Treatment
LPS (from Escherichia coli, Sigma-Aldrich) was dissolved in CMRL-1066 medium to
make a stock solution of 2 mg/mL. Placental explants were treated with 10 µg/mL
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for 4 to 6 days depending on the experimental protocol (medium was changed every
24 h). This concentration was chosen because of successful experiments by Okada
et al. [1997], Uh et al. [2008], Torricelli et al. [2011] and by members of our group.
Forskolin Treatment
Forskolin (from Coleus forskohlii, EMD Millipore) was dissolved in DMSO to make
a stock solution of 100 mM. BeWo cells were treated with 100 µM forskolin at a
confluency between 60 and 80% for 24 or 48 h, depending on the experimental pro-
tocol. This concentration was chosen because of successful experiments by Wice
et al. [1990], Delidaki et al. [2011] and by members of our group.
Dexamethasone Treatment
Dexamethasone (Sigma-Aldrich) was diluted in 100% ethanol to make a stock so-
lution of 10−2 M. BeWo, HEK 293 and HeLa cells were treated with 1 µM dex-
amethasone for various time points depending on the experimental protocol. This
concentration was chosen because of successful experiments by Mark and Waddell
[2006] and by members of the NICHD-based group.
Hydrocortisone (= Cortisol) Treatment
Hydrocortisone solution (50 µM, sterile-filtered, BioXtra, suitable for cell culture,
Sigma-Aldrich) was used at various concentrations (100 nM - 2 µM) in BeWo cell
culture depending on the experimental protocol.
Kinase Inhibitor Treatments
MAPK (p38 and ERK1/2) inhibitors SB202190 (In solution (DMSO), Calbiochem),
UO126 (stock concentration was 10 mM in DMSO, Calbiochem) as well as PI3K
inhibitor Wortmannin (In solution (DMSO), Calbiochem) were used. BeWo cells
were pre-treated with the inhibitors SB202190, UO126 and Wortmannin for 24 h
at concentrations of 2.5 µM, 10 µM and 300 nM, respectively. BeWo cells were
subsequently treated depending on the experimental protocol in the presence of the
inhibitors. These concentrations were chosen based on the instructions in the chem-
ical manuals provided by the companies and because of successful experiments by
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members of our group.
Staurosporine Treatment
Staurosporine (from Streptomyces sp, Sigma-Aldrich) was dissolved in DMSO to
make a stock solution of 2 mM. Placental explants were treated with 10 µM stau-
rosporine to induce apoptosis (= positive control for M30-staining and MSD Multi-
plex ELISA). BeWo cells were treated with 1 µM staurosporine (= positive control
for ApoONE R© Homogeneous Caspase-3/7 Assay). These concentrations were cho-
sen based on the information provided by the manufacturer’s website and because
of successful experiments by Jacobsen et al. [1996].
2.2.2 Transfection
2.2.2.1 siRNA Transfection
The siRNA (Control-siRNA A, 11β-HSD2 siRNA from Santa Cruz) was purchased
as lyophilized powder and dissolved by adding the appropriate amount of RNase-free
water. The dissolved chemicals were vortexed, aliquoted and stored at -20◦C.
To transfect BeWo cells with siRNA, cells were seeded in 24- or 6-well plates and
grown until they reached a confluency of 50-60%. On the day of transfection, siRNA
was diluted in Opti-Mem, transfection reagent (Attractene, Qiagen) was added and
the tube was vortexed briefly. During an incubation time of 10-15 min at room
temperature, the medium of the cells was aspirated and replaced with Opti-Mem
(Life Technologies) containing 5% FBS (Triple 0.1 µm Sterile-Filtered, Gemini Bio-
Products). The mixture of siRNA and transfection reagent was added to the cells
and the culture plate was rocked gently (see table 2.2 for volumes and concentra-
tions).
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well- Volume Volume siRNA Attrac-
plate 5% FBS in Opti-MEM nM tene
Opti-MEM in µL in µL
in mL
24 0.5 50 15 1.5
6 1.5 100 15 4.5
Table 2.2: siRNA Transfection. Volumes and concentrations of siRNA and trans-
fection reagent were chosen based on the manufacturer’s instructions and group
member’s expertise.
2.2.2.2 DNA-Vector Transfection
DNA-Vectors
The pMMTV-luc DNA-vector, which expresses the firefly-luciferase under the con-
trol of a mouse mammary tumor virus (MMTV) promoter with four glucocorticoid
response elements (GREs) (Figure 2.2, Guido et al. [1996]), was a gift from G.L.
Hager (National Cancer Institute, MD, USA). The pRShGRα DNA-vector, which
expresses the human GR receptor, contains an RSV (Rous sarcoma virus) pro-
moter (Gigue`re et al. [1986]) and was a gift from Dr. R. M. Evans (Salk Institute,
La Jolla, CA, USA). The pGL4.73-Rluc DNA-vector, which expresses the renilla-
luciferase, contains a Simian virus 40 promoter and was purchased from Promega.
The pGL4.73-Rluc vector was used as an expression control vector in reporter-gene-
assays.
Figure 2.2: Promoter of the MMTV-luc DNA vector. Adapted from Guido
et al. [1996].
DNA-Vector Transfection Protocol
To transfect BeWo, HEK 293, or HeLa cells with DNA-vectors, cells were seeded
in 12- or 6-well plates. On the day of transfection, DNA-vectors and Lipofectamine
2000 (Invitrogen, Life Technologies) were diluted in Opti-MEM (Life Technologies)
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seperately before combining them with gentle mixing. During an incubation time of
5 min, medium of the cells was aspirated and replaced with fresh complete medium.
The mixture of DNA-vector and transfection reagent was added to the cells and the
culture plate was rocked gently (see table 2.3 and 2.4 for volumes and concentra-
tions).
For reporter-gene-assays, pMMTV-luc was co-transfected with pGL.4.73-
Rluc with and without pRShGRα in a 12-well plate. After 4 h of transfection,
medium was changed and cells were treated with dexamethasone with and without
forskolin for 4 or 20 h before performing the Dual-Luciferase-Assay (see subchapter
below).
For qRT-PCR experiments, pRShGRα was transfected in a 6-well plate. 4
h after transfection, medium was changed and cells were treated further depending
on the experimental protocol with dexamethasone with and without forskolin for 20
h before extracting mRNA (Chapter 2.3).
well- Volume Volume Volume
plate Opti-MEM medium Lipofectamine
in µL in mL in µL
12 2 x 50 0.5 1.75
6 2 x 150 1 7.5
Table 2.3: DNA Transfection (Volumes). Volumes of Opti-MEM, medium, and
lipofectamine for DNA-transfection experiments were chosen based on the manufac-
turer’s instructions and group member’s expertise.
well- pMMTV Rluc pRShGRα
plate in µg in µg in µg
12 0.25 0.025 ±0.2
6 2
Table 2.4: DNA Transfection (Concentrations). Concentrations of DNA-
vectors for DNA-transfection experiments were chosen based on the manufacturer’s
instructions and group member’s expertise.
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Dual-Luciferase Assay
Measurement of luminescence from luciferase-containing DNA-vectors was performed
using the Dual-Luciferase R© Reporter Assay System (Promega).
After transfection with firefly- and renilla-containing DNA-vectors and subsequent
incubation with glucocorticoids with and without further treatments, cells were once
washed with PBS and lysed with 250 µL (for one well in 12-well plate) 1X Passive
Lysis Buffer (component of the kit) for 25 min, shaken. 20 µL of supernatant was
transferred in one well of a black or white 96-well plate for measurement of lumines-
cence (in relative light units = RLU). Readings were performed with a luminometer.
2.2.3 Treatment Protocols
Figure 2.3 shows the different treatment protocols of cell culture experiments.
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Figure 2.3: Treatment protocols. Experimental procedure of (1) siRNA transfec-
tion in BeWo cells, (2) DNA-vector transfection in BeWo, HEK 293 and HeLa cells
and (3) experiments with inhibitors/CRH to investigate regulation of 11β-HSD2 in
BeWo cells. All protocols start with a 24 to 48 h incubation to allow cells to reach
cell confluency of 50-60%. Then different treatments were carried out according to
the purpose of the experiments.
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2.3 mRNA Quantification
2.3.1 mRNA Isolation
Total RNA was isolated using the GenElute Mammalian Total RNA Miniprep Kit
(Sigma) according to the manufacturer’s instructions. Briefly, 300 µL of lysis buffer
(complemented with 1% 2-mercaptoethanol) per well (6-well plate) were used to lyse
cells (BeWo, HEK293, HeLa). After transferring the lysate to a filtration column
which separates the RNA-containing liquid from cell debris, an equal volume of 70%
ethanol was added to the filtered lysate and vortexed. The lysate/ethanol mixture
was loaded onto a binding column. Several wash steps with Wash buffer 1 and 2
were performed. 30-50 µL of elution buffer were used to elute the mRNA from the
column.
Determination of mRNA (Nanodrop)
The isolated mRNA was quantified by measuring the absorbance at 260 nm using
the Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).
The RNA quality was verified by assessing the A260/280 and the A260/230 ratio
(with the nanodrop) and by performing agarose gel electrophoresis with 1 µg of
mRNA (Figure 2.4). Intact total RNA is represented by two bands (28S and 18S
rRNA) and the ratio of their intensities should be 2:1 (28S rRNA : 18S rRNA).
Figure 2.4: mRNA gel image. First DNA ladder: DNA marker high molecular
weight, second DNA ladder: DNA marker low molecular weight, lane 1-4: 1 µg of
isolated mRNA from BeWo cells (lane 1, 2) and from HEK 293 (lane 3, 4).
2.3.2 cDNA Synthesis of isolated mRNA
Isolated mRNA (400 ng) was reverse transcribed using Taqman R© Reverse Tran-
scription Reagents (Invitrogen
TM
, Life Technologies). Four hundred ng (in 7.2 µL
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of H2O) was incubated with 12.8 µL mix (Table 2.5) for 10 min at 25
◦C, 30 min at
48◦C, and 5 min at 95◦C.
Or 500 ng isolated mRNA was reverse transcribed using reagents from Fer-
mentas in a total volume of 20 µL. Five hundred ng was incubated for 5 min with
1 µL 0.5 µg/µL random hexamers in a volume of 12 µL H2O at 70
◦C before adding
8 µL mix (Table 2.6) and incubating for 1 h at 37◦C followed by 10 min at 70◦C.
Reagent Volume in µL
RT Buffer 10x 2
25 mM Mg Cl2 4.4
dNTP 2.5 mM 4
Hexamer 50 µM 1
Oligo dT 50 µM 0.5
RNase Inhibitor (20 U/µL) 0.4
MultiScribe
TM
RT (50 U/µL) 0.5
Table 2.5: cDNA synthesis of mRNA using Taqman R© Reverse Transcrip-
tion Reagents. Volumes of reagents needed for cDNA synthesis.
Reagent Volume in µL
5x Reaction Buffer 4
10 mM dNTP mix 2
Ribolock RNase Inhibitor (20 U/µL) 1
Revertaid H-Minus-MuLV RT (2000 U/µL) 1
Table 2.6: cDNA synthesis of mRNA using the Fermentas Reagents. Vol-
umes of reagents needed for cDNA synthesis.
2.3.3 Quantitative RT-PCR
2.3.3.1 Taqman R©-based quantitative RT-PCR
Messenger RNA expression of 11β-HSD2, Anxa1, Dusp1, Sync1, Sync2, SGK1,
ATP1A1, GR, and MR (Table 2.7) were quantified using the Taqman-based quan-
titative RT-PCR. 18S rRNA was used as a housekeeping gene. 10 µL of cDNA
dilution was mixed with 11 µL of mastermix (10 µL 2x Taqman R© Gene Expression
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Master Mix (Applied Biosystems R©, Life Technologies) + 1 µL 10x primer) and in-
cubated using the following program: 2 min at 50◦C, 10 min at 95◦C, 40x: 15 s
95◦C + 1 min 60◦C.
Primer Catalog number
11β-HSD2 (HSD11B2) Hs00388669 m1
Sync-1 (ERVW-1) Hs00205893 m1
Sync-2 (ERVFRD-1) Hs01652148 m1
GRα (NR3C1) Hs00353740 m1
MR (NR3C2) Hs01031809 m1
Dusp1 Hs00610256 g1
Anxa1 Hs00167549 m1
SGK1 Hs00985033 g1
ATP1A1 Hs00167556 m1
18S rRNA 4319413E
β-actin (ACTB) 4333762T
GAPDH 4333764T
Table 2.7: Primer for Taqman R© qPCR. Primer were purchased from Life Tech-
nologies.
2.3.3.2 SYBR R© Green-based quantitative RT-PCR
Primer Design
Primer for SYBR R© Green-based quantitative RT-PCR were designed using the pro-
gramme Primer 3 Plus with the following settings: amplicon size = 70-150 bp,
primer size = 18-24 bp, Tm = 55-65
◦C, and GC content = 40-60%. The target
sequence was gained from the PubMed nucleotide or Ensembl database and the
primer specificity was verified by making a BLAST or a BLAT search.
Purification of Primer
Lyophilized powder of primer were resuspended in 300 µL distilled water and cen-
trifuged for 5 min at maximum speed to remove debris. Supernatant was transferred
to a new tube and 6 µL of 5 M NaCl and 600 µL of 100% EtOH were added. After
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vortexing briefly, the samples were stored at -20◦C for 30 min and then centrifuged
for 30 min at 4◦C at maximum speed. Supernatant was aspirated, 500 µL of 70%
EtOH added and centrifuged for 5 min at maximum speed. Supernatant was as-
pirated and pellet was dried. Dry pellet was resuspended in 200 µL of TE and
concentration was measured with the nanodrop. Molarity of the primer solution
was calculated with the following equation:
DNA (pmol/µL = µM) = DNA concentration (ng/µL) x 1000 / Molecular Weight
(MW)
MW = 330 x number of nucleotides
A stock solution of 10 µM was stored at -20◦C.
SYBR R© Green-based quantitative RT-PCR of mRNA
Messenger RNA expression of Per1, Gilz, CRH, CRH-R1, CRH-R2, ASCT2 and
MFSD2 (Table 2.8) were quantified using the SYBR R© Green-based quantitative
PCR. As a housekeeping gene GAPDH, β-actin and RPLP0 mRNA was used. Five
µL of cDNA dilution was mixed with 15 µL of mastermix (10 µL 2x Power SYBR R©
Green PCR Master Mix (Applied Biosystems R©, Life Technologies) + 1 µL 10 µM
primer F + 1 µL 10 µM primer R + 3 µL H2O) and incubated using the following
program: 10 min at 95◦C, 40x: 15 s 95◦C + 1 min 60◦C. In order to confirm a single
PCR product, melting curve analysis has been performed after the amplification of
the PCR product (Figure 2.5).
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Primer Sequence
GAPDH F 5’-GAGTCAACGGATTTGGTCGT-3’
GAPDH R 5’-GACAAGCTTCCCGTTCTCAG-3’
β-actin (ACTB) F 5’-CGGCATCGTCACCAACTG-3’
β-actin (ACTB) R 5’-AAGGTGTGGTGCCAGATTTTCT-3’
RPLP0 F 5’-CAATGGCAGCATCTACAACC-3’
RPLP0 R 5’-TGATGCAACAGTTGGGTAGC-3’
Per1 F 5’-CACTGGCCTGTGTCAAGC-3’
Per1 R 5’-GTGTACTCAGACGTGATGTG-3’
GILZ F 5’-GATGTGGTTTCCGTTAAGC-3’
GILZ R 5’-CTCTCTCACAGCATACATCAG-3’
CRH F 5’-TCCCATCTCCCTGGATCTCAC-3’
CRH R 5’-GTGAGCTTGCTGTGCTAACTGCT-3’
CRH-R1 F 5’-CGCATCCTCATGACCAAGCT-3’
CRH-R1 R 5’-TCACAGCCTTCCTGTACTGAATG-3’
CRH-R2 F 5’-TGCGGAGCATTCGCTGT-3’
CRH-R2 R 5’-TTTCGCAGGATAAAGGTGGTG-3’
ASCT2 F 5’-ACATCCTGGGCTTGGTAGTG-3’
ASCT2 R 5’-GGGCAAAGAGTAAACCCACA-3’
MFSD2 F 5’-CCTTGTTTCCAGGACCTCAA-3’
MFSD2 R 5’-GAAGTAGGCGATTGGCTCAG-3’
Table 2.8: Primer for SYBR R© Green qRT-PCR.
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Figure 2.5: Melting Curves of SYBR Green qRT-PCR Products. Melt-
ing Curves of products of GAPDH, Per1, Gilz, CRH, CRH-R1, CRH-R2, RPLP0,
ASCT2, and MFSD2 are shown, representative graphs are shown.
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2.3.3.3 Analysis of qRT-PCR
The results were analysed with the ∆∆Ct method to calculate the fold mRNA ex-
pression compared to the basal treatment condition. The following equations were
used to calculate the relative quantity (RQ):
∆Ct=Ct(gene of interest)-Ct(housekeeping gene)
∆∆Ct=∆Ct(sample)-∆Ct(control)
RQ=2-∆∆Ct
2.4 Protein Quantification
2.4.1 Preparation of Protein Lysate
At the end of the experiment, medium was aspirated and the cells were washed with
ice-cold PBS before adding RIPA buffer (200 µL in one well of a 6-well plate or 50 µL
in one well of a 24-well plate) supplemented with 10 µL PMSF, 10 µL orthovanadate
and 10 µL protease inhibitor cocktail per mL RIPA buffer (components of the kit).
Protein lysate was transferred in a tube and centrifuged for 10 min (4◦C, maximal
speed). The supernatant was transferred in a new tube and stored at -80◦C.
2.4.2 Measurement of Protein Concentration
Protein concentration of the protein lysates was measured in duplicates using the
BCA Protein Assay Kit (Thermo Scientific) according to manufacturer’s instruc-
tions. Briefly, protein lysate was diluted 1:5 in RIPA buffer, and 25 µL of each
sample was used for the assay. Standard curve samples were diluted in RIPA buffer
according to the manufacturer’s dilution protocol to generate samples with a con-
centration between 25 and -2000 µg/mL BSA. Two hundred µL of working reagent
(component provided by the kit) was added to each well and the microtiter plate
was incubated at 37◦C for 15 min before measuring the absorbance at 590 nm.
With the help of the linear equation for the standard curve (Figure 2.6), the protein
concentration for each sample was calculated.
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Figure 2.6: BSA standard curve. BSA standard (from BCA Protein Assay Kit)
was diluted in RIPA buffer to produce a standard curve with concentrations between
25-2000 µg/mL.
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2.4.3 Laemmli Lysate
Protein samples were appropriately diluted in Laemmli 2x Sample Buffer (Sigma-
Aldrich) to achieve an end concentration of 0.5 µg/µL and incubated at 95◦C in a
heating block for 5 min before cooling the samples on ice and storing them at -20◦C.
2.4.4 Gel Electrophoresis
Gel Preparation
The resolving gel (Table 2.9) was poured between 2 glass plates of the Mini-Protean
III Electrophoresis Cell and was overlaid with distilled water to polymerize within
30 min. The water was removed with Watmann filter paper, the stacking gel (Table
2.9) was poured on top of the resolving gel, a comb was inserted and the gel poly-
merized within 20 min.
Solution components Resolving Gel Stacking Gel
(for 8 gels)
Distilled H2O 9.9 mL 5.8 mL
Tris HCl 1.5 mM pH 8.8 6.25 mL -
Tris HCl 0.5 mM pH 6.8 - 2.5 mL
Protogel 8.35 mL 1.5 mL
10% SDS 250 µL 100 µL
APS 250 µL 100 µL
TEMED 25 µL 15 µL
Table 2.9: Volumes for gel preparation. Resolving and stacking gel were pre-
pared according to the volumes of this table. Protogel is an acrylamide/methylene
bisacrylamide (37.5/1 ratio) solution (National Diagnostics). The ammonium per-
sulphate (APS) was freshly prepared as a 10% solution with distilled water.
Electrophoresis
Fifteen µL of Laemmli lysate was loaded in one slot of a 4-20% Tris-Glycin gel
(Novex 4-20% Tris-Glycin Express Kit 1.0 mm 12 well, Life Technologies) or self-
made gel (see above), as a marker 10 µL of PageRuler Prestained Protein Ladder
(Thermo Scientific) was used. Electrophoresis conditions were set to 200 V for 1.5
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h. Running Buffer was 10x Tris/Glycin/SDS Buffer (National Diagnostics) or a self-
made 10x Running Buffer (30 g Tris-HCl, 144 g glycine, 10 g SDS, distilled water
to 1000 mL) diluted with deionized water to obtain a 1x solution.
2.4.5 Blotting
Protein was transferred onto a nitrocellulose membrane (Novex, Life Technologies)
for 1 h at 100 V. Transfer buffer was 25x Novex Tris-Glycin Transfer Buffer (Invit-
rogen, Life Technologies) or a self-made 10x Transfer Buffer (7.575 g Tris-HCl, 36 g
glycine, 500 mL methanol, distilled water to 2500 mL) diluted with deionized water
and methanol to obtain a 1x solution with 20% methanol.
2.4.6 Visualization of Proteins
2.4.6.1 ECL Detection
Nitrocellulose membranes were blocked for 1 h at room temperature, shaken, with
5% BSA (Sigma-Aldrich) in Tris-buffered saline containing 0.05% Tween 20 (=TBST,
10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20). After one wash step with TBST,
the membranes were incubated with primary antibody (Table 2.10) diluted in 1%
BSA (Sigma-Aldrich) or milk in TBST overnight at 4◦C, shaken. The next day,
membranes were washed three times with TBST before incubating with secondary
antibody (goat anti-mouse IgG-HRP or goat anti-rabbit IgG-HRP (Santa Cruz))
diluted 1:5000 in 1% BSA or milk in TBST for 1 h at room temperature, shaken.
After three wash steps, protein bands were visualized on chemiluminescence film
(High performance chemiluminescence film, GE Healthcare) using ECL Western
Blotting Detection Reagents (GE Healthcare) and band intensities were quantified
using Image J software. Bands of interest were normalized to β-actin or α-tubulin
protein expression (Table 2.10). To re-probe the membranes with the primary anti-
body β-actin or α-tubulin, the membranes were incubated in Restore PLUS Western
Blot Stripping Buffer (Thermo Scientific) for 15 min at room temperature, shaken,
washed once with TBST and blocked again with 5% BSA or milk in TBST before
incubating in primary and secondary antibody as described above.
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Primary Antibody Blocking Dilution
11β-HSD2 antibody (H-145) Odyssey Blocking 1:800 (Odyssey)
(Santa Cruz (sc-20176)) or 5% BSA 1:1000 (ECL)
GR antibody (P-20) 5% BSA 1:200 - 1:500 (ECL)
(Santa Cruz (sc-1002)) or milk
GR antibody (H-300) 5% BSA 1:200 - 1:500 (ECL)
(Santa Cruz (sc-8992)) or milk
MR antibody (H-300) 5% BSA 1:200 (ECL)
(Santa Cruz (sc-11412)) or milk
MR antibody 5% BSA 1:1000 (ECL)
(Abcam (ab-97834)) or milk
FKBP51 (D-4) Odyssey Blocking 1:100 (Odyssey)
(Santa Cruz (sc-271547))
β-actin Odyssey Blocking 1:10000 (Odyssey)
(Abcam (ab8226)) or 5% BSA 1:1000 (ECL)
α-tubulin 5% BSA 1:10000 (ECL)
(Abcam (ab80779))
Table 2.10: Primary antibodies with blocking conditions and dilutions for
western blot.
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2.4.6.2 Odyssey Infrared Imaging System
Nitrocellulose membranes were blocked for 1 h at room temperature, shaken, with
Odyssey Blocking Buffer (LI-COR Biosciences). The membranes were incubated
with primary antibody (Table 2.10) diluted in Odyssey Blocking Buffer overnight
at 4◦C, shaken. Membranes were washed three times with TBST (24.2 g Tris-base,
80 g NaCl, distilled water to 1000 mL, pH 7.6, 0.1% Tween-20 (= 10x) diluted with
distilled water to 1x solution) before incubating with secondary antibody (IRDye
800CW conjugated goat anti-rabbit IgG (H+L) antibody (LI-COR Biosciences) or
ALEXA Fluor 680 conjugated goat anti-mouse IgG (H+L) antibody (Life Technolo-
gies)) diluted 1:5000 in Odyssey Blocking Buffer for 1 h at room temperature (in
the dark), shaken. After three wash steps in TBST and one wash in TBS, protein
bands were visualized with the Odyssey Infrared Imaging System and bands were
quantified with the Odyssey software version 2.1. To re-probe the membranes with
the primary antibody β-actin, the membranes were incubated twice in self-made
stripping buffer (25 mM glycine pH 2, 2% (w/v) SDS) for 15 min at room tem-
perature, shaken, washed twice with TBST and blocked again with the Odyssey
Blocking Buffer before incubating in primary and secondary antibody as described
above.
2.4.6.3 Western Blot Detection of GR and MR
The quantification of GR and MR protein expression was not possible due to prob-
lems with antibodies employed to identify GR and MR (Table 2.10, Figure 2.7).
Regarding GR, the first GR antibody (sc-1002) did not give a band at the predicted
size of 90/95 kDa. The second GR antibody tested (sc-8992) gave white bands on
a dark background. This phenomenon is caused by excess of primary and/or sec-
ondary antibody and it could have been improved with diluting the primary or the
secondary antibody or both. But nonetheless, no pale band was observed at the
correct size. Regarding MR, a lot of unspecific bands were observable of which a
band above the 100 kDa marker band could potentially be MR as its size is 107
kDA. But due to the various stronger unspecific bands, this band was not regarded
as being specific for MR. Despite numerous attempts to improve results with these
antibodies, this was not possible.
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Figure 2.7: Protein expression of GR and MR in BeWo, HEK 293 and
HeLa cells. Blot 1: Samples were protein lysates from BeWo control (= lane 1)
and forskolin-treated BeWo (= lane 2), Blot 2 and 3: Samples were protein lysates
from BeWo control (= lane 1) and forskolin-treated BeWo (= lane 2), from HEK
293 control (= lane 3) and HeLa control (= lane 4). Size of GR: 90/95 kDa, size of
MR: 107 kDa.
2.5 Microscopy
2.5.1 Immunofluorescence
Immunostaining for fluorescent Microscope
To perform fluorescent immunocytochemistry staining on BeWo cells, the cells were
seeded onto sterile glass plates in 6-well plates. After the appropriate treatments, the
cells were washed with PBS before fixing them with 4% paraformaldehyd solution
for 15 min. After three washing steps with PBS for 5 min, the cells were blocked
and permeabilized with 3% BSA in 0.015% Triton-X-100 in PBS for 1 h at room
temperature. Then, the cells were washed 3 times with 0.015% Triton-X-100-PBS
for 5 min and the primary antibody (1:50 dilutions for 11β-HSD2, E-Cadherin,
Syncytin-1, CRH-R1, CRH-R2 primary antibodies), which was diluted in 0.015%
Triton-X-100-PBS, was incubated overnight in a wet chamber. The next day, after
3 washing steps with 0.015% Triton-X-100-PBS, the fluorescent secondary antibody
(donkey anti-mouse/rabbit/goat ALEXA Fluor 488 or 633 (Life Technologies), 1:
400 diluted in 0.015% Triton-X-100-PBS) was incubated for 1 h at room temperature
in the dark. After another 3 washing steps with 0.015% Triton-X-100-PBS and a
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final washing step with filtered PBS, the cells were mounted in vectashield mounting
medium containing DAPI (Vector laboratories) and the glass slide was placed up-
side-down onto a microscope slide and sealed with nail polish. Images were taken
using a confocal microscope (SP2, Leica, Milton Keynes, UK).
Vybrant
TM
Cell-Labeling
BeWo cells were trypsinized and dissolved in serum-free medium at a concentra-
tion of 1 x 106 /mL. Cells were separated into two populations and either 5 µL of
Vybrant DiI or 5 µL of Vybrant DiO cell-labeling solution were added to 1 mL of
cell suspension and incubated at 37◦C for 20 min. Cells were centrifuged at 1500
rpm for 5 min, supernatant was aspirated, and cells were resuspended in complete
medium. This wash step was repeated twice. Cells of both populations were mixed
and seeded. 100 µM forskolin was added after two days and incubated for 24 h and
48 h. Live cell fluorescent microscopy was performed every 24 h (day 1-4), DiI has
its emission maxima at 565 nm and was detected with a filter for red fluorescence,
DiO has its emission maxima at 501 nm and was detected with a filter for green
fluorescence. When cells fuse, they exhibit fluorescence at both wavelengths (565
and 501 nm) which is visualized by a yellow staining.
Caspase-3/7 staining
For fluorescent staining of activated caspase-3/7, CellEvent
TM
Caspase-3/7 Green
ReadyProbes
TM
Reagent (Molecular Probes R©, Life Technologies) was used. The
principle of this assay is a nucleic acid binding dye which is conjugated to a DEVD-
peptide. This dye is not fluorescent when the DEVD-peptide is conjugated and the
complex is not bound to DNA. Activation of caspase-3/7 leads to cleavage of the
DEVD, the dye binds to nucleic acid and becomes fluorescent.
BeWo cells were seeded in 6- or 24-well plates and treated according to the
experimental protocol. On the day of detection of activated caspase-3/7, two drops
of CellEvent
TM
Caspase-3/7 Green ReadyProbes
TM
Reagent per mL of medium
were incubated for 30 min at 37◦C. After this incubation, 2 drops of NucBlue R© Live
ReadyProbes
TM
Reagent (Molecular Probes R©, Life Technologies) per mL of medium
were added to stain all nuclei and incubated for 15 min at room temperature. Images
were taken using a fluorescence microscope.
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2.5.2 Immunohistochemistry
Tissue Sectioning
Placental explant tissue embedded in wax after being parafinized was cut into 3 µm
thick sections using a rotary microtome. The sections were then picked up with a
microscope slide from a water bath at 45◦C and drained in an incubator at 65◦C
for a minimum of 60 minutes.
Dewaxing
Before starting the immunocytochemical protocols, the sections were dewaxed with
two incubation steps in xylene for 2-3 minutes, followed by incubation steps with
100% ethanol (twice), 90% ethanol and distilled water for 2-3 minutes each.
Antigen Retrieval
A PickCell antigen retrieval unit was used in order to recover the protein epitopes
of the cut sections. Briefly, the slides were placed into the Retriever Slide Chamber
containing 70 mL of buffer A (pH 6) or B (pH 8). The Slide Chambers were placed
in a rack and the retriever unit was filled with 200 mL of deionized water. After
closing the retriever unit, a programme of 2:20 hours was started with 20 minutes
of a heating process under pressure and 2 hours of a cooling process.
Optimization of primary Antibodies
For every antibody, the antigen retrieval was optimised by testing different buffers
during the antigen retrieval process. For the antibodies M30 (M30 CytoDeath mouse
monoclonal antibody, Roche), Ki67 (anti-Ki67 antibody (clone MIB-1), DAKO) and
11β-HSD2 (H-145, Santa Cruz), buffer A (pH 6) and buffer B (pH 8) were tested and
buffer A gave stronger staining results for all antibodies. Furthermore, the sections
were stained at a range of serial dilutions of the antibodies in order to determine
the best antibody dilution for following stainings (Figure 2.8 for staining of human
bowel (as a positive control tissue) and placental explant with a serial dilution of
the M30 antibody). Optimal primary antibody dilution for M30 was 1:160, for Ki67
1:200 and for 11β-HSD2 1:300.
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Figure 2.8: IHC with M30 antibody (serial dilution). Human bowel (as a pos-
itive control tissue) and placental explant were stained with different concentrations
of the M30 antibody (weak staining in 1:20 dilution because the antibody solution
did not cover the slide completely) to determine the optimal dilution for the follow-
ing experiments. Representative images are shown, blue staining = haematoxylin
staining, brown staining = M30 staining.
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Immunostaining with Novolink Polymer Detection Kit
The Novolink Polymer Detection Kit (Leica) was used for performing the immunos-
taining and all described solutions were part of the kit unless otherwise stated.
Following antigen retrieval, the sections were washed with distilled water and the
borders around the tissue were marked with a PAP (hydrophobic) pen. After one
washing step with TBST for 5 minutes, the endogenous peroxidase activity was
blocked with the peroxidase block solution (2 drops = approximately 100 µL) for 5
minutes. Then after two washing steps with TBST for 5 minutes, the sections were
incubated with 2 drops of protein block solution. After another two washing steps
with TBST for 5 minutes, sections were incubated in primary antibody at optimal
dilution (approximately 200 µL) overnight at 4◦C. The next day, after two washing
steps with TBST for 5 minutes, the sections were incubated in post primary block
solution (2 drops) for 30 minutes. After further two washing steps with TBST for 5
minutes, sections were incubated with 2 drops of polymer solution for 30 minutes.
Then, following two washing steps with TBST for 5 minutes, the sections were
incubated with DAB working solution (1:20 dilution of DAB chromogen in DAB
substrate) for 7 minutes. Before staining with haematoxylin solution for 1 minute,
the sections were washed twice with distilled water. After a last wash with TBST for
5 minutes, the sections were dehydrated. Therefore, they were incubated each for
2-3 minutes in distilled water, 90% ethanol, 100% ethanol and xylene. Brightfield
microscopy of the sections was carried out after mounting the slides.
2.6 ELISA
2.6.1 Single ELISA
BeWo cells and placental explants were cultured according to the experimental pro-
tocol. Supernatant was centrifuged (500 g, 5 min) before measuring the concentra-
tions of hCG, progesterone, estradiol and cortisol using electrochemiluminescence
immunoassays (Elecsys R© ECLIA Kits, Roche Diagnostics). The measurements were
carried out by the Department of Biochemistry (University Hospitals Coventry and
Warwickshire NHS Trust).
2.6.2 Multiplex ELISA
Multiplex ELISA was carried out using the MSD Multiplex Apoptosis Panel Whole
Cell Lysate Kit (Meso Scale Discovery) and the MSD Sector Imager 6000 (Meso
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Scale Discovery). This ELISA technique uses a sandwich assay principle: capture
antibodies against cleaved PARP, cleaved caspase-3, total p53 and phospho-p53 are
coated on an electrode surface of a 96-well plate, binding of sample molecules to
the capture antibodies occurs, and the SULFO-TAG labelled detection antibody
binds to the sample molecules. After adding the provided read buffer, signals are
detected as emitted light by the SULFO-TAG labels after voltage is applied to the
plate electrodes (electrochemiluminescent detection).
Samples from placental explants were mechanically lysed in RIPA buffer
(Santa Cruz) containing 10µL protease-inhibitor-cocktail (PIC), 10 µL PMSF, 10
µL orthovanadate (components of RIPA buffer kit) and 1:100-diluted phosphatase-
inhibitor I and II (Sigma). After measuring the protein concentration using the BCA
assay (Pierce) (see Chapter 2.4.2), samples were diluted in the above described lysis
buffer with 0.1% Blocker A (part of the MSD Multiplex Apoptosis Panel Whole
Cell Lysis Kit) to get a concentration of 16 µg protein per well (this correlates to a
concentration of 0.64 µg/µL because 25 µL of sample were used in one well).
All materials described below are part of the MSD Multiplex Apoptosis Panel
Whole Cell Lysate Kit (cleaved PARP, total p53, phospho-p53, cleaved caspase-3)
and were made and diluted according to the manufacturer’s instructions. The coated
96-well plate was washed once with 1x Tris Wash Buffer (=TWB) (prepared with
deionized water) and then blocked with 150 µL of 3% blocking solution-A (diluted in
1x TWB), sealed, for 1 h at room temperature (=RT) with shaking. After 3 washing
steps with 150 µL 1x TWB, 25 µL of 1% blocking solution-B (diluted in 1x TWB)
was added to each well together with 25 µL of cell lysate and subsequently the plate
was sealed and incubated for 1 h (during initial measurement) or 3 h (subsequent
measurements) at RT with shaking. This incubation time was increased to augment
the possibility to detect changes for p-p53 and t-p53 as increasing the total protein
level was limited. After another 3 washing steps with 150 µL 1x TWB, 25 µL of
detection antibody (diluted in 1x TWB with 1% Blocker A and 10 µL/mL Blocker
D-R) was added to each well and then the plate was sealed and incubated for 1 h
(during initial measurement) or 2 h (subsequent measurements) at RT with shaking.
This incubation time was increased to augment the possibility to detect changes for
p-p53 and t-p53. 150 µL 1x read buffer T (diluted in distilled water) was added to
each well after 3 wash steps with 150 µL 1x TWB and then the plate was measured
with the MSD Sector Imager 6000 (Meso Scale Discovery) immediately.
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Determination of necessary Protein Concentration for Multiplex ELISA
An initial experiment using two placental explant samples (control or 10 µM stau-
rosporine treated, cultured for five days with daily treatment) was performed in or-
der to determine the protein concentration which is necessary for detecting changes
in four molecules involved in apoptosis, namely cleaved caspase-3, cleaved PARP,
total p53 and phosphorylated p53. Dilutions of the two samples (protein concen-
trations between 0.5 and 32 µg protein per well) were measured to test the signal
intensity for cleaved caspase-3, cleaved PARP, total p53 and phosphorylated p53.
Figure 2.9 A and B show that a measurable difference (>2 fold) in signal for cleaved
caspase-3 between control and staurosporine-treated sample could be detected at all
protein concentration (max. 3.9-fold increase of cleaved caspase-3) and for cleaved
PARP at 32 µg protein per well (2.6-fold increase of cleaved PARP). Figure 2.9 C
and D show that no difference between the two samples could be detected for total
p53 and phosphorylated p53 over the range of protein concentrations tested. In sub-
sequent experiments, a concentration of 16 µg protein per well was chosen because
this was the highest concentration available to perform all assays. To compensate
for the protein concentration available, the two incubation steps were increased from
1 h to 3 h as mentioned above.
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Figure 2.9: Determination of necessary protein concentration for multi-
plex ELISA. Analysis of the signal intensity for cleaved caspase-3, cleaved PARP,
total p53 and phosphorylated p53 (pp53) at different protein concentrations from a
control and a staurosporine (STS)-treated placental explant sample, n=1. Signals
were detected using the multiplex ELISA system ”‘MSD Multiplex Apoptosis Panel
Whole Cell Lysis Kit”’.
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2.7 Viability and Apoptosis Assays
2.7.1 CellTiter 96 R© AQueous One Solution Cell Proliferation Assay
(MTS)
To measure cell viability, the CellTiter 96 R© AQueous One Solution Cell Proliferation
Assay (MTS) was used. The principle of the assay is the reduction of the MTS tetra-
zolium compound to the coloured formazan product. Living cells produce NADPH
and NADH which is required in the conversion of MTS into formazan and so the
measured signal at 490 nm is proportional to the number of living cells [Cory et al.,
1991; Berridge and Tan, 1993].
BeWo cells were seeded in a 24-well plate and treated according to the exper-
imental protocol. On the last day, medium was removed and 500 µL F12K/DMEM
medium without phenol red (Life Technologies) was added to each well with 50 µL
of MTS solution. After incubating for 2 h at 37◦C, the plate was rocked, 100 µL of
supernatant of each well was transfered into a 96-well plate and absorbance at 490
nm was measured.
2.7.2 CellTiter-Blue R© Cell Viability Assay
To measure cell viability in combination with apoptosis, the CellTiter-Blue R© Cell
Viability Assay was used. The principle of the assay is the reduction of the com-
pound resazurin into the fluorescent resorufin (579Ex/584Em) product by living cells
[Gloeckner et al., 2001].
BeWo cells were seeded in a 24-well plate and treated according to the exper-
imental protocol. On the last day, 50 µL of Cell Titer Blue solution was added to
each well. After incubating for 2 h at 37◦C, the plate was rocked, 100 µL of super-
natant of each well was transfered into a 96-well plate and fluorescence at 590 nm
was measured. Subsequently, a multiplex assay with the ApoONE R© Homogeneous
Caspase-3/7 Assay was possible (Chapter 2.7.3).
2.7.3 ApoONE R© Homogeneous Caspase-3/7 Assay
To measure activated caspase-3/7, the ApoONE R© Homogeneous Caspase-3/7 Assay
was used. The principle of this manufactured Caspase-3/7 assay is the detection of
a fluorescent cleaved substrate at 521 nm (= emission maximum). The activated
caspase-3 and -7 cleave their substrates at the amino acid recognition site DEVD
[Thornberry et al., 1997; Nicholson, 1999]. The profluorescent substrate (Z-DEVD-
Rhodamine 110, provided by the kit) contains this DEVD amino acid sequence and
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activated caspase-3 and -7 cleave this form and the fluorescent substrate Rhodamine
110 is generated.
BeWo cells were seeded in a 24-well plate and treated according to the ex-
perimental protocol. On the last day, 100 µL of ApoONE solution (1 µL substrate
in 1 mL buffer, substrate and buffer were components of the kit) was added to each
well. After incubating for 4 h at room temperature, the plate was rocked, 200 µL of
supernatant of each well was transfered into a black 96-well plate and fluorescence
at 530 nm was measured.
As a positive control experiment, BeWo cell were treated with 1 µM stau-
rosporine (which induces caspase-3/7 activation) for 4 h before the ApoONE was
added. Furthermore, background fluorescence was determined by adding ApoONE
to F12K medium (without cells). Figure 2.10 shows that background fluorescence
was minimal with 51 arbitrary units and that staurosporine activated caspase-3/7
significantly.
Figure 2.10: Activation of caspase-3/7 in BeWo cells by staurosporine.
BeWo cells were treated with 1 µM staurosporine (STS) for 4 h before the ApoONE
assay was performed. n=3, t-test: p<0.001 (=***).
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2.8 Statistical Analysis
Data were analyzed and graphs were prepared using the GraphPad Prism 4 software.
Experiments were repeated independently at least three times to allow statistical
analysis. Depending on the design of the experiment, comparisons among treat-
ment groups were made using Student’s t-test (when comparing two groups), 1-way
or 2-way ANOVA (when comparing more than two groups) to test for statistical
significance. In case of ANOVA analysis, Bonferroni post-test analysis was applied
to perform multiple comparison tests. The mentioned parametric tests are based
on the assumption of normally distributed data. To fulfill this requirement, data
of qRT-PCR and percentage data was log-transformed prior to analysis. However,
tests for normality could not be carried out as the number of experiments was too
small. To perform parametric tests with small sample numbers, it is important that
the measured samples are representative of the population. Small sample size is only
reasonable under the assumption that the variability within the population is small.
As data from cell lines can be considered to have a low variation between the sam-
ples, parametric tests were used for analysis in this thesis. Furthermore, data from
placental explants were analyzed with parametric tests as the tissue was collected
from healthy patients (and not from patients with a pathological condition whose
tissue can be expected to give data with a greater variation between the samples).
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Chapter 3
Effects of CRH and LPS on
Hormone Secretion and Cell
Turnover of Placental Explants
The placental explant culture is a suitable model for the analysis of hCG secretion
by the syncytiotrophoblast and its characteristics are described in this chapter. Fur-
thermore, the responsiveness of the placental explant tissue (for details see chapter
2.1.1) to external stimuli was investigated. The hormone CRH is of particular in-
terest because it is elevated in placenta-related diseases [Laatikainen et al., 1991;
Goland et al., 1993; Warren et al., 1992]. To further investigate whether an inflam-
matory environment changes the effects of CRH, LPS was used as another external
stimuli. Inflammatory environments are often observed in placental pathologies such
as pre-eclampsia (Chapter 1.3.1.1) and placental infection, in maternal pathologies
such as diabetes and obesity (Chapter 1.3.2) as well as in the physiological partu-
rition process (Figure 1.17). LPS binds to the toll-like receptor 4 (= TLR4) which
has been shown to be expressed in the placenta in all trimesters [Holmlund et al.,
2002; Beijar et al., 2006]. Holmlund et al. [2002] further showed that treatment
of placental explants with LPS leads to an induction of IL-6 and IL-8 production,
suggesting the presence of a functional TLR 4 in the placenta and a signalling in-
flammatory response via the TLR4-NFκB pathway.
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3.1 Detection of Proliferation in Placental Explants
For the detection of proliferation in placental explants, immunohistochemical Ki67
staining was performed (see chapter 2.5.2 for experimental details). The Ki67 anti-
body stains proliferating cells by binding to a nuclear antigen which is only present
in proliferating cells [Gerdes et al., 1983].
As an initial experiment, freshly isolated placental explant tissue and hu-
man tonsil (positive control for Ki67 antibody) were stained for Ki67. Figure 3.1
A shows that the Ki67 staining was carried out successfully since the tonsil shows
strong Ki67 staining. Also the placental tissue showed that a few trophoblast nuclei
were positively stained for Ki67 (Figure 3.1 C, D). The negative control did not
show any detectable Ki67 staining (Figure 3.1 B).
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Figure 3.1: Proliferation in placental tissue. Ki67-staining of (A) human tonsil
(= positive control tissue for the Ki67 antibody), (B) human tonsil (= negative
control, no Ki67 antibody), (C, D) placental explant tissue. A, B: 20x objective,
C, D: 40x objective. n = 2 placentae, representative images are shown. Blue
staining = haematoxylin staining. Arrows indicate brown staining from the Ki67-
staining.
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Responsiveness of Placental Explant Proliferation to CRH and LPS
To investigate whether CRH and/or LPS alter placental proliferation, placental
explants were treated with 1 µM CRH and/or 10 µg/mL LPS for five days (see
chapter 2.2 for treatment protocol, CRH and LPS were replenished every 24 h).
Subsequently, the tissue was processed for the immunohistochemical detection of
Ki67.
Qualitative assessment showed that the different treatments with 1 µM CRH
and 10 µg/mL LPS did not show any detectable difference in cell proliferation
of placental explants after five days of treatment (Figure 3.2). An experienced
histochemistry-biomedical scientist confirmed this and the samples were not pro-
cessed for quantitative assessment.
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Figure 3.2: Effect of CRH and LPS on placental explant proliferation. Ki67
staining of placental explants after being cultured for five days and treated with 1
µM CRH and/or 10 µg/mL LPS. 40x objective, n = 2 placentae, representative
images are shown. Blue staining = haematoxylin staining, brown staining = Ki67-
staining.
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3.2 Measurement of secreted Hormones and its Respon-
siveness to CRH and LPS
Placental explants were treated for 6 days with 1 µM CRH and/or 10 µg/mL LPS
and the hCG release in the supernatant was assessed every 24 h. On day 6, the
explants from each well were collected to determine the protein concentration (see
Chapter 2.1.1 for experimental details).
3.2.1 CRH and LPS Effects on hCG Secretion
Sima´n et al. [2001] described that cultured placental explants lose their syncytiotro-
phoblast layer after the first day of culture and that a new functional syncytiotro-
phoblast layer is regenerated by day 4. During culture of placental explants, fo-
cussing on the basal treatment, a decrease in hCG secretion was observed in the
first few days of culture by 80% when comparing hCG secretion from day 1 with
day 2 (Figure 3.3 A) suggesting that the existing syncytiotrophoblast layer was
lost at this stage of the experiment. On day 2 and 3 the minimal amount of hCG
was measured in the supernatant (day 2: 59.7 mIU/mL ± 9.2 SEM, day 3: 62.2
mIU/mL ± 7.1 SEM). On day 4 the hCG secretion had started to increase, peaking
at an hCG secretion of 107.7 mIU/mL ± 18.2 SEM on day 5 until it started to drop
again on day 6. This observation suggests that a new syncytiotrophoblast layer was
regenerated during this time which is in agreement with Sima´n et al. [2001].
This pattern of hCG release, namely the reduction in hCG release from day
1 to day 2, the plateau phase from day 2 to day 3 and the increase of hCG release
characteristics from day 3 to day 6 peaking at day 5, was not altered in the presence
of the four different treatments (basal, 1 µM CRH, 10 µg/mL LPS, 1 µM CRH +
10 µg/mL LPS, Figure 3.3 A).
However, Figure 3.3 B to E show the differences in the increase of hCG under
the different treatments (B = basal, C = CRH, D = LPS, E = CRH+LPS) from
day 2 to day 5 of explant culture. Under basal conditions, there was a significant in-
crease of hCG secretion by 80% from day 2 to day 5 (Figure 3.3 B). CRH treatment
led to a significant enhancement of hCG secretion by 160% during the same period
(Figure 3.3 C). In contrast, LPS treatment did not increase hCG secretion between
day 2 and day 5 (Figure 3.3 D). Simultaneous treatment of CRH and LPS led to a
significant hCG increase by 78% (Figure 3.3 E) which is comparable to basal culture
conditions (Figure 3.3 B).
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Figure 3.3: Effect of CRH and LPS on hCG production of placental ex-
plants. (A) Daily hCG release by cultured placental explants treated with 1 µM
CRH, with and without 10 µg/mL LPS. (B-E) hCG secretion on day 2 and 5 under
the different treatments. hCG concentration was normalized to protein concentra-
tion, n=3 different placentae (treatments in triplicates), data are expressed as mean
value ± SEM, t-test: ns = non-significant, p<0.05 (=*), p<0.01 (=**).
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3.2.2 Inconsistency of Placental Explants
Even though all of the placentae were obtained from healthy individuals, consid-
erable differences in the hCG secretion levels as early as on day 1 was observed.
Figure 3.4 shows the hCG secretion on day 1 from the placentae labelled as ”‘high
hCG responders”’ (data from these placentae were presented in Figure 3.3) which
was significantly higher than the hCG secretion from placentae labelled as ”‘low
hCG responders”’. During preparation of the low hCG responder explants, these
placentae revealed different morphological characteristics such as a pale rose color,
a lot of red blood cells in the wells during the whole period of the 6-day culture,
white colored firm fragments in the soft placental tissue, and one patient had an
elevated blood pressure.
Figure 3.4: hCG secretion on day 1 of placental explant culture. hCG con-
centration was normalized to protein concentration, n=3 different placentae (treat-
ments in triplicates), data are expressed as mean value ± SEM, t-test: p<0.001
(=***).
In these low hCG responding placentae, the responsiveness to treatments
with CRH and LPS was different (Figure 3.5) compared to the high hCG responder
placentae (previously shown in Figure 3.3). Figure 3.5 A shows that basal culture
conditions without any stimuli led to the lowest hCG secretion between day 2 and
day 6. Figure 3.5 B to E show that all culture conditions led to a significant in-
crease of hCG secretion between day 2 and day 5. Under basal conditions, there
was an increase of hCG secretion by 5.8-fold from day 2 to day 5 (Figure 3.3 B).
CRH treatment further increased the hCG secretion by 9.1-fold from day 2 to day
5 (Figure 3.3 C). LPS treatment enhanced hCG secretion by 7.2-fold between day
2 and day 5 (Figure 3.3 D). Simultaneous treatment of CRH and LPS led to the
highest increase of hCG secretion by 10.9-fold (Figure 3.3 E) suggesting a synergistic
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effect of CRH and LPS on hCG secretion. It seemed that placentae with a low hCG
secretion on day 1 of the explant culture were highly responsive to various stimuli.
Because all of the placentae (high and low hCG responders) were obtained from
individuals without any established or confirmed pathology, it was concluded that
the considerable variation in responses is a major limitation of this experimental
approach.
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Figure 3.5: Effect of CRH and LPS on hCG production of low hCG re-
sponder placentae. (A) Daily hCG release by cultured placental explants treated
with 1 µM CRH, with and without 10 µg/mL LPS. (B-E) hCG secretion on day 2
and 5 under the different treatments. hCG concentration was normalized to protein
concentration, n=3 different placentae (treatments in triplicates), data are expressed
as mean value ± SEM, t-test: p<0.001 (=***).
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3.3 Detection of Apoptosis in Placental Explants
Detection of apoptosis in placental explants was performed both qualitatively and
quantitatively after CRH and/or LPS treatment. Previous studies linked CRH to
apoptotic processes and both a pro- and an anti-apoptotic role for CRH has been
shown under different circumstances [Schmid et al., 2011; Fox et al., 1993; Facci
et al., 2003; Dermitzaki et al., 2002; Minas et al., 2007]. For example, Schmid et al.
[2011] shows an anti-apoptotic effect of CRH on apoptosis in rat INS-1 insulinoma
cells and Fox et al. [1993] and Facci et al. [2003] could demonstrate a neuroprotective
effect of CRH against apoptosis in brain slices and in cerebral granule neurons,
whereas Dermitzaki et al. [2002] detected a pro-apoptotic effect of CRH in PC12
cells which involves the CRH-R1 signalling and Minas et al. [2007] shows that CRH
induces apoptosis via Fas-activation in extravillous trophoblasts. As CRH is elevated
in placental-related diseases, it was considered possible that CRH is also involved in
apoptotic processes in cytotrophoblast cells or in the syncytiotrophoblast and this
might affect hCG release.
As a qualitative method, an immunohistochemical staining (M30-staining)
for cleaved cytokeratin-18, which is a substrate of activated caspase-3, was per-
formed. The M30-staining is a specific staining for apoptotic trophoblasts [Kadyrov
et al., 2001]. As the quantitative method, the apoptosis marker molecules cleaved
caspase-3, cleaved PARP, p53 and phosphorylated p53 were measured with a mul-
tiplex ELISA technique.
3.3.1 Qualitative Detection of cleaved Cytokeratin-18
Induction of Apoptosis by Staurosporine
In order to evaluate the M30-staining, placental explants were treated with 10 µM
staurosporine (STS) for five days (fresh STS was added every 24 h). Staurosporine
inhibits the protein kinase-C, which leads to the activation of caspase-3 (=cleavage
of procaspase-3 to caspase-3) [Tamaoki and Nakano, 1990; Jacobsen et al., 1996] and
can therefore be used as a positive control to demonstrate activation of apoptosis
mechanisms.
Indeed, staurosporine-treated placental explants were stained for cleaved
cytokeratin-18 and they showed, as expected, a strong positive M30-staining (Figure
3.6).
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Figure 3.6: Effect of staurosporine on placental explant proliferation. M30-
staining of staurosporine-treated placental explant. The explants were treated for
five days with 10 µM staurosporine. Left: 20x objective, right: 40x objective. n = 3
placentae, representative images are shown. Blue staining = haematoxylin staining,
brown staining = M30-staining.
Apoptosis of Fresh Placental Tissue
Fresh tissue from the placenta exhibited low apoptotic processes in the villous tissue
as only minimal staining for cleaved cytokeratin-18 could be detected (Figure 3.7).
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Figure 3.7: Apoptosis in fresh placental explant tissue. M30-staining of fresh
placental tissue (= day 0). Neither cytotrophoblast areas nor syncytiotrophoblast
areas showed positive staining for M30 (= no brown staining). Top: 20x objective,
bottom: 40x objective. n = 2 placentae, representative images are shown. Blue
staining = haematoxylin staining.
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3.3.2 CRH and LPS Effects on Apoptosis in placental Explants
(qualitative)
M30-staining of placental explant sections, which were cultured and treated with 1
µM CRH and/or 10 µg/mL LPS for five days, showed a positive staining for cleaved
cytokeratin-18 (Figure 3.8 and 3.9). Qualitative assessment indicated that the dif-
ferent treatments (control, CRH, LPS, CRH+LPS) showed a positive staining in the
same amount (Figure 3.8). In contrast, treatment with CRH in another placental
explant experiment showed a positive M30-staining to a lesser degree compared to
the control tissue (Figure 3.9).
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Figure 3.8: Effect of CRH and LPS on placental explant apoptosis. M30-
staining of placental explants after treatment with 1 µM CRH and/or 10 µg/mL
LPS for five days. 20x objective. n = 2 placentae, representative images are shown.
Blue staining = haematoxylin staining, brown staining = M30-staining.
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Figure 3.9: Effect of CRH on placental explant apoptosis. M30-staining of
placental explants after treatment with 1 µM CRH for five days. 20x objective.
n = 2 placentae, representative images are shown. Blue staining = haematoxylin
staining, brown staining = M30-staining.
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3.3.3 Quantitative Detection of four Marker Molecules of Apopto-
sis
Since the M30-staining is a qualitative method to detect apoptosis, an ELISA tech-
nique allowing a more precise quantitative measurement was performed to measure
apoptotic marker molecules.
Placental explants were cultured for four and five days before the tissue was
lysed and molecules involved in apoptosis (cleaved caspase-3, cleaved PARP, total
p53 and phosphorylated p53) were measured with the multiplex ELISA technology
(for methodological details see Chapter 2.6.2). Additionally, an internal control from
day 0 was taken to be able to determine the initial apoptosis status in the tissue
before starting the treatments.
In later stages of the apoptotic process, effector procaspases such as pro-
caspase-3 are being activated (cleaved) by initiator caspases (caspase-8 and -9)
(Figure 1.13). These activated forms are called (cleaved) caspases and they have
proteolytic activity and cleave many substrates including PARP (= poly-(ADP-
ribose)-polymerase). The apoptosis can be initiated by the extrinsic or intrinsic
pathway (Chapter 1.2.6.1). The molecule p53 can activate apoptosis via the intrin-
sic pathway as p53 has been shown to upregulate the proapoptotic member Bax of
the Bcl-2 family, the proapoptotic factor PUMA (= p53 upregulated modulator of
apoptosis) and Apaf-1 (= apoptotic protease activating factor-1) which is a com-
ponent of the apoptosome [Miyashita and Reed, 1995; Nakano and Vousden, 2001;
Moroni et al., 2001]. Also, p53 can interact with the anti-apoptotic members Bcl-2
and Bcl-XL of the Bcl-2 family and is thereby involved in the regulation of apoptosis
[Vaseva and Moll, 2009].
Apoptosis under basal Placental Culture Condition
In order to determine whether the culture conditions led to an increase in apopto-
sis, we cultured placental explants for four and five days with daily medium change.
Figure 3.10 shows that culturing of placental explants for several days led to a 5.9-
fold and 4.8-fold increase in cleaved caspase-3 expression after four and five days of
culture compared to day 0 cleaved caspase-3 levels. Cleaved PARP, total p53 and
phosphorylated p53 expression did not increase after several days of culture. The
result suggests that possibly the apoptotic cascade is stopped because cleavage of
the caspase-3 substrate PARP did not occur.
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Figure 3.10: Activation of apoptotic marker molecules after 4 and 5 days
of basal placental explant culture. Quantitative analysis of cleaved caspase-3,
cleaved PARP, total p53 and phosphorylated p53 expression in placental explants
after four and five days of culture compared to day 0. Results are from n = 3
placentae (treatments in duplicates), data are expressed as mean value ± SEM, t-
test: p<0.001 (=***) comparison of day 4/5 with day 0 for every marker molecule.
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3.3.4 CRH and LPS Effects on Placental Explants (quantitative)
Subsequent experiments investigated whether CRH and/or LPS treatments of pla-
cental explants altered expression of molecules of apoptosis (cleaved caspase-3,
cleaved PARP, total p53 and phosphorylated p53). As described, the explants were
treated every day with either 1 µM CRH, or 10 µg/mL LPS, or 1 µM CRH + 10
µg/mL LPS. Figure 3.11 shows that none of the treatments led to a significantly al-
tered expression of cleaved caspase-3, cleaved PARP, total p53 and phosphorylated
p53 after four or five days of culture.
Figure 3.11: Effect of CRH and LPS on activation of apoptotic marker
molecules. Quantitative analysis of cleaved caspase-3 (A), cleaved PARP (B),
total p53 (C) and phosphorylated p53 (D) expression in placental explants following
treatment with 1 µM CRH, 10 µg/mL LPS or 1 µM CRH + 10 µg/mL LPS for
four and five days. Results are from n = 3 placentae (treatments in duplicates),
data are expressed as mean value ± SEM, 2ANOVA with Bonferroni post test: no
significances. Y-axis: Signal is shown in arbitrary units.
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3.4 Initial Characterization of Proteins involved in GC
Metabolism in Placental Explants
3.4.1 Detection of 11β-HSD2 and P-glycoprotein (ABCB1) mRNA
Expression in Placental Explants
In an initial experiment, mRNA expression of 11β-HSD2 and P-glycoprotein, which
are both components of the placental glucocorticoid barrier, was determined to val-
idate the qRT-PCR method in the placental explant system. As a positive control,
placental explants were treated with 1 µM Dexamethasone (Dex), which leads to in-
duction of glucocorticoid-responsive genes, every 24 h for five days of culture. Figure
3.12 A and B show that 1 µM Dex highly up-regulated 11β-HSD2 and P-gp mRNA
expression. The triplicates shown derive from three different wells with placental
explants isolated from one placenta and the relative substantial differences in the
expression of 11β-HSD2 and P-glycoprotein mRNA suggest intravariability in the
placental explant system. Intravariability describes the variability between samples
collected from one placenta. This intravariability led to a revised protocol focusing
on protein expression in the subsequent experiments.
Figure 3.12: mRNA expression of 11β-HSD2 and P-gp in placental ex-
plants. qRT-PCR result of a pilot experiment. Placental explants were cultured
for five days with 1 µM Dex before mRNA was isolated and qRT-PCR for (A) 11β-
HSD2 and (B) P-gp was performed. n = 1 placenta (triplicates for each treatment).
qRT-PCR data was normalized to 18rRNA.
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3.4.2 Detection of 11β-HSD2 Protein in Placental Explants
As a positive control tissue for immunohistochemical 11β-HSD2 staining human
bowel was used and indeed it displayed a strong staining for 11β-HSD2 (Figure 3.13
A). Staining was specific since the negative control did not show a brown staining
(Figure 3.13 B). The placental explant which was cultured for five days under basal
conditions displayed a strong staining for 11β-HSD2 in the syncytiotrophoblast layer
and some of the trophoblast cells had a weak staining for 11β-HSD2 as well (Figure
3.13 C).
Figure 3.13: Immunohistochemical staining for 11β-HSD2 in placental ex-
plants. (A) Human bowel (= positive control). (B) Human bowel without primary
antibody (= negative control). (C) Placental explant tissue cultured for five days
before it was stained for 11β-HSD2. n=2, representative images are shown. Blue
staining = haematoxylin staining, brown staining = 11β-HSD2 staining.
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The 11β-HSD2 protein expression after CRH treatment was quantitatively
determined by western blot analysis of placental explants. Figure 3.14 B shows the
quantification of the western blot (Figure 3.14 A). Again, as with the quantification
of mRNA, the same treatment (lane 3 and 4 = 100 nM CRH, lane 5 and 6 = 1
µM CRH in Figure 3.14 A) gave inconsistent responses in the tissue of one placenta
suggesting a great intravariability. Moreover, analysis of a second experiment with
another placenta (Figure 3.14 C and D) showed in addition to intravariability af-
ter treatment with 1 µM CRH an intervariability compared to the first placenta.
Intervariability describes the variability between samples collected from different
placentas. In these placental explants, the CRH treatment led to a downregulation
of 11β-HSD2 protein (Figure 3.14 C and D), whereas in the first placenta this did
not happen (Figure 3.14 A).
Figure 3.14: Protein expression of 11β-HSD2 in placental explants. Placen-
tal explants were cultured for five days with 100 nM or 1 µM CRH before protein
lysate was prepared and WB for 11β-HSD2 was performed. (A) WB of one explant
experiment (Lane 1, 2 = basal, lane 3, 4 = 100 nM CRH, lane 5, 6 = 1 µM CRH)
with analysis (B), (C) WB of another explant experiment (lane 1, 2 = basal, lane
3, 4 = 1 µM CRH) with analysis (D), duplicates for each treatment. Normalisation
to β-actin.
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3.4.3 Detection of a Glucocorticoid-responsive Gene in Placental
Explants
To test glucocorticoid responsiveness of placental explants, expression of FKBP5,
a known glucocorticoid-responsive gene [U et al., 2004], was determined. FKBP5
protein was upregulated by 35-fold in placental explants after five days of 1 µM Dex
for treatment (Figure 3.15). Comparison of FKBP5 protein amount on day 0 (fresh
placenta) with the amount after 5 days of basal culture shows a decline by 25% in
FKBP5 protein expression.
Figure 3.15: Protein expression of FKBP5 in placental explants. Placental
explants were cultured for five days with 1 µM Dex before protein lysate was pre-
pared and WB for FKBP5 was performed. (A) WB of one explant experiment with
(B) analysis. M=Marker, Lane 1: fresh placenta (day 0), Lane 2: basal day 5, Lane
3: 1 µM Dex day 5. Normalisation to β-actin.
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3.5 Discussion of Chapter 3
Placental endocrine function and cell turnover have been shown to be altered in var-
ious placenta-associated diseases such as pre-eclampsia and IUGR [Arnholdt et al.,
1991; Ishihara et al., 2002; Ruebner et al., 2010]. These alterations can lead to a less
efficiently functioning placenta which, as a result, could have detrimental effects on
fetal development. In this chapter, I attempted to standardize methodologies that
would allow measurement of proliferation, of hCG secretion, and of apoptosis in the
placental explant culture. Responsiveness of the system to external stimuli such as
CRH and/or LPS was investigated in the placental explant model. Furthermore, an
initial characterization of molecules involved in the glucocorticoid metabolism was
started in pilot experiments.
Despite many proposed roles of CRH on placental biology, its role, especially
in challenging circumstances, has not been fully investigated. It has been suggested
that CRH is involved in the onset of labour because it plays a role in maintaining the
vascular tone and then late in pregnancy in stimulating secretion of prostaglandins
which might be involved in the parturition process [McLean et al., 1995; Clifton
et al., 1995; Jones and Challis, 1989; Benedetto et al., 1994]. The concentration of
placental CRH rises towards the end of pregnancy and interestingly, in placental
diseases the concentration of placental CRH rises even further towards the end of
pregnancy than in normal pregnancies [Frim et al., 1988; Laatikainen et al., 1991].
The production of excess CRH might occur due to a possible regulatory function of
CRH in disease states. In this study, the capacity of CRH to affect the placental
hormone production and placental cell turnover was investigated. The hypothesis
of the study was that CRH might play a beneficial role on placental biology and
that this effect might only become apparent in case of a challenging environment.
LPS was chosen to activate the receptor TLR4 which has been shown to
be expressed in the placenta [Holmlund et al., 2002]. Activation of TLR4 leads to
activation of the NFκB pathway and ultimately evokes an inflammatory response
by the cell. As the parturition process is characterized by an inflammatory mi-
lieu (Figure 1.17), the use of LPS and its provoked inflammatory response mimics
features of term and pre-term labour. Also, pregnancy-related diseases such as pre-
eclampsia show increased inflammatory processes which might affect the placenta
(Chapter 1.3.1.1) and conditions such as obesity and diabetes during pregnancy are
characterized by a low-grade inflammation (Chapter 1.3.2).
An interplay of CRH and LPS pathways can be observed in the placenta. For
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example, Torricelli et al. [2011] found a higher concentration of CRH mRNA in pre-
term placentae with chorioamnionitis than in pre-term placenta without chorioam-
nionitis. Furthermore, they showed that treatment of placental explants with LPS
increased CRH mRNA. Also in a trophoblast cell line model, treatment with LPS
led to an upregulated CRH production in JEG-3 cells [Uh et al., 2008]. So, it seems
that placental CRH concentration rises possibly through a TLR4-induced mecha-
nism. In addition to CRH treatment, LPS treatment in order to investigate its
effect on placental hormone production and cell turnover was carried out. Hypoth-
esis was that LPS might have a detrimental role on placental biology which might
be counter-regulated by an elevated CRH concentration.
Regarding detection of trophoblast proliferation, Ki67-staining has been suc-
cessfully used by other groups to detect proliferation in the placenta and in placental
explants [Unek et al., 2014; Matos et al., 2014]. Proliferation of placental explants
after CRH and LPS treatment was investigated because some, but not all, groups
found that proliferation indices of disease placentae might be altered. Arnholdt
et al. [1991] showed that cytotrophoblast proliferation is increased in placentae from
pre-eclampsia patients compared to placentae from healthy patients. Jeschke et al.
[2006] showed a significantly increased cytotrophoblast proliferation in patients with
the HELLP syndrome, but not in patients with pre-eclampsia or IUGR. Smith et al.
[1998b] did not find a difference in trophoblast proliferation in placentae from IUGR.
Since the cause of the altered trophoblast proliferation is not known yet and since
these placental disease phenomenons are associated with elevated CRH levels, it
was tested whether CRH (with and without the presence of LPS) is involved in
proliferation of trophoblast tissue.
Qualitatively it appears that neither CRH nor LPS treatment had an effect
on proliferation of placental explants on day 5 of culture. It might be possible that
alterations of proliferation events could have been detected to an earlier time point
of the placental explant culture. For example, Arnholdt et al. [1991] and Smith
et al. [1998b] showed less proliferation in term than in early gestation. This sug-
gests that investigation of proliferation in placental explants between day 1 and 3 of
culture (when the old syncytiotrophobast is lost and the new syncytiotrophoblast is
generated) might be a suitable timing for future experiments.
Sima´n et al. [2001] described the pattern of hCG secretion by placental ex-
plants and because the hCG release in our experiments followed this pattern, it
was concluded that our experimental protocol of culturing placental explants was
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in agreement with the published literature. Treatment with CRH or LPS altered
the secretion of hCG between culturing days three and six. Analysis of hCG secre-
tion on day 5 (compared to day 2) revealed that CRH increased hCG production
and that LPS showed a possible inhibitory action on hCG secretion. Simultane-
ous treatment with both LPS and CRH reached a similar level as the basal hCG
production, suggesting that the effect of LPS on hCG production was abolished by
simultaneous treatment with CRH. Thus, CRH (alone or in co-treatment) seems to
have the ability to stimulate hCG production of syncytiotrophoblast. This observa-
tion suggests that CRH might play a role in placental diseases as it might maintain
hCG secretion which, as described in the introduction (Chapter 1.2.7.2), fulfils many
important roles in maintaining pregnancy.
We observed inconsistent responses of placentae which were broadly divided
into ”‘high hCG responders”’ and ”‘low hCG responders”’ marked by a significantly
different initial hCG release on day one of culture. One problem with this observa-
tion is that it is not possible to predict whether a placenta is a high or low hCG
responder. There might be clues from the morphological appearance of the placenta
during preparation of the placental explants, but this is not an objective criteria.
The difference was apparent only after measuring the hCG concentration after the
first 24 h of culture. Nevertheless, for the analysis of the experiments in this study,
placentae displaying a low hCG production on day one were defined as low hCG
responders and placentae displaying a high hCG production on day one were defined
as high hCG responders (Figure 3.4). This definition led to interesting differences
in the responsiveness of the two groups to stimuli such as CRH and LPS as the
low hCG responder placentae showed increased hCG secretion after all treatments
suggesting that they might be hyperresponsive to various stimuli.
Comparing these data with data from literature, the relevant literature is
characterized by inconsistent findings. Crocker et al. [2004] measured a decreased
hCG production of placental explants after treatment with TNF-α. Also, Leisser
et al. [2006] demonstrated the inhibitory effect of TNF-α on hCG-β mRNA expres-
sion and hCG secretion in primary trophoblast cells isolated from healthy term pla-
centae. Okada et al. [1997] used chorioamnionitis as a disease-related model. They
observed less hCG production in tissue fragments cultured for 24 h from pre-term
placentae with chorioamnionitis compared to pre-term without chorioamnionitis.
Also, they showed that treatment of primary trophoblast cells isolated from healthy
placentae with LPS secreted less hCG than control treated cells. These findings are
in agreement with my data after LPS treatment of placental explants from high hCG
responder placentae. In contrast to these data, some groups postulated a stimula-
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tory effect of TNF-α on hCG secretion of trophoblast cells. In cellular models, hCG
secretion was increased after TNF-α treatment of JEG-3 and JAR cells [Pedersen
et al., 1995; Jiang et al., 2006]. However, the cell line characteristics might have
changed the regulation of hormone production and therefore, these data might not
be directly comparable to my experiments. Furthermore, Li et al. [1992] showed
that TNF-α had a stimulatory effect on hCG production from normal trophoblast
cells. On the other hand, this experiment was performed with trophoblasts isolated
from first trimester placentae, which might exhibit different characteristics com-
pared to term placentae. But conversely, Leisser et al. [2006] observed a decreased
hCG secretion after TNF-α treatment in placental explant culture prepared from
first trimester placentae.
Finally, the intra- and intervariability seem to be a common feature when do-
ing experiments with placental explant culture as it has been recognized by Turner
et al. [2006]. Because of this and the unpredictability of obtaining a high hCG
responder placenta and the difficulty of setting a standard for the characteristic of
high hCG responder, it was decided to shift focus towards pursuing experiments
with the BeWo cell line (see subsequent chapters 4 to 6).
Apoptosis is a molecular key mechanism that determines the overall responses
of placental explants. The changes of hCG secretion by placental explants after dif-
ferent stimuli treatments might be associated with potential alterations in the apop-
totic process. Also, apoptotic features are observed during cytotrophoblast differen-
tiation (Chapter 1.2.6.3) linking the two processes of apoptosis and differentiation. It
appears that CRH can alter the biochemical differentiation of trophoblasts as it had
an effect on the hCG secretion of the placental explants (discussed above). Whether
CRH plays a pro- or anti-apoptotic role on placental explant biology is not known.
Other studies revealed conflicting results regarding the pro- and anti-apoptotic ef-
fect of CRH. Dermitzaki et al. [2002] showed that CRH has a pro-apoptotic effect
in pheochromocytoma PC12 cells. An anti-apoptotic effect of CRH in pancreatic
cells was demonstrated by Schmid et al. [2011].
Apoptotic processes are also elevated in several placenta-related diseases. For
example, apoptosis is increased in placentae from pre-eclamptic and IUGR preg-
nancies [Leung et al., 2001; Ishihara et al., 2002]. Saglam et al. [2013] showed more
apoptosis in the fetal membranes in preterm premature rupture of fetal membranes
(PPROM). And Levy et al. [2002] showed a higher rate of trophoblast apoptosis
in fetal growth restriction accompanied by an elevated p53 expression. These ex-
amples demonstrate a deregulation of trophoblast apoptosis during several different
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placental disease states. In my study, co-treatment with LPS was performed to in-
vestigate whether CRH has effects on trophoblast apoptosis under conditions which
are characterized by activation of TLR4.
The M30-staining was used as a qualitative measurement of apoptosis. Again,
as it was shown for hCG secretion, placental explants showed inconsistent and vari-
able results regarding apoptosis. In order to quantify apoptotic events in placental
explants, multiplex ELISA for four apoptotic marker molecules (cleaved caspase-3,
cleaved PARP, p53, phospho-p53) was performed. The staurosporine treatment in
the initial experiment (shown in the Material and Methods Chapter) revealed that
the sample protein concentration in the subsequent experiments with CRH and LPS
was probably too low in order to detect differences in p53 and pp53 expression. How-
ever, the experiments were pursued in order to detect potential differences in the
cleavage of caspase-3 and PARP.
The culture conditions during the placental explant culture seem to have
an effect on the activation of caspase-3 as after four and five days of culture more
activated caspase-3 was detected. However, none of the other markers was changed.
This might be explained by the fact that the concentration of protein was not enough
for detecting changes (as explained in the paragraph above). On the other hand, it
could also mean that even though caspase-3 is activated, the apoptotic process is
executed incompletely suggesting that the tissue is not fully apoptotic.
Treatments with CRH and LPS did not lead to the detection of differences
in the expression of cleaved caspase-3, cleaved PARP, p53 and pp53. Possibly, CRH
and LPS do not affect apoptosis in placental cells. Or as the same experiment was
performed with BeWo cells by another student of our group and only a minimal effect
of LPS and CRH treatment on the expression of cleaved caspase-3 was detectable,
this shows that this method might not be the most suitable for tissues as it is always
more difficult to detect differences in a heterogenous tissue than in a homogenous
cell line.
Taken together, in this study due to limitations of detection methods and
the intervariable nature of placental explants, no reproducible effect of CRH and
LPS on placental explant apoptosis could be detected.
The initial characterization of molecules involved in glucocorticoid action in
placental tissue showed that 11β-HSD2, P-gp, and FKBP5 are expressed in pla-
cental explants. In my study, 11β-HSD2 and P-gp mRNA were upregulated after
treatment with dexamethasone. In a similar manner, Audette et al. [2010] observed
an upregulation of 11β-HSD2 mRNA after treating placental explants with dexam-
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ethasone. However, quantification of mRNA from the placental explants showed
a great variability between responses with the same treatment in my study. The
quality of the isolated mRNA was not good (low RNA yield, contamination of RNA
was detected by a low A260/280 and A260/230 ratios) and this might be a reason
for the variability.
Also the quantification of protein isolated from the placental explants showed
intravariability. Moreover, treatment with CRH had an inconsistent effect on 11β-
HSD2 protein expression suggesting an intervariability between placentae. The
problems could arise from the different percentages of syncytiotrophoblast, cytotro-
phoblast, mesenchymal cells and other cell types in the placental fragments. Also
possibly, the different explant samples could vary in their CRH receptor expression
as well as in CRH receptor linkage to G proteins.
Taken together, the preliminary data shows that placental explants retain
the trophoblast expression pattern of 11β-HSD2 as most of the protein is expressed
in the syncytiotrophblast layer. Furthermore, 11β-HSD2 is inducible in placental
explants upon stimulation as shown by treatment with dexamethasone. Also the
induction of FKBP5 (a known glucocorticoid responsive gene) by dexamethasone
demonstrates the responsiveness of placental tissue to glucocorticoids. However,
quantification of mRNA and protein isolated from placental explants revealed tech-
nical problems which were another reason to pause performing experiments on pla-
cental explants and to focus most subsequent studies on the BeWo cell line.
As a consequence of the various difficulties (intra- and intervariability of pla-
cental explants in hormone secretion and protein expression, poor mRNA quality,
high cost of performing placental explant experiments), the cell line BeWo was used
as an alternative placental model system (see chapter 4 for characterization of BeWo
cell line) in the subsequent chapters. Nevertheless under appropriate standardiza-
tion of methodologies, placental explants can allow a suitable system to investigate
placental endocrine function as well as glucocorticoid-driven mechanisms.
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Chapter 4
Characterization of BeWo Cells
as a suitable Model System
The placental explant culture experiments (shown in the previous chapter 3) identi-
fied a series of important issues in the investigation of placental responses to stress
hormones. This led to seek alternative models to increase robustness of experi-
ments. I chose the human choriocarcinoma cell line BeWo, a well-established model
for placental differentiation, as an in vitro cell model for the studies investigating
the trophoblast enzyme 11β-HSD2 and the trophoblast glucocorticoid metabolism
(Chapter 5 and 6).
I established in the initial stages of my investigation the characteristics of
BeWo cells regarding their cell turnover, endocrine capacity and expression of pro-
teins involved in the stress response and glucocorticoid action molecular machinery
such as CRH and its receptors, gluco- and mineralocorticoid receptor, and the en-
zyme 11β-HSD2.
In contrast to primary trophoblast cells, BeWo cells require treatment with
a cAMP-stimulator such as forskolin to initiate the differentiation process [Wice
et al., 1990; Delidaki et al., 2011]. The differentiation process involves cell fusion
and upregulation of key proteins including hormones such as hCG and progesterone
(Chapter 4.1). In addition to cell fusion and endocrine capacity, expression of molec-
ular components which are involved in the cellular stress response and glucocorticoid
action were characterized (Chapter 4.2).
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4.1 Differentiation of BeWo Cells with Forskolin
4.1.1 Fusion of BeWo Cells
Cell fusion was investigated with a nuclear staining, immunodetection of the cell ad-
hesion molecule E-Cadherin (= E-Cadherin staining), and a fluorescent cell-labeling
assay which monitors fusion processes (see chapter 2.5.1 for cell-labeling assay de-
tails). The brightfield images with nuclei staining showed areas of condensed nuclei
after 48 h of forskolin treatment (”‘forskolin 24 h + basal 24 h”’ and ”‘forskolin 48
h”’) (Figure 4.1) suggesting presence of fused BeWo cells. The E-Cadherin staining
showed an extensive reorganization and remodelling of the E-Cadherin distribution
after 48 h of forskolin treatment (”‘forskolin 24 h + basal 24 h”’ and ”‘forskolin 48
h”’) (Figure 4.2) compared to basal conditions also suggesting that BeWo cells have
fused. The fluorescent fusion assay showed large yellow stained areas which repre-
sent the fused cells after 48 h of forskolin treatment (Day 4) (Figure 4.3). These
detection methods also showed after 24 h of forskolin treatment only few areas with
condensed nuclei (nuclear staining) and break-up of the E-Cadherin structure only
in some areas suggesting that the fusions process has started after 24 h of forskolin
treatment, but was not sufficient for complete fusion of BeWo cells.
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Figure 4.1: Fusion of BeWo cells demonstrated by brightfield microscopy
(right) with DAPI staining (left). BeWo cells were cultured with and without
100 µM forskolin for various time points before their nuclei were stained with DAPI,
which is shown in blue. Representative images are shown, n=3, bar = 100 µm,
arrows indicate areas with fused cells.
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Figure 4.2: Fusion of BeWo cells demonstrated by E-Cadherin staining.
BeWo cells were cultured with and without 100 µM forskolin for various time points
before they were stained for E-Cadherin (a membrane protein), which is shown in
green. Nuclei are stained blue with DAPI. Representative images are shown, n=3,
Left: bar = 40 µm, right: bar = 17 µm.
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Figure 4.3: Fusion of BeWo cells demonstrated by monitoring two BeWo
cell populations labelled with two different cell tracer dyes (Dil or DiO),
seeded together. BeWo cells were grown for two days before treating them with
100 µM forskolin for 24 (= Day 3) and 48 h (= Day 4). Green = DiO staining, red
= Dil staining, yellow = Dil and DiO staining. Representative images are shown,
n=2, bar = 100 µm, arrows indicate fused cells.
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4.1.2 Expression of Fusogenic Genes and their Receptors
Successful differentiation and cell fusion of trophoblast cells depend on upregula-
tion of expression of the endogenous fusogenic retroviral proteins Syncytin-1 and
Syncytin-2 which bind to the receptors ASCT2 and MFSD2, respectively. In agree-
ment with the established models of trophoblast differentiation, treatment of cells
with forskolin showed qualitatively the protein expression of Syncytin-1 in the BeWo
cell line (Figure 4.4 A). Both Syncytin-1 and -2 were significantly increased by 2.1-
fold and 8.2-fold, respectively, after 24 h of 100 µM forskolin exposure at mRNA
level compared to control-treated cells (Figure 4.4 B, C). After 48 h of 100 µM
forskolin stimulation, there was a reduction of the forskolin-induced Syncytin-1 and
-2 mRNA expression compared to the 24 h time point, although their expression
was still significantly upregulated by 1.6-fold and 1.7-fold, respectively, compared
to control-treated cells (Figure 4.4 D, E).
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Figure 4.4: Expression of Syncytin-1 and -2 after forskolin treatment. BeWo
cells were treated with 100 µM forskolin for 24 h before (A) staining for Syncytin-1
protein was performed or for 24 h and 48 h before (B-E) mRNA was extracted
and qRT-PCR for Syncytin-1 and -2 was performed. (A) Green = Syncytin-1, blue
(DAPI staining)= nuclei. Representative image is shown. (B-E) Normalization to
18S rRNA, n=6 (24 h) and n=3 (48 h), data are expressed as mean values ± SEM,
t-test: p<0.05 (=*), p<0.01 (=**), p<0.001 (=***).
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I also investigated the expression of the Syncytin-1 receptor ASCT2 mRNA
which showed a trend of downregulation after forskolin treatment, despite failure to
reach statistical significance (Figure 4.5 A), whereas the Syncytin-2 receptor MFSD2
mRNA was significantly up-regulated after 24 h of 100 µM forskolin treatment (Fig-
ure 4.5 B).
Figure 4.5: Expression of the Syncytin-1 and -2 receptors (ASCT2 and
MFSD2) after forskolin treatment. BeWo cells were treated with 100 µM
forskolin for 24 h before mRNA was extracted and qRT-PCR for (A) ASCT2 and
(B) MFSD2 was performed. qRT-PCRs were normalized to RPLP0 mRNA expres-
sion, n=3, data are expressed as mean values ± SEM, t-test: ns = non-significant,
p<0.001 (=***).
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4.1.3 Caspase-3/7 Activation during the Fusion Process
The effect of forskolin on BeWo cell apoptosis was investigated because activation
of the trophoblast fusion process involves apoptotic mechanisms (Chapter 1.2.6.3).
Treatment of BeWo cells with 100 µM forskolin caused a time-dependent
increase in caspase-3/7 activation (Figure 4.6). Non-treated cells (Figure 4.6 A)
displayed only a few scattered cells positively stained with a specific antibody for
actived caspase-3/7. After 24 h treatment with forskolin, there was an increase in
the number of signal-positive cells mostly found within areas of cell fusion into a
syncytium (Figure 4.6 B). In contrast, non-fused areas did not exhibit a staining for
activated caspase-3/7. After 48 h of exposure to forskolin, large areas of the cells
were fused and were positive for activated caspase-3/7 staining (Figure 4.6 C).
Interestingly, the medium change after 24 h also had an influence on the
activation of caspase-3/7 in the cells. The non-treated cells without medium change
had more green-stained cells than the non-treated cells with medium change (Fig-
ure 4.6 compare D with B). This effect was also observed in forskolin-treated cells
as cells treated with forskolin for 48 h without a medium change displayed more
signal-positive cells than cells treated with forskolin for 48 h with a medium change
(Figure 4.6 compare E with C).
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Figure 4.6: Activated caspase-3/7 after 24 h and 48 h of forskolin treatment
(with and without medium change after 24 h). BeWo cells were cultured
with and without 100 µM forskolin for 24 h and 48 h before a staining for activated
caspase-3/7 was performed. Nuclei are stained blue with DAPI. Left: overlay of
DAPI and caspase-3/7 staining (green), right: brightfield image. Representative
images are shown, n=2, bar = 100 µm, arrows in the brightfield images indicate
areas of fused cells.
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To obtain quantitative information, I employed an additional approach based
on the detection of a fluorescent substrate which is cleaved by activated caspase-3
and -7 (= ApoONE assay, see chapter 2.7.3 for details). This quantitative measure-
ment of activated caspase-3/7 after 24 h of 100 µM forskolin treatment showed a
significant increase in activated caspase-3/7 by 1.8-fold (Figure 4.7).
Figure 4.7: Activated caspase-3/7 after 24 h of forskolin treatment in BeWo
cells. BeWo cells were cultured with and without 100 µM forskolin for 24 h before
the ApoONE assay was performed which measures activated caspase-3/7. Data are
expressed as mean values ± SEM, n=3, t-test: p<0.01 (=**).
4.1.4 Hormone Production of BeWo Cells
Having established that upon forskolin stimulation the BeWo cells fuse, the fusogenic
machinery is upregulated and proapoptotic cascades are activated, I then investi-
gated the BeWo cell capacity to secrete hormones. The placenta is an endocrine
organ secreting peptide and steroid hormones such as hCG, progesterone (P4), and
estradiol (E2). The capacity of BeWo cells for the production of hCG, P4, E2 and
cortisol was investigated in un- and differentiated BeWo cells. It has been estab-
lished that placental cell lines have the capacity to synthesize and release steroid
and peptide hormones, especially under conditions of induced differentiation [Knoth
et al., 1969; Pattillo et al., 1971; Sullivan, 2004].
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4.1.4.1 hCG, P4, and E2 Production of BeWo Cells
Human CG, P4, and E2 secretion was monitored at various time points (24 and 48
h) after 100 µM forskolin treatment. Figure 4.8 A shows a significant 8-fold increase
of hCG release after 24 h of forskolin treatment (mean 3043 mIU/L ± 160 SEM)
compared to non-treated cells (mean 374 mIU/L ± 11 SEM). The hCG production
was further increased after 48 h of forskolin stimulation, although basal hCG release
was also slightly increased (mean concentration of 5383 mIU/L ± 96 SEM and 612
mIU/L ± 62 SEM, respectively).
Figure 4.8 B shows that forskolin treatment led to a significant increase in
P4 production compared to control-treated cells by 3-fold both after 24 h and 48 h.
In contrast, forskolin treatment for 24 and 48 h did not affect estradiol se-
cretion compared to control-treated cells (Figure 4.8 C).
Figure 4.8: hCG, P4, and E2 production of BeWo cells. BeWo cells were
cultured with and without 100 µM forskolin for 24 h and 48 h and the concentration
of secreted hCG, P4, and E2 was measured in the supernatant. Hormone concen-
tration was normalized to protein concentration of BeWo cells. Data are expressed
as mean values ± SEM, n=4, t-test: p<0.01 (=**), p<0.001 (=***).
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E2 Production is dependent on FBS
The enzyme cytochrome P450 17A1 (= steroid 17-alpha-hydroxylase), which is en-
coded by the CYP17A1 gene, is lacking in the placenta and as a consequence the
placenta can not produce estrogen de novo. In vivo, the placenta is supplied with
DHEA and DHEAS as precursor molecules for estrogens (see ”‘Estrogen”’ in chap-
ter 1.2.7.2) and the enzymes sulfatase, 3β-HSD, 17β-HSD, and P450 aromatase are
involved in the production of the hormones estrone and estradiol (E2). Similar to
the in vivo situation, BeWo cells require precursor molecules for E2 production.
Ugele and Simon [1999] showed that BeWo cells can uptake DHEA-S. Also it has
been shown by Pattillo et al. [1972] that BeWo cells can produce E2 from DHEA.
Furthermore, Bahn et al. [1981] saw that BeWo cells can produce E2 when FCS is
available in the cell culture.
Since in our BeWo cell culture we could measure E2 secretion, I investigated
whether E2 production was dependent on precursors found in cell culture medium.
BeWo cells produced estradiol in an FBS concentration-dependent manner as shown
in Figure 4.9 leading to the conclusion that fetal bovine serum contains the precur-
sor molecules.
4.1.4.2 Cortisol Production of BeWo Cells
Because of the lack of the enzyme steroid 21-hydroxylase, which is encoded by
CYP21A2, cortisol can not be produced by the placenta de novo [Sullivan, 2004].
In vitro, BeWo cells in their undifferentiated state (without forskolin treatment) did
not produce any detectable levels of cortisol (mean cortisol concentration = 5.33
nmol/L ± 0.091 SEM) as the F12K medium with 10% FBS supplement contained
5.62 nmol/L (± SEM) itself (data not shown). Treatment with 100 µM forskolin led
to a small (24%), but significant, increase of cortisol in the supernatant from 5.33
nmol/L (± 0.091 SEM) in basal condition to 6.60 nmol/L (± 0.287 SEM) after 24 h
and from 6.84 nmol/L (± 0.790 SEM) in basal conditions to 10.18 nmol/L (± 1.079
SEM) (=49%) after 48 h (Figure 4.10) suggesting that the immortalized BeWo cell
line has acquired some ability to produce small amounts of cortisol.
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Figure 4.9: FBS-dependent E2 production of BeWo cells. BeWo cells were
cultured with different concentrations of FBS (0-10%) for 24 h and the concentration
of secreted E2 was measured in the supernatant. E2 concentration is normalized to
protein concentration of BeWo cells. Data are expressed as mean values ± SEM,
n=3, 1-way ANOVA, Bonferroni Posttest: p<0.05 (=*), p<0.001 (=***), compared
to 0% FBS.
Figure 4.10: Cortisol production of BeWo cells. BeWo cells were cultured with
and without 100 µM forskolin for 24 h and 48 h and the concentration of cortisol
was measured in the supernatant. Cortisol concentration is normalized to protein
concentration of BeWo cells. Data are expressed as mean values ± SEM, n=4, t-test:
p<0.05 (=*).
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4.2 Expression of Molecules involved in Stress Response
CRH, the master regulator of the stress axis (HPA axis), is also expressed in the
placenta (Chapter 1.1.2.2) playing a potential role in regulatory processes during
trophoblast development and feto-maternal communication. Also, the presence of
the glucocorticoid barrier in the placenta plays a key role for the appropriate de-
velopment of the fetus. The main component of the glucocorticoid barrier is the
enzyme 11β-HSD2 which converts cortisol into its inactive form cortisone (Chapter
1.1.5). Additionally, transporter molecules such as P-gp which can transport cor-
tisol out of the cell are components of the glucocorticoid barrier (Chapter 1.1.6).
Furthermore, the expression of receptors which bind cortisol, namely the gluco- and
mineralocorticoid receptor (Chapter 1.1.3), determines the action of cortisol within
the cells. In this chapter, to obtain a better understanding of the molecules involved
in the adaptive mechanisms of stress responses, I investigated the expression of hor-
mones and receptors in BeWo cells which are involved in the stress response and
glucocorticoid action.
In vivo, the placenta expresses the hormone CRH and its two receptors CRH-
R1 and -R2, the two steroid receptors glucocorticoid receptor (GR) and mineralo-
corticoid receptor (MR), the enzyme 11β-HSD2, and the transporter molecules P-gp
and BCRP and so it was important to characterize the expression of these molecules
in the BeWo cell line. Furthermore, the expression of these molecules after forskolin-
induced differentiation was investigated.
4.2.1 Expression of CRH, CRH-R1 and -R2 in BeWo Cells
CRH might coordinate placental glucocorticoid action because a positive-forward-
loop between CRH and cortisol in the placenta has been demonstrated (Chapter
1.1.2.2, Robinson et al. [1988]). In the BeWo cells, mRNA expression of CRH and
both of its receptors CRH-R1 and CRH-R2 was significantly upregulated by 2.2-,
3.0- and 2.1-fold, respectively, after 24 h of 100 µM forskolin treatment compared
to control-treated cells (Figure 4.11). In case mRNA is translated into protein, this
suggests that differentiated BeWo cells are more responsive to CRH cellular action.
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Figure 4.11: mRNA expression of CRH, CRH-R1, and CRH-R2 in BeWo
cells after forskolin treatment. BeWo cells were treated with 100 µM forskolin
for 24 h before mRNA was isolated and qRT-PCR for CRH (A), CRH-R1 (B),
and CRH-R2 (C) was performed. Samples were normalized to GAPDH mRNA
expression, data are expressed as mean values ± SEM, n=6, t-test: p<0.05 (=*),
p<0.001 (=***).
A qualitative immunostaining for CRH-R1 and -R2 revealed their protein
expression in forskolin-treated BeWo cells (Figure 4.12).
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Figure 4.12: CRH-R1 and -R2 staining in BeWo cells after forskolin treat-
ment. BeWo cells were treated with 100 µM fsk for 24 h before an immunostaining
for CRH-R1 and -R2 was performed. Only images of forskolin-treated cells are
shown. Secondary antibody for CRH-R1 staining was ALEXA-633, shown in red.
Secondary antibody for CRH-R2 was ALEXA-488, shown in green. Blue DAPI-
staining of the nuclei. Representative images are shown, left images: bar = 47.62
µm, right images: bar = 24.83 µm.
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4.2.2 Expression of GR and MR in BeWo Cells
Previous studies identified MR expression in the placenta throughout pregnancy
in the cytotrophoblast cells as well as in the syncytiotrophoblast [Hirasawa et al.,
2000]. The GR was also identified in cytotrophoblast cells and to a lesser degree
in syncytiotrophoblast [Lee et al., 2005]. Using qRT-PCR, the steroid receptor GR
and MR mRNA were identified in the BeWo cells (Figure 4.13). GR mRNA expres-
sion was not affected by 100 µM forskolin treatment (Figure 4.13 A), whereas MR
mRNA expression was significantly downregulated by 72% and 34%, respectively,
after 24 h and 48 h of forskolin treatment (Figure 4.13 B). Analysis of GR and
MR protein expression was not successful because of problems with antibodies (see
chapter 2.4.6.3 for details).
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Figure 4.13: mRNA expression of GRα and MR in BeWo cells after
forskolin treatment. BeWo cells were treated with 100 µM forskolin for 24 h
(left graphs) or plus another 24 h of fresh medium (= 48 h, right graphs) before
mRNA was isolated and qRT-PCR for GRα (A) and MR (B) was performed. Sam-
ples were normalized to 18S rRNA expression, n=6 (for 24 h), n=3 (for 48 h), data
are expressed as mean values ± SEM, t-test: ns = non-significant, p<0.01 (=**),
p<0.001 (=***).
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4.2.3 Expression of 11β-HSD2 in BeWo cells
Because the enzyme 11β-HSD2 inactivates cortisol, its expression is extremely im-
portant in the regulation of glucocorticoid action within cells. In the placenta,
11β-HSD2 is highly expressed in the syncytiotrophoblast layer as it was shown pre-
viously (Figure 3.13 in Chapter 3.4.2). Figure 4.14 A shows that mRNA expression
of 11β-HSD2 was highly upregulated by 30-fold by forskolin treatment after 24 h.
However, this increase was transient and prolonged stimulation with forskolin for 48
h led to an increase by only 4.8-fold (Figure 4.14 B).
Figure 4.14: mRNA expression of 11β-HSD2 in BeWo cells after forskolin
treatment. BeWo cells were treated with 100 µM forskolin for (A) 24 and (B) 48
h before mRNA was isolated and a qRT-PCR for 11β-HSD2 was performed. qRT-
PCR was normalized to 18S rRNA expression, n=6 (for 24 h), n=3 (for 48 h), t-test:
p<0.001 (=***).
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Immunostaining for 11β-HSD2 in BeWo cells demonstrated cytoplasmic ex-
pression (Figure 4.15). Treatment with forskolin for 24 h led to a substantial increase
in 11β-HSD2 immunostaining compared to basal condition.
Figure 4.15: 11β-HSD2 staining in BeWo cells after forskolin treatment.
BeWo cells were treated with 100 µM forskolin for 24 h before an immunostaining
for 11β-HSD2 was performed. Secondary antibody used was ALEXA-633, shown in
red. Blue DAPI-staining of the nuclei. Representative images are shown, n=3, top:
bar = 40 µm, bottom: bar = 17 µm.
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Cortisol Inactivation in BeWo Cells
As the enzyme 11β-HSD2 inactivates cortisol, the measurement of its activity in
addition to the mRNA and protein expression was very important. Furthermore,
since forskolin treatment led to a very high increase in 11β-HSD2 expression, it
was hypothesized that forskolin-treated differentiated BeWo cells would be able to
metabolize cortisol much more effectively than undifferentiated BeWo cells. In order
to test this hypothesis, an 11β-HSD2 activity assay which indirectly measures 11β-
HSD2 activity was designed.
BeWo cells were treated with different concentrations of exogenous cortisol
in the presence or absence of forskolin treatment for 24 h. At the end of the incu-
bation period remaining cortisol was measured in the supernatant. The BeWo cells
produced only very low amounts of cortisol (1.27 nmol/L) after forskolin treatment
for 24 h (Chapter 4.1.4.2) which was negligible for this method.
Figure 4.16 A and B show that exogenous cortisol was metabolized differen-
tially by un- and differentiated BeWo cells (with and without forskolin treatment).
In undifferentiated BeWo cells (Figure 4.16 A), 85% of the 100 nM exogenous corti-
sol was metabolized, 65% of the 250 nM cortisol, and around 35% of the 500, 1000,
1500 and 2000 nM cortisol. In differentiated BeWo cells (Figure 4.16 B), 100, 250,
500 nM of exogenous cortisol were metabolized in excess of 95%. Treatment with
1000, 1500 and 2000 nM of cortisol led to its inactivation by 83%, 70% and by 56%.
This result suggests that forskolin treatment leads to a more effective inactivation
of cortisol presumably by increased expression of 11β-HSD2 which is in agreement
with the forskolin-induced upregulation of 11β-HSD2 expression (Chapter 4.2.3).
This assay successfully monitored the activity of the enzyme 11β-HSD2 in
an indirect manner and was used in the subsequent experiments to determine the
11β-HSD2 activity.
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Figure 4.16: Activity of 11β-HSD2 in BeWo cells. BeWo cells were treated
with varying concentrations of cortisol (B) with and (A) without 100 µM forskolin
for 24 h before the remaining cortisol was measured in the supernatant. Cortisol
concentration is normalized to protein concentration of BeWo cells, n=4.
4.2.4 Expression of Transporter Proteins P-gp and BCRP in BeWo
Cells
I also attempted to determine the effect of forskolin on P-glycoprotein (ABCB1) and
BCRP (ABCG2) expression. P-pg and BCRP mRNAs were expressed in the BeWo
cells and were both significantly upregulated by forskolin treatment compared to
control-treated cells (Figure 4.17). However, further analysis of P-gp in subsequent
chapters was not considered suitable due to its low level of expression (mean Ct
value was 34.4).
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Figure 4.17: mRNA expression of P-gp and BCRP in BeWo cells after
forskolin treatment. BeWo cells were treated with 100 µM forskolin for 24 h
before mRNA was isolated and a qRT-PCR for P-gp (A) and BCRP (B) was per-
formed. qRT-PCR was normalized to 18S rRNA expression, n=3, data are expressed
as mean values ± SEM, t-test: p<0.05 (=*), p<0.01 (=**).
4.3 Discussion of Chapter 4
The data of this chapter show that BeWo cell fusion and differentiation can be
successfully established and monitored upon forskolin stimulation (Figure 4.18 for
summary) in agreement with previous studies [Ringler and Strauss, 1990; Wice
et al., 1990; Sullivan, 2004; Orendi et al., 2011]. BeWo cells morphologically fuse
after forskolin treatment which is associated with an upregulation of the fusogenes
Syncytin-1 and Syncytin-2. In parallel, biochemical differentiation of the BeWo cells
is activated. During this process, endocrine activity of BeWo cells is established as
shown by the upregulation of the hormones hCG and progesterone. Furthermore,
the expression of the hormone CRH and its receptors CRH-R1 and CRH-R2 is
increased after forskolin treatment which might increase cell responsiveness to au-
tocrine actions of CRH. Also, the glucocorticoid barrier enhances upon trophoblast
differentiation as the enzyme 11β-HSD2 and cortisol transporter molecules are up-
regulated. Regarding glucocorticoid action, the two cortisol-binding receptors gluco-
and mineralocorticoid receptor are expressed in the BeWo cells, the latter being
downregulated during differentiation. This might act as a counterregulatory mech-
anism to protect the cells against inappropriate MR-stimulation.
These data demonstrate that BeWo cells are an appropriate model to inves-
tigate the trophoblast biological functions of 11β-HSD2, its cross-talk with CRH
and glucocorticoids and placental cortisol metabolism (see chapters 5 and 6).
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Figure 4.18: Summary of forskolin effects on BeWo cell biology.
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A very important process in the lifespan of a placenta is the differentiation
of cytotrophoblasts into a syncytium. In vivo, the cytotrophoblast cells start their
cellular differentiation and ultimately fuse with the adjacent syncytiotrophoblast.
During this process, the biochemical characteristics of the cells change, e.g. the
syncytiotrophoblast produces large amounts of hormones such as hCG, progesterone
and placental lactogen [Reis et al., 2001]. Hence, a key task of this experimental
approach was to show that the BeWo cells are able to fuse as well as undergo
biochemical differentiation.
In order to monitor the fusion process of BeWo cells, three different methods
(brightfield microscopy with nuclei staining, fluorescent membrane staining, fluo-
rescent cell tracker staining) were used since the detection of the fusion process is
challenging. Brightfield images with a DAPI-nuclei staining is the easiest method
and it lets presume that in my experiment BeWo cells have fused after forskolin
treatment in some areas shown by a more dense accumulation of nuclei. However,
staining of the cell membrane is a more appropriate method since it is able to
demonstrate the loss of the cell membranes which is a characteristic of cell fusion.
Coutifaris et al. [1991] investigated the E-Cadherin expression in primary isolated
cytotrophoblasts as well as in BeWo cells and in non-fusing JEG-3 cells. They
showed that in BeWo cells, treated with 8-bromo cyclic AMP, and in primary cells
the E-Cadherin disappeares in fused cells, whereas in JEG-3 cells no difference in
E-Cadherin staining is detectable. In agreement with this, 48 h of forskolin treat-
ment in my experiment also led to disappearance of E-Cadherin staining in areas
of fused cells. Another method to detect cell fusion was based on the labeling of
two BeWo cell populations with different cell tracker dyes and their subsequent pro-
liferation and differentiation after mixing the two populations. During the fusion
process, cytoplasmic content is exchanged between the fused cells and in case of us-
ing the cell tracker dyes Dil (red fluorescence) and DiO (green fluorescence), fused
cells are detectable as double-fluorescent yellow (overlay of red and green) stained
cells as it was in my experiment after treating the BeWo cells with forskolin. Borges
et al. [2003] and Wang et al. [2014a] used a comparable cell tracker dye method to
show the fusion in BeWo, JEG-3, JAR cells and in primary trophoblast cells. Sim-
ilarly to my results, they observed double-stained areas in BeWo cell and primary
trophoblast cell populations, but not in JEG-3 nor JAR cells.
Borges et al. [2003] showed only minimal BeWo cell fusion after 24 h of 50
µM forskolin treatment which is in agreement with my observation. After 48 h of
forskolin treatment, they detect considerably more fused cells than after 24 h. Also,
Kudo et al. [2003a] showed maximal fusion of BeWo cells after 100 µM forskolin
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treatment for 48 h. Taken these results together, it can be concluded that the fu-
sion process of BeWo slowly progresses for the first 24 h of forskolin treatment, but
48 h of forskolin treatment is required to allow significant fusion of BeWo cells to
be detected consistently.
Important molecules involved in the fusion process of trophobast cells are
the fusogenes Syncytin-1 and Syncytin-2 with their receptors. Syncytins and their
receptors play a fundamental role in the fusion process of cytotrophoblasts into the
syncytium in the placenta [Po¨tgens et al., 2004] as well as in fusion of primary cells
and cell lines (see subchapter ”‘Synctin-1 and Syncytin-2”’ in chapter 1.2.5.3).
Several groups have shown that BeWo cells express Syncytin-1 and -2 and
that forskolin treatment upregulates their expression [Kudo and Boyd, 2002; Vargas
et al., 2009]. Similarly, my data confirmed an upregulation of Syncytin-1 and -2 on
mRNA level after forskolin treatment. Interestingly, it showed a higher upregulation
of Syncytin-1 and -2 occurs after 24 h than after 48 h of forskolin treatment. Thus
it seems that, after 24 h of forskolin treatment the fusogenes Syncytin-1 and -2 are
highly upregulated, but the physical fusion process is at its early stages and requires
at least 48 h for detectable fusion.
Regarding the fusogene receptors ASCT2 (Syncytin-1 receptor) and MFSD2
(Syncytin-2 receptor), mRNA expression of ASCT2 showed a trend to be downreg-
ulated after 24 h of forskolin, whereas MFSD2 mRNA was upregulated. Similar to
these findings, Kudo et al. [2004] and Kudo et al. [2003c] detected a downregulation
of ASCT2 mRNA after forskolin treatment in BeWo cells. Furthermore, Toufaily
et al. [2013] observed an upregulation of MFSD2 mRNA and protein in forskolin-
treated BeWo cells. My data concerning the syncytins and their receptors appear
to be in agreement with the previously published literature.
Viability and apoptosis studies on BeWo cells have shown that forskolin
treatment affects cell viability and apoptosis [Al-Nasiry et al., 2006; Chen et al.,
2011]. Compared to the in vivo situation in the placenta, this treatment with a
possibly toxic chemical substance is a disadvantage of the BeWo cell system. On
the other hand, the most representative system available are primary trophoblast
cells or placental explants, but as mentioned in the previous chapter, placental
explants are characterized by poor reproducibility. Similar issues might be present
when performing experiments with primary trophoblast cells, however this might
be less present as primary cells consist of one homogenous cell type.
As differentiation processes seem to be linked to apoptotic processes (Chapter
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1.2.6.3), apoptosis in BeWo cells after forskolin treatment was investigated. Areas
of fused cells displayed activated caspase-3/7 which indicates that the differentiation
process is linked to apoptotic processes in BeWos cells similar to the situation in
vivo. In my staining experiments, longer incubation with forskolin (when compar-
ing 24 h with 48 h of forskolin treatment) activated more caspase-3/7. Chen et al.
[2011] also showed an activation of caspase-3 as early as after 24 h of treatment with
8-Br-cAMP. Because after 48 h of forskolin treatment detached floating BeWo cells
were observed in addition to apoptotic processes, forskolin treatment was set to 24
h for all subsequent experiments. This experimental design ensured that the BeWo
cells were viable during other treatments and that results would be compromised as
little as possible by apoptosis. Moreover, the observed downregulation of forskolin-
induced expression of Syncytin-1 and -2 as well as 11β-HSD2 after 48 h compared
to 24 h of forskolin stimulation might result from the apoptotic processes.
hCG is the hormone which is most often used as a marker for biochemical
differentiation of trophoblast cells in many studies which used primary trophoblast
cells or trophoblast cell line systems. In my experiments, incubation of BeWo cells
with forskolin increased the hCG secretion by 8-fold. Likewise, Chou et al. [1978],
Futamura et al. [1987] and Delidaki et al. [2011] showed that stimulation of cAMP
increases the hCG production in BeWos. Ringler et al. [1989b] treated primary tro-
phoblast cells with forskolin which induced hCG production. Even though, primary
trophoblast cells are capable of secreting hCG without stimulation of cAMP with
forskolin or other cAMP-stimulating agents, this result reveals that forskolin has
the same effect in primary cells as in trophoblast cell lines. Thus, BeWo cells seem
to behave similar to primary cells after being treated with forskolin.
Interestingly, it has been shown by Al-Nasiry et al. [2006] and Orendi et al.
[2010] that the fusion process of cells is uncoupled from the biochemical differen-
tiation. Al-Nasiry et al. [2006] showed that in the non-fusing trophoblast cell line
JEG-3, forskolin stimulation leads to an increase in hCG production while no fusion
is occuring. Orendi et al. [2010] observed an hCG production in forskolin-stimulated
BeWo cells after blocking the cell fusion. Similarly to these findings, my data showed
that fusion events are barely detectable after 24 h of forskolin treatment whereas
hCG production was already increased by 8-fold suggesting that biochemical differ-
entiation is progressing more rapidely in BeWo cells. Another possibility is that hCG
production might accelerate the BeWo cell fusion process in an autocrine manner.
In support of this, Dhar et al. [2004] showed that after blocking the endogenous hCG
with an antibody, primary cytotrophoblast fusion is impaired. The expression of the
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hCG receptor in placental tissue was shown by Reshef et al. [1990], and Shi et al.
[1993] also showed that hCG regulates cytotrophoblast differentiation in primary
cells.
The hormones progesterone (P4) and estradiol (E2) have multiple very im-
portant functions in placentation and fetal development and growth (see chapter
1.2.7.2) and therefore, they would be important marker molecules for endocrine func-
tionality. Progesterone secretion increased after forskolin treatment in BeWo cells.
This finding is consistent with the result from Nulsen et al. [1989] and Maldonado-
Mercado et al. [2008]. They showed that stimulation of cAMP upregulates proges-
terone secretion in BeWo cells. Progesterone might act in an autocrine manner on
BeWo cells as these are shown to express different progesterone receptors [Zachari-
ades et al., 2011]. Also, a cross-talk of hCG with P4 might occur in the BeWo cell
line since Dhar et al. [2004] showed that blocking of hCG by using an hCG antibody
decreased the production of progesterone in primary trophoblast cells. So it might
be possible that hCG is an autocrine inducer of P4 production which could explain
the similar secretion pattern of both hormones after forskolin treatment. Further-
more, progesterone then might have a positive effect on cell fusion as Noorali et al.
[2009] detected the upregulation of Syncytin-1 by progesterone in a trophoblast cell
line.
Cortisol can not be produced by trophoblasts because the enzymes 21-hydro-
xylase (CYP21A2) and 11β-hydroxylase (CYP11B1) are absent [Sullivan, 2004]. In-
terestingly, there seems to be a different setting in BeWo cells. My result showed a
small increase of cortisol production after forskolin treatment. Jeschke et al. [2007]
also observed that BeWo cells can produce cortisol. They did not treat the cells
with forskolin, but they observed a small increase in cortisol production after treat-
ment with glycodelin A N-glycan. Nevertheless, it shows that BeWo cells seem to
be capable of producing small amounts of cortisol.
Investigations of additional molecules showed that BeWo cells expressed CRH
and both receptor (CRH-R1 and -R2) mRNA and all of which were upregulated
after forskolin treatment. Similar to my studies, Chen et al. [2013] showed that
8-Br-cAMP treatment leads to an upregulation of CRH and both CRH-R1 and -R2
mRNAs in BeWo cells. Furthermore, this is identical to the up-regulation of CRH
by forskolin and 8-Br-cAMP in primary trophoblast cells [Cheng et al., 2000]. Like
the hormones hCG and progesterone, CRH might have an effect on the fusion of
the BeWo cells. Chen et al. [2013] showed that treatment of BeWo cells with CRH
leads to an upregulation of Syncytin-1 and increased the fusion process. On the
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other hand, even though Fahlbusch et al. [2012] could demonstrate a CRH-induced
upregulation of Syncytin-1 in primary trophoblast cells, they did not detect an as-
sociated increased syncytialisation process. These discrepancies indicate that the
role of CRH is unclear.
Placental tissue is responsive to glucocorticoids [Giannopoulos et al., 1983;
Lo´pez Bernal et al., 1984] and both receptors, gluco- and mineralocorticoid recep-
tor, are expressed [Hirasawa et al., 2000; Driver et al., 2003; Patel et al., 2003; Chan
et al., 2003]. In my experiments, BeWo cells expressed the glucocorticoid and the
mineralocortiocid receptor mRNA, and interestingly the latter was downregulated
after forskolin treatment, whereas the glucocorticoid receptor was not affected. The
downregulation of the mineralocorticoid receptor seems to be a mechanism which
leads to protection of the cells against inappropriate stimulation of MR by cortisol
in their differentiated state (i.e. syncytium-like state). Mark and Waddell [2006]
detected a low expression of GR in BeWo cells which prompted them to use a GRα
expression vector in their studies.
The syncytiotrophoblast of the placenta highly expresses 11β-HSD2 and this
successfully inactivates cortisol, protecting the fetus from excess cortisol [Krozowski
et al., 1995]. This is considered to be the main function of placental 11β-HSD2 and
has been subject to extensive research over the past years.
After differentiation (treatment with forskolin) the BeWo cells expressed con-
siderably higher levels of 11β-HSD2 mRNA and protein than the undifferentiated
cells suggesting that BeWo cells decrease cortisol action in their differentiated state.
This pattern seems to be similar to the placental in vivo situation where the syncy-
tiotrophoblast layer expresses high amounts of 11β-HSD2 [Krozowski et al., 1995].
In addition, it has been shown before that stimulation of cAMP induces 11β-HSD2
expression in primary trophoblast cells [Sun et al., 1998]. Thus, the regulation of
11β-HSD2 in BeWo cells seems to be comparable to other cell systems. Na´ray-
Fejes-To´th and Fejes-To´th [1996] investigated the localisation of 11β-HSD2 with a
GFP-fusion protein and discovered its localisation in the cytosol, more specifically
as a reticular network, but no expression of the enzyme in the membrane nor in
the nucleus of CHO cells. In contrast, Shimojo et al. [1997] observed a proportion
of 11β-HSD2 localized in the nucleus in kidney sections. So, the localisation of the
enzyme seems to be celltype-specific and the BeWo cells displayed a cytoplasmic
localisation of the 11β-HSD2.
11β-HSD2 also influences the local glucocorticoid action within the tro-
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phoblast cells. By inactivating cortisol into cortisone, less cortisol molecules are
available within the syncytiotrophoblast to bind to the gluco- as well as mineralocor-
ticoid receptor and consequently, less glucocorticoid action takes place. Thus, 11β-
HSD2 limits the local glucocorticoid action within the placenta. In mineralocorticoid-
target tissue, the main function of 11β-HSD2 is considered to be the protection of the
MR against cortisol binding [Edwards et al., 1988; Funder et al., 1988]. Potentially
this function of 11β-HSD2 within the placenta might also be of high importance.
Driver et al. [2003] characterized the placenta as a mineralocorticoid-target tissue
due to its expression of a functional MR. Especially, the observation that forskolin
downregulates the MR expression during BeWo cell differentiation (see above) com-
bined with the high upregulation of 11β-HSD2 after forskolin treatment might pro-
vide clues that during trophoblast differentiation, the system prevents inappropriate
effects of cortisol via MR.
Another important player in regulating glucocorticoid action are transporter
molecules (see chapter 1.1.6). Both ABC transporter molecules P-glycoprotein
(ABCB1) and BCRP (ABCG2) are expressed in the placenta [Ceckova et al., 2006].
It has been shown that the transporter P-glycoprotein can transport cortisol mole-
cules out of the cell. The BeWo cells did express P-glycoprotein mRNA, but due to
its low expression, investigation of this transporter was not pursued further. Even
though Utoguchi et al. [2000] and Mark and Waddell [2006] observed a functional
P-glycoprotein transporter in BeWo cells, several other groups did report a low
expression of P-glycoprotein in BeWo cells [Atkinson et al., 2003; Evseenko et al.,
2006]. In addition, Ceckova et al. [2006], Magnarin et al. [2008] and Crowe and
Keelan [2012] did not detect any P-glycoprotein in BeWo cells.
The eﬄux transporter molecule BCRP is predicted to transport cortisol
[Mares-Sa´mano et al., 2009] and its mRNA expression was very high in BeWo cells
and was further upregulated by forskolin treatment. Consistent with this result,
Ceckova et al. [2006] showed a high expression of BCRP in BeWo cells and Evseenko
et al. [2006] showed that BCRP mRNA increases during primary trophoblast differ-
entiation. In the subsequent chapters, only analysis of the transporter BCRP was
further pursued.
Characterization of the BeWo cells revealed that once the cells differentiate,
they elevate hormone secretion suggesting an increased endocrine activity which
mimics the endocrine capacity of the placental syncytiotrophoblast. They also se-
crete more steroid hormones whereby a more progestogenic environment is estab-
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lished. Moreover, they become more resilient in dealing with excess cortisol by
highly upregulating 11β-HSD2 which resembles the in vivo situation where the syn-
cytiotrophoblast expresses high amounts of this enzyme. Interestingly, they become
less responsive to cortisol-induced MR effects by downregulating MR and this could
be the subject of future experiments characterizing how the placenta protects itself
against MR effects and how these dynamics are altered during placental diseases.
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Chapter 5
Role of 11β-HSD2 in BeWo Cell
Biology
In this chapter, the role of 11β-HSD2 in trophoblast biology using the choriocarci-
noma cell line BeWo was investigated. The enzyme 11β-HSD2 is the main compo-
nent of the so-called glucocorticoid barrier in the placenta preventing excess cortisol
to reach the fetus [Benediktsson et al., 1997]. Maternal cortisol levels are five to ten
times higher than fetal levels suggesting a very efficient catabolism of active corti-
sol to inactive cortisone by 11β-HSD2 [Beitins et al., 1973; Campbell and Murphy,
1977]. Through this mechanism, the fetus is protected against maternal cortisol,
which in excess can lead to detrimental effects during fetal development and growth
[Reynolds, 2013a]. However, it has been shown that the expression and activity of
11β-HSD2 is decreased in various placenta-related diseases such as pre-eclampsia,
IUGR, and HELLP. Furthermore, molecules which are able to downregulate 11β-
HSD2 have been identified and many of them are involved in the pathogenesis of
these placenta-related diseases. Proinflammatory cytokines such as TNF-α, IL-
1β, and IL-6 reduce 11β-HSD2 activity [Chisaka et al., 2005; Kossintseva et al.,
2006], and hypoxia is involved in the downregulation of 11β-HSD2 [Homan et al.,
2006]. Thus, many different pathological conditions lead to the downregulation of
the important enzyme 11β-HSD2 and the effects of this pathological feature on the
placental biology has not been investigated so far.
The aim of this chapter was to investigate which putative effects the downreg-
ulation of 11β-HSD2 has in trophoblast biology including cell viability and apoptosis,
endocrine function, and expression of proteins involved in the stress response and
glucocorticoid action molecular machinery. This possibility of altering trophoblast
function was addressed in this chapter by choosing an siRNA approach to downreg-
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ulate 11β-HSD2 in BeWo cells.
Furthermore, the potential regulation of 11β-HSD2 by CRH was investigated.
In the placenta, CRH and cortisol are interconnected via a positive feedback loop
which is in contrast to the negative feedback regulation of cortisol on hypothalamic
CRH production [Robinson et al., 1988]. As 11β-HSD2 is an important modulator of
active cortisol availability within cells, its expression and activity has the potential
to influence the positive feedback loop between cortisol and CRH. So it might be
possible that CRH can influence the expression and activity of 11β-HSD2 in order
to fine-tune this dynamic equilibrium of cortisol and CRH concentration.
BeWo cells were chosen as a suitable model because, as shown in chapter
4.2.3, they express high endogenous levels of 11β-HSD2 (Figure 4.14 and 4.15).
Moreover, its expression mimics the placental in vivo situation as differentiation of
BeWo cells leads to a substantial upregulation of 11β-HSD2 which resembles the
higher expression in the syncytiotrophoblast compared to cytotrophoblasts (Figure
3.13 C, [Krozowski et al., 1995; Driver et al., 2001]).
5.1 Knockdown of 11β-HSD2 in BeWo Cells
To investigate the role of 11β-HSD2 in BeWo cells, they were treated with an siRNA
which downregulates the 11β-HSD2 expression. This siRNA, which targets 11β-
HSD2 mRNA, is referred to as siHSD2 in all subsequent sections.
siRNA Transfection in BeWo Cells
Before investigating conditions that downregulate 11β-HSD2 in BeWo cells, the
siRNA transfection capacity of BeWo cells was tested using a lipid-based trans-
fection of fluorescently-labelled non-targeting siRNA. The widespread red staining
(fluorescently-labelled siRNA) in Figure 5.1 shows a successful transfection of BeWo
cells and so this experimental condition was used for the subsequent experiments.
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Figure 5.1: BeWo cells transfected with ALEXA555-labelled non-targeting
siRNA. BeWo cells were transfected with 15 nM fluorescently-labelled (ALEXA-
555) siRNA for 24 h (left images), which is shown in red and the nuclei were stained
with Hoechst (middle images), which is shown in blue. Overlay (right images),
representative images are shown.
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5.1.1 Knockdown of 11β-HSD2 mRNA and Protein
Following establishment of conditions required to transfect BeWo cells with siRNA
(see above), the kinetics of the activity of siHSD2 was evaluated. BeWo cells were
treated with siHSD2 for 24, 48, and 72 h. Figure 5.2 shows that siHSD2 reached
the maximum effect 24 h after transfection, i.e. within 24 h siHSD2 induced a
significant inhibition of 11β-HSD2 mRNA by 77.7% (Figure 5.2 A). After 48 and 72
h of siHSD2 treatment, 11β-HSD2 mRNA expression was significantly reduced by
73.1% and by 50.2%, respectively (Figure 5.2 B and C).
In addition to downregulation of mRNA, I also measured putative effects
on the protein level. Similarly to 11β-HSD2 mRNA, 11β-HSD2 protein was also
downregulated on protein level for up to 72 h (Figure 5.2 D).
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Figure 5.2: 11β-HSD2 knockdown in BeWo cells. BeWo cells were transfected
with 15 nM siHSD2 or 15 nM control-siRNA (= control-si) for 24 h, 48 h and 72
h before qRT-PCR and western blot for 11β-HSD2 were performed. (A, B, C)
mRNA level of 11β-HSD2 after siRNA treatment, (D) protein level of 11β-HDS2
after siRNA treatment. (A, B, C) qRT-PCR data was normalized to 18S rRNA
expression, data are expressed as mean values ± SEM, n=3, t-test: p<0.01 (=**),
p<0.001 (=***). (D) β-actin (red band) was used as a loading control in the western
blot, a representative blot is shown.
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Having established conditions required to achieve effective inhibition on 11β-
HSD2 mRNA and protein expression, I investigated the knockdown of 11β-HSD2
during differentiation of the BeWo cells. The following protocol of transfection with
forskolin treatment was used in the subsequent experiments: (1) 24 h of siRNA
treatment with subsequent 24 h forskolin treatment and (2) 48 h of siRNA treatment
with subsequent 24 h forskolin treatment (for treatment protocol see Figure 2.3
(1b) in chapter Material and Methods) as both time points showed a successful
downregulation of 11β-HSD2 on mRNA and protein level (Figure 5.2).
Figure 5.3 A shows the downregulation of 11β-HSD2 mRNA after 24 h of
siHSD2 treatment in un- and differentiated BeWo cells (± 100 µM forskolin for 24
h). Forskolin led to a strong upregulation of 11β-HSD2 mRNA compared to undif-
ferentiated cells as previously also shown in chapter 4.2.3 (Figure 4.14). In undiffer-
entiated cells (without forskolin treatment), siHSD2 led to a significant decrease of
11β-HSD2 mRNA expression by 60% in the cells compared to control-siRNA treated
cells. In differentiated cells (with forskolin treatment), the significant decrease in
11β-HSD2 mRNA was comparable (57%) after siHSD2 treatment. Forty-eight hours
of siHSD2 treatment combined with forskolin treatment led to a similarly successful
downregulation of 11β-HSD2 mRNA (data not shown).
Figure 5.3 B and C show the downregulation of 11β-HSD2 protein after 24
h and 48 h of siHSD2 treatment with or without a subsequent treatment with 100
µM forskolin for 24 h. Similar to the mRNA data, the siHSD2 led to a successful
downregulation of 11β-HSD2 in un- and differentiated cells on protein level.
147
Figure 5.3: 11β-HSD2 knockdown in un- and differentiated BeWo cells.
BeWo cells were treated with siRNA (control-siRNA or siHSD2) for 24 h or 48 h
with further incubation with and without 100 µM forskolin before qRT-PCR (A)
and western blot (B, C) for 11β-HSD2 was performed. (A) qRT-PCR data was
normalized to 18S rRNA expression, data are expressed as mean values ± SEM,
2-way ANOVA with Bonferoni post test: n=4, p<0.001 (=***). (B, C) β-actin
(red band) was used as a loading control in the western blot, representative blots
are shown.
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5.1.2 11β-HSD2 Activity after Knockdown of 11β-HSD2
Following the successful effect of siHSD2 on 11β-HSD2 mRNA and protein expres-
sion, I determined whether this downregulation was associated with a decrease in
11β-HSD2 activity and the ability of cells to metabolize cortisol. As shown in chapter
4.2.3 (Cortisol Inactivation in BeWo cells), the activity of 11β-HSD2 was indirectly
estimated by quantifying the remaining cortisol concentration in the supernatant
after incubation of the cells with 500 nM cortisol for 24 h. The experimental proto-
col from the previous subchapter was repeated in the presence and absence of 500
nM cortisol (Figure 2.3 (1b) in chapter Material and Methods).
Results showed that undifferentiated BeWo cells metabolized 58% of the 500
nM of the exogenous cortisol, whereas the knockdown of 11β-HSD2 with siHSD2
significantly attenuated the metabolism of cortisol (Figure 5.4). The differentiated
BeWo cells (with forskolin treatment) metabolized 96% of the exogenous cortisol re-
flecting the upregulation of 11β-HSD2 after forskolin treatment. When downregulat-
ing 11β-HSD2 with siHSD2, the differentiated BeWo cells metabolized significantly
less cortisol and four times more cortisol remained in the cell culture supernatant.
These results suggest that treatment of BeWo cells with siHSD2 reduced activity of
11β-HSD2 compared to control cells in both un- and differentiated BeWo cells.
149
Figure 5.4: Activity of 11β-HSD2 in BeWo cells after 11β-HSD2 knock-
down. BeWo cells were transfected with 15 nM control- or siHSD2-siRNA for 24 h
with subsequent treatment with 500 nM cortisol with and without 100 µM forskolin
for 24 h before measuring the remaining cortisol concentration in the supernatant.
Cortisol concentration was normalized to protein concentration, data are expressed
as mean values ± SEM, n=4, 2-way ANOVA with Bonferroni post test: p<0.001
(=***).
5.2 Role of 11β-HSD2 on Morphological Differentiation
of BeWo Cells
The potential effect of 11β-HSD2 on morphological differentiation of BeWo cells was
investigated. As differentiation of cytotrophoblast cells into syncytiotrophoblast is
essential to maintain the physiological function of the syncytium, the mRNA expres-
sion of the fusogenic proteins Syncytin-1 and -2 and their receptors was examined.
Figure 5.5 shows that forskolin upregulated mRNA expression of Syncytin-1,
Syncytin-2 and MFSD2, whereas mRNA expression of ASCT2 was slightly down-
regulated which is in agreement with the data obtained in chapter 4.1.2 (Figure
4.4 and 4.5). In undifferentiated cells (without forskolin treatment), knockdown
of 11β-HSD2 did not change the mRNA expression of Syncytin-1, Syncytin-2 and
their receptors MFSD2 and ASCT2 (Figure 5.5 A, B, C and D). In forskolin-induced
differentiated cells, the mRNA expression of the fusogenic genes Syncytin-1 and -2
did not change after 11β-HSD2 knockdown (Figure 5.5 A and B), but the mRNA
expression of their receptors ASCT2 and MFSD2 were significantly reduced by 21%
and 43%, respectively, after downregulation of 11β-HSD2 (Figure 5.5 C and D).
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These results suggested a pro-differentiating effect of 11β-HSD2 as a limited num-
ber of Syncytin receptors (after 11β-HSD2 downregulation) might impair the fusion
process.
Figure 5.5: Expression of Syncytin-1 and -2 and their receptors after 11β-
HSD2 knockdown. BeWo cells were pre-treated with siRNA for 24 h followed by
a subsequent treatment for 24 h with and without 100 µM forskolin before mRNA
extraction and determination of Syncytin-1 (A), Syncytin-2 (B), ASCT2 (C), and
MFSD2 (D) by qRT-PCR was performed. Data were normalized to 18S rRNA (in
Syncytin-1 and -2) or to RPLP0 mRNA levels (in ASCT2 and MFSD2). Data are
expressed as mean values ± SEM, n=4, 2-way ANOVA with Bonferroni post test:
ns = non-significant, p<0.05 (=*), p<0.01 (=**).
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5.3 Role of 11β-HSD2 on Hormone Production of BeWo
Cells
BeWo differentiation is associated with increased production of hCG. The role of
11β-HSD2 in this process was further investigated.
BeWo cells were treated with siRNA (control-siRNA or siHSD2) for 24, 48,
or 72 h and the secreted hCG was measured in the cell culture supernatant. Figure
5.6 shows that 11β-HSD2 knockdown led to a significant reduction in hCG produc-
tion at all time points tested compared to control-treated cells (41%, 36%, and 31%
decrease after 24, 48, and 72 h, respectively).
Figure 5.6: hCG production of BeWo cells after 11β-HSD2 knockdown.
BeWo cells were cultured with siRNA for 24 h, 48 h, and 72 h before the concentra-
tion of secreted hCG was measured in the cell culture supernatant. hCG concentra-
tion was normalized to protein concentration of BeWo cells, data are expressed as
mean values ± SEM, n=3, t-test: p<0.01 (=**), p<0.001 (=***).
To investigate the effect of 11β-HSD2 on hCG secretion in un- as well as
differentiated cells, BeWo cells were treated with siRNA for 24 h with a subsequent
incubation with fresh medium with or without 100 µM forskolin. The concentration
of hCG was measured in the cell culture supernatant.
Forskolin treatment led to an increase in hCG secretion as previously shown
in chapter 4.1.4 (Figure 4.8). In undifferentiated cells after 24 h of siHSD2 treat-
ment, hCG concentration showed a trend to be decreased compared to control-
siRNA treated cells, but just failed to reach statistical significance. In differentiated
cells (with forskolin treatment), knockdown of 11β-HSD2 led to a significant de-
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crease in hCG secretion by 48% compared to control-siRNA treated cells.
Figure 5.7: hCG production of BeWo cells after 11β-HSD2 knockdown
and forskolin treatment. BeWo cells were cultured with siRNA for 24 h and
subsequently incubated with or without 100 µM forskolin for 24 h before the con-
centration of secreted hCG was measured in the supernatant. hCG concentration
was normalized to protein concentration of BeWo cells, data are expressed as mean
values ± SEM, n=3, 2-way ANOVA with Bonferroni post test: ns = non-significant,
p<0.05 (=*).
As previous results (Chapter 5.1.1) showed that knockdown of 11β-HSD2
was still evident after siHSD2 incubation for 48 h, in the subsequent experiments
the incubation time with siRNA was increased to 48 h to test whether the prolonged
downregulation of 11β-HSD2 might have a more profound effect on hCG produc-
tion. Furthermore, forskolin treatment of 24 h was combined with 500 nM cortisol
treatment to test the hypothesis whether an altered cortisol availability might be
involved in the reduced hCG secretion associated with downregulation of 11β-HSD2.
A 48 h incubation of cells with siRNA had a similar inhibitory effect on hCG
production (Figure 5.8 A) as the previous experiment with 24 h of siRNA incubation
(Figure 5.7). In undifferentiated as well as in forskolin-treated differentiated cells,
knockdown of 11β-HSD2 led to a significantly decreased hCG production by 52%
and 53% compared to control-siRNA treated cells. Forskolin treatment led to an
increase in hCG secretion as previously shown in chapter 4.1.4 (Figure 4.8). In
contrast, cortisol treatment did not have an effect on hCG production suggesting
that in this cellular system differentiation and hCG production occurs independently
of any action of cortisol and 11β-HSD2 might target different signalling pathways.
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In addition to measuring the hCG secretion, concentrations of progesterone
(P4) and estradiol (E2) were also quantified in the cell culture supernatant to deter-
mine whether the observed hCG decrease after 11β-HSD2 knockdown was a specific
effect. Forskolin treatment led to an increase of P4 secretion as previously shown
in chapter 4.1.4 (Figure 4.8). In addition to hCG, progesterone also seems to be
sensitive to 11β-HSD2 expression. In siHSD2-treated undifferentiated BeWos, P4
concentration showed a trend to be decreased compared to control-siRNA treated
cells, although it failed to reach statistical significance. In differentiated BeWos,
knockdown of 11β-HSD2 significantly decreased in P4 secretion by 47% compared
to control-siRNA treated cells (Figure 5.8 B). Again, cortisol treatment did not
change the siHSD2-induced decrease in P4 production.
Unlike hCG and progesterone, estradiol (E2) secretion was not affected by
knockdown of 11β-HSD2 (Figure 5.8 C) suggesting that the effects of 11β-HSD2
downregulation on pathways regulating hCG and P4 production were selective.
Again, cortisol treatment did not alter E2 production.
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Figure 5.8: hCG, P4, and E2 production of BeWo cells after 11β-HSD2
knockdown. BeWo cells were cultured with siRNA for 48 h and subsequently
incubated with fresh medium with and without 100 µM forskolin and/or 500 nM
cortisol for 24 h before the concentration of secreted hCG (A), P4 (B), and E2
(C) was measured in the cell culture supernatant. hCG, P4 and E2 concentration
were normalized to protein concentration of BeWo cells, data are expressed as mean
values ± SEM, n = 3, 2-way ANOVA with Bonferroni post test: ns = non-significant,
p<0.05 (=*), p<0.001 (=***).
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5.4 Role of 11β-HSD2 on BeWo Cell Turnover
As the enzymes 11β-HSD1 and 11β-HSD2 have been linked to the regulation of cell
proliferation and apoptosis in different cell types [Hundertmark et al., 1997; Lipka
et al., 2004; Terao et al., 2013], such potential effects were investigated in the BeWo
cells after knockdown of 11β-HSD2.
5.4.1 Role of 11β-HSD2 on BeWo Cell Viability
To investigate the role of 11β-HSD2 on BeWo cell viability, the MTS assay which
measures formazan production by living cells was chosen. The measured signal
(absorbance at 490 nm) is proportional to the living cell number. The BeWo cells
were treated for 24 h and 48 h: the 24 h timepoint represents a treatment with
control-siRNA or siHSD2 only for 24 h, whereas the 48 h timepoint represents a 24
h siRNA treatment followed by another 24 h with fresh medium with or without
forskolin treatment (Figure 5.9 A).
Figure 5.9 B shows that siHSD2-treated cells were significantly less in num-
ber after 24 h of siRNA treatment compared to control-siRNA treated cells. A fur-
ther 24 h incubation period with fresh medium with and without 100 µM forskolin
treatment showed a trend (but not significant) to less cells in the siHSD2-treated
compared to control-siRNA treated cells (Figure 5.9 C). This result suggests that
initially downregulation of 11β-HSD2 leads to a reduced cell viability.
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Figure 5.9: Viability in BeWo Cells after 11β-HSD2 knockdown. (A) Treat-
ment protocol. BeWo cells were transfected with 15 nM control- or siHSD2-siRNA
for 24 h (B) with and without a further treatment with 100 µM forskolin for 24 h
(C) before measuring cell viability, n=3, data are expressed as mean values ± SEM,
(B) t-test: p<0.001 (=***), (C) 2-way ANOVA with Bonferroni post-test: ns =
non-significant.
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5.4.2 Role of 11β-HSD2 on Apoptosis of BeWo Cells
These effects on cell viability led us to investigate the role of 11β-HSD2 on apopto-
sis. In undifferentiated BeWo cells, 11β-HSD2 was downregulated with siRNA for
24 h before employing detection of activated caspase-3/7 as a marker molecule for
apoptosis. In parallel, to investigate the effect of 11β-HSD2 on apoptosis in dif-
ferentiated BeWo cells, an incubation for another 24 h after knockdown with fresh
medium with or without 100 µM forskolin was performed before measurement of
activated caspase-3/7.
Qualitative Staining for activated Caspase-3/7
An increased signal for activated caspase-3/7 suggested that knockdown of 11β-
HSD2 enhanced apoptosis after 24 h compared to control-siRNA treated cells (Figure
5.10). Therefore, the cell viability result (Figure 5.9 B), which showed a decrease in
cell number after downregulation of 11β-HSD2, might be explained by an increased
apoptosis after 11β-HSD2 downregulation.
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Figure 5.10: Apoptosis of BeWo Cells after knockdown of 11β-HSD2
demonstrated by activated caspase-3/7 staining. BeWo cells were treated
for 24 h with either control-siRNA or siHSD2 before they were stained for activated
caspase-3/7. Green staining = activated caspase-3/7 staining, nuclei are stained blue
with DAPI, n=2, representative images are shown, each experimental condition is
shown with two images.
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Next, the 11β-HSD2 knockdown was followed by a further incubation with
and without forskolin treatment (Figure 5.11). No difference in caspase-3/7 acti-
vation was detected between control-siRNA and siHSD2-treated cells in un- and
differentiated cells suggesting that the initial activation of caspase-3/7 after 11β-
HSD2 knockdown was attenuated by continuing cultivation of cells. The forskolin
treatment led to more activated caspase-3/7 which is in agreement with the result
from chapter 4.1.3 (Figure 4.6). In the immunofluorescent images, areas with a high
cell density, detected by nuclei staining, displayed most activation of caspase-3/7.
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Figure 5.11: Apoptosis of BeWo Cells after knockdown of 11β-HSD2 with
forskolin treatment for further 24 h demonstrated by activated caspase-
3/7 staining. BeWo cells were treated for 24 h with either control-siRNA or siHSD2
and then for an additional 24 h with or without forskolin before they were stained for
activated caspase-3/7. Green staining = activated caspase-3/7 staining, nuclei are
stained blue with DAPI, n=2, representative images are shown, each experimental
condition is shown with two images.
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Quantitative Measurement of activated Caspase-3/7
The same protocol was applied in a different experimental approach aiming at quan-
tifying the caspase-3/7 activation by measuring levels of a fluorescent substrate
which is generated after being cleaved by activated caspase-3/7 (Figure 5.12 A).
Figure 5.12 B shows that BeWo cells treated with siHSD2 activated more
caspase-3/7 than control-siRNA treated cells during the period of 24 h which is in
agreement with the images obtained from the qualitative measurement of activated
caspase-3/7 (Figure 5.10). This result suggests that 11β-HSD2 limits activation of
caspase-3/7.
A further incubation of cells for 24 h led to a similar activation of caspase-3/7
in siHSD2-treated cells compared to control-siRNA treated cells in un- and differen-
tiated BeWo cells (Figure 5.12 C). Forskolin treatment led to increased activation of
caspase-3/7 which is in agreement with the result above and the result from chapter
4 (Figure 4.7) which showed an activation of caspase-3/7 after forskolin treatment.
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Figure 5.12: Caspase-3/7 activation in BeWo cells after 11β-HSD2 knock-
down. (A) Treatment protocol. BeWo cells were treated with 15 nM siRNA for
(B) 24 h or (C) for a further 24 h with or without 100 µM forskolin treatment
before detecting activated caspase-3/7 with the ApoOne Assay which measured a
fluorescent cleaved substrate. n=3, data are expressed as mean values ± SEM,
(B) t-test: p<0.001 (=***), (C) 2-way ANOVA with Bonferroni post-test: ns =
non-significant.
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5.5 Role of 11β-HSD2 on Expression of Molecules in-
volved in Stress Response
As the enzyme 11β-HSD2 regulates the availability of active cortisol inside of cells,
downregulation of 11β-HSD2 might affect the stress response molecular machinery.
In order to investigate such a potential deregulation, mRNA levels of CRH and its
receptors, GR, MR, glucocorticoid- and mineralocorticoid-responsive genes as well
as the transporter molecule BCRP were determined following siRNA knockdown of
11β-HSD2.
5.5.1 Role of 11β-HSD2 on Expression of CRH and its Receptors
Downregulation of 11β-HSD2 significantly increased CRH, CRH-R1 and CRH-R2
mRNA expression by 3.0-fold, 2.6-fold and 3.7-fold, respectively, after 24 h of siRNA
treatment (Figure 5.13). Treatment for 48 h with siRNA showed a more variable
and less potent result, but an upregulation of the three molecules was still evident
after 11β-HSD2 depletion.
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Figure 5.13: Expression of CRH and its receptors in BeWo cells after
11β-HSD2 knockdown. BeWo cells were treated for 24 h or 48 h with either
control-siRNA or siHSD2 before qRT-PCR for CRH (A, B), CRH-R1 (C, D)
and CRH-R2 (E, F) mRNA was performed. qRT-PCR data was normalized to
RPLP0 expression, n=4, data are expressed as mean values ± SEM, t-test: ns =
non-significant, p<0.05 (=*), p<0.01 (=**), p<0.001 (=***).
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The relationship between CRH, CRH-R1, CRH-R2 and 11β-HSD2 was also
tested in differentiated BeWo cells (for treatment protocol see Figure 2.3 (1b) in
chapter Material and Methods).
Figure 5.14 (A and C) show that the previously observed significant up-
regulation of CRH and CRH-R2 after siHSD2 treatment was still detectable in
undifferentiated BeWo cells under an experimental setup that included treatment
with 24 h siRNA with and without 100 µM forskolin. The expression of CRH-R1
showed a trend to an upregulation after 11β-HSD2 knockdown, although it failed to
reach significance (Figure 5.14 B). Forskolin treatment led to upregulation of CRH
and its receptors which is in agreement with the result from chapter 4.2.1 (Figure
4.11). Regarding CRH and CRH-R2, a combination of 11β-HSD2 knockdown and
forskolin treatment led to the highest upregulation of CRH and CRH-R2 suggesting
that forskolin effects were more potent in the absence of 11β-HSD2 (Figure 5.14 A
and C).
I also investigated whether absence of 11β-HSD2 rendered the system more
sensitive to the action of cortisol. The cortisol treatment abolished the siHSD2-
induced upregulation of CRH and CRH-R2 in undifferentiated cells, whereas it did
not have an effect in states of cAMP/PKA activation (induced by forskolin) (Figure
5.14 A). Regulation of CRH-R1 was neither influenced by 11β-HSD2 knockdown nor
by cortisol (Figure 5.14 B), however in the presence of cortisol 11β-HSD2 knockdown
led to an upregulation of CRH-R1 mRNA in differentiated cells (Figure 5.14 D).
166
Figure 5.14: Expression of CRH and its receptors after 11β-HSD2 knock-
down (± forskolin and cortisol treatment). BeWo cells were treated for 24 h
with either control-siRNA or siHSD2 and for another 24 h with 100 µM forskolin
and 500 nM cortisol before qRT-PCR for CRH (A), CRH-R1 (B) and CRH-R2
(C) was performed. qRT-PCR data was normalized to RPLP0 mRNA expression,
n=4, data are expressed as mean values ± SEM, 2-way ANOVA with Bonferroni
post test: ns = non-significant, p<0.05 (=*), p<0.01 (=**).
167
5.5.2 Role of 11β-HSD2 on Expression of GR, MR and its Target
Genes
5.5.2.1 Role of 11β-HSD2 on Expression of GR, MR
I next investigated whether 11β-HSD2 played a role in regulating cortisol interac-
tions with its intracellular receptors GR and MR. The mRNA level of GR and MR
were determined in cells depleted of 11β-HSD2 and stimulated with either forskolin,
cortisol or both. Figure 5.15 A shows that in undifferentiated cells neither knock-
down of 11β-HSD2 nor cortisol treatment had a significant effect on GR mRNA
expression. In differentiated cells, cortisol after 11β-HSD2 depletion led to a slight
upregulation by 1.4-fold of GR mRNA compared to cells treated with cortisol in
the presence of 11β-HSD2 (Figure 5.15 A), whereas all other treatments did not
influence expression of GR.
Regarding MR mRNA expression, forskolin had an inhibitory effect by down-
regulating MR mRNA expression (Figure 5.15 B), as previously shown (Figure 4.13).
In differentiated cells, cortisol after 11β-HSD2 depletion significantly, but slightly
upregulated MR mRNA expression compared to cells treated with cortisol in the
presence of 11β-HSD2 and compared to cells depleted of 11β-HSD2 (without corti-
sol treatment), whereas under all other experimental conditions no effect of siHSD2
was detectable. This result suggests that cortisol in the absence of 11β-HSD2 was
able to modulate effects on GR and MR mRNA expression in differentiated cells.
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Figure 5.15: Expression of GR and MR after 11β-HSD2 knockdown (±
forskolin and cortisol treatment). BeWo cells were treated for 24 h with either
control-siRNA or siHSD2 and for another 24 h ± 500 nM cortisol in the absence
or presence of 100 µM forskolin before qRT-PCR for GR (A) and MR (B) was
performed. qRT-PCR was normalized to 18S rRNA expression, n=4, data are ex-
pressed as mean values ± SEM, 2-way ANOVA with Bonferroni post test: ns =
non-significant, p<0.05 (=*), p<0.01 (=**).
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5.5.2.2 Role of 11β-HSD2 on Expression of Gluco- and Mineralocorti-
coid Target Genes
Since the enzyme 11β-HSD2 regulates the availability of active cortisol within the
cells and ultimately cell responsiveness to cortisol, mRNA expression of two gluco-
corticoid-responsive genes, Dusp1 (dual specificity protein phosphatase 1) and Per1
(period circadian protein homolog 1), were investigated in BeWo cells after 11β-
HSD2 knockdown and treatment with forskolin. Moreover, cells were stimulated
with cortisol to determine the cell responsiveness to cortisol after 11β-HSD2 deple-
tion. Figure 5.16 A shows that neither 11β-HSD2 knockdown nor cortisol had an
effect on the mRNA expression of Dusp1 in un- and differentiated BeWo cells. Sim-
ilarly, mRNA expression of Per1 was not affected by 11β-HSD2 knockdown nor by
cortisol in differentiated cells (Figure 5.16 B). Only in undifferentiated cells, a slight
1.3-fold upregulation of Per1 mRNA after 11β-HSD2 knockdown was observed, this
effect was abolished by simultaneous cortisol treatment. Since these genes are nor-
mally extremely sensitive to the action of cortisol, this minimal increase observed
here raised concerns about its biological relevance. In contrast, treatment of BeWo
cells with forskolin led to an up-regulation of both Dusp1 and Per1 mRNA in all
experimental conditions. This forskolin-induced effect showed no synergistic action
of cortisol nor by the 11β-HSD2 knockdown. This results suggests that regulation
of glucocorticoid-responsive genes in the BeWo cells might be under the control of
the cAMP pathway and might not be regulated by cortisol.
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Figure 5.16: Expression of Dusp1 and Per1 after 11β-HSD2 knockdown
(± forskolin and cortisol treatment). BeWo cells were treated for 24 h with
either control-siRNA or siHSD2 and another 24 h ± 500 nM cortisol in the absence
or presence of 100 µM forskolin before qRT-PCR for Dusp1 (A) and Per1 (B) was
performed. Dusp1 qRT-PCR was normalized to 18S rRNA and Per1 qRT-PCR
to RLPL0 mRNA expression, n=4, data are expressed as mean values ± SEM, 2-
way ANOVA with Bonferroni post test: ns = non-significant, p<0.05 (=*), p<0.01
(=**).
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It might be possible that cortisol preferentially binds and activates MR rather
than GR because of its higher affinity to the MR. Therefore, mRNA levels of SGK1
(serum- and glucocorticoid-regulated kinase 1) and ATP1A1 (ATPase subunit α 1),
which are regulated by both GR and MR, were determined after 11β-HSD2 knock-
down. Figure 5.17 A and B show that, similar to the regulation of the glucocorticoid-
responsive genes (see above), the genes SGK1 and ATP1A1 were neither affected
by siHSD2 nor cortisol, while forskolin treatment led to a significant upregulation
of both molecules. Also this result suggests that regulation of mineralocorticoid-
responsive genes in the BeWo cells might be under the control of the cAMP pathway
and might not be regulated by cortisol.
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Figure 5.17: Expression of SGK1 and ATP1A1 after 11β-HSD2 knockdown
(± forskolin and cortisol treatment). BeWo cells were treated for 24 h with
either control-siRNA or siHSD2 and another 24 h ± 500 nM cortisol in the absence
or presence of 100 µM forskolin before qRT-PCR for SGK1 (A) and ATP1A1 (B)
was performed. Normalization to 18S rRNA, n=4, data are expressed as mean
values ± SEM, 2-way ANOVA with Bonferroni post test: ns = non-significant.
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5.5.3 Role of 11β-HSD2 on Expression of BCRP
The transporter molecule BCRP was upregulated by forskolin (Figure 5.18) which
was in agreement with the result from chapter 4.2.4 (Figure 4.17). Again, treatments
with either siHSD2 or cortisol did not influence the mRNA expression of BCRP.
Figure 5.18: Expression of BCRP after 11β-HSD2 knockdown (± forskolin
and cortisol treatment). BeWo cells were treated for 24 h with either control-
siRNA or siHSD2 and another 24 h ± 500 nM cortisol in the absence or presence
of 100 µM forskolin before qRT-PCR for BCRP was performed. Normalization to
18S rRNA, n=4, data are expressed as mean values ± SEM, 2-way ANOVA with
Bonferroni post test: ns = non-significant.
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5.6 Regulation of 11β-HSD2 by CRH
Previous studies identified placental 11β-HSD2 as a target of pathological processes
that are associated with adaptive responses and raised CRH. Therefore, the possible
regulation of 11β-HSD2 by CRH was investigated.
In primary trophoblasts, it has been shown by Sharma et al. [2009] that
11β-HSD2 expression and activity is diminished by a p38 MAPK inhibitor and it
has been shown by Guan et al. [2013] that 11β-HSD2 expression and activity is
increased by an ERK1/2 MAPK inhibitor. Therefore, the p38 MAPK inhibitor
SB202190 and the ERK1/2 MAPK inhibitor UO126 were used to confirm this in
my experimental setup in addition to the PI3K (phosphatidyinositide 3 kinase)
inhibitor Wortmannin to test whether the PI3K signalling pathway is also involved
in the 11β-HSD2 regulation as well.
The experimental setup included a 24 h pre-treatment with the inhibitors
(for treatment protocol see Figure 2.3 (3) in chapter Material and Methods). Sub-
sequently, for measuring 11β-HSD2 mRNA levels, BeWo cells were incubated with
and without 100 µM forskolin for 24 h in the presence of the inhibitors. For deter-
mining the 11β-HSD2 activity by measuring the remaining cortisol concentration in
the supernatant, BeWo cells were incubated with and without 100 µM forskolin for
24 h in the presence of 500 nM cortisol and the inhibitors.
Inhibition of p38 activity with the inhibitor SB202190 led to a significant
decrease of 11β-HSD2 mRNA expression by 87% in undifferentiated BeWo cells
compared to control-treated cells (Figure 5.19 A). Also, in differentiated BeWo
cells (with forskolin treatment), the SB202190 inhibitor significantly attenuated
the forskolin-induced upregulation of 11β-HSD2 mRNA, albeit to a lesser extent
(45%). The 11β-HSD2 activity assay showed that treatment with SB202190 com-
pared to control samples (Figure 5.19 B) decreased 11β-HSD2 activity (= increased
remaining cortisol in the supernatant) in un- and differentiated BeWo cells which
is consistent with the lower mRNA expression of 11β-HSD2 after inhibition of the
p38 MAP-kinase.
In agreement with published data, use of the UO126 inhibitor significantly
increased the 11β-HSD2 mRNA in un- and differentiated BeWo cells and enhanced
enzymatic activity as shown by a significantly lower concentration of remaining
cortisol in the supernatant compared with its control samples (Figures 5.19 C and
D).
These data confirm previous reports that p38 and ERK1/2 MAPKs exert
opposing effects on 11β-HSD2 mRNA expression and activity in primary trophoblast
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cells as it was shown by Sharma et al. [2009] and Guan et al. [2013], respectively.
Inhibition of PI3-kinase by Wortmannin did not alter 11β-HSD2 mRNA ex-
pression nor activity in un- and differentiated BeWo cells, although a trend to a
higher mRNA expression and activity of 11β-HSD2 was observed (Figures 5.19 E
and F).
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Figure 5.19: Signalling pathways involved in the regulation of 11β-HSD2.
BeWo cells were pre-treated for 24 h with (A, B) p38 inhibitor SB202190, (C,
D) ERK1/2 inhibitor UO126 and (E, F) PI3K inhibitor Wortmannin. After pre-
treatment, the cells were treated with the inhibitors for further 24 h with or without
100 µM forskolin for qRT-PCR experiments (in the absence of cortisol) (A, C,
E) or in the presence of 1 µM cortisol for measuring the cortisol concentration in
the supernatant (B, D, F). (A, C, E) Normalization to 18S rRNA, (B, D, F)
normalization to protein concentration, n=3, data are expressed as mean values ±
SEM, 2-way ANOVA with Bonferroni post test: ns = non-significant, p<0.05 (=*),
p<0.01 (=**), p<0.001 (=***).
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Since previous studies showed that CRH activates both p38 and ERK1/2
MAPK signalling cascades, I next investigated a potential regulation of 11β-HSD2
by CRH. BeWo cells were treated with different concentrations of CRH with and
without forskolin in the absence (to measure 11β-HSD2 mRNA expression) or pres-
ence of cortisol (to estimate 11β-HSD2 activity). High CRH concentration (1 µM
CRH) led to a small, but significant, increase in 11β-HSD2 mRNA in differentiated
BeWo cells (Figure 5.20). However, 11β-HSD2 activity did not seem to be affected
by this effect, as no difference in remaining cortisol concentration in the supernatant
in this condition could be detected. This result suggests that CRH does not regulate
the activity of 11β-HSD2.
Figure 5.20: CRH effect on 11β-HSD2 activity. BeWo cells were pre-treated
for 24 h with 100 nM or 1 µM CRH. After pre-treatment, the cells were treated with
CRH for further 24 h with or without 100 µM forskolin for qRT-PCR experiments
(in the absence of cortisol) (A) or in the presence of 1 µM cortisol for measuring the
cortisol concentration in the supernatant (B). (A) Normalization to 18S rRNA, (B)
normalization to protein concentration, n=3, data are expressed as mean values ±
SEM, 2-way ANOVA with Bonferroni post test: ns = non-significant, p<0.05 (=*).
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5.7 Discussion of Chapter 5
The data of this chapter show that the enzyme 11β-HSD2 plays key roles in essential
BeWo cell biology processes that are not directly associated with cortisol action
(Figure 5.21 for summary). Cell differentiation is positively regulated by 11β-HSD2
since knockdown of 11β-HSD2 limited the differentiation effect, both on the cell
fusion process as well as on the biochemical differentiation of BeWo cells. Moreover,
11β-HSD2 seemed to enhance BeWo cell viability and protected against apoptosis
as knockdown of the enzyme led to a transient decrease in cell viability associated
with increased apoptosis. A critical role of 11β-HSD2 in the regulation of placental
hormones such as CRH was also demonstrated in the BeWo cells. Expression of
CRH and selectively its receptor CRH-R2 was limited by 11β-HSD2 which might
prevent an overactivation of the CRH-cortisol positive feedback loop in the placenta.
Furthermore, neither 11β-HSD2 nor cortisol were involved in the expression of gluco-
and mineralocorticoid target genes, but instead cAMP signalling might control the
regulation of these genes in BeWo cells.
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Figure 5.21: Summary of effects after 11β-HSD2 downregulation.
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The fusogenes Syncytin-1 and -2 and their receptors are involved in the fusion
process of trophoblast cells. Upregulation of Syncytin-1 and -2 mRNA after forskolin
treatment in BeWo cells is well established (Chapter 4.1.2) and was confirmed in the
experiments of this chapter. In differentiated BeWo cells, both Syncytin receptors
ASCT2 and MFSD2 were positively regulated by 11β-HSD2. A reduced expression
of Syncytin receptors might diminish activation of signalling pathways which trig-
ger fusion of BeWo cells even though enough ligand is available. This result might
suggest a pro-differentiating role of 11β-HSD2. Possibly, the potential alterations
in the stimulation of the Syncytin receptors might be associated with activation of
apoptosis as Knerr et al. [2007] and Knerr et al. [2008] showed that overexpression of
Syncytin-1 in HEK 293 and CHO attenuated STS- and antimycin A-induced apop-
tosis.
Downregulation of 11β-HSD2 in BeWo cells led to a decreased secretion of
hCG and progesterone in un- and differentiated cells suggesting a role of 11β-HSD2
in promoting placental endocrine function and hormone secretion. Cortisol treat-
ment did not display any effect on either hCG or progesterone secretion suggesting
that 11β-HSD2 might have additional roles besides its enzymatic inactivation of cor-
tisol. Because secretion of estradiol was not reduced after 11β-HSD2 knockdown,
the reduced secretion of hCG and progesterone appears to be a selective effect.
Comparing these data with results from the other relevant studies, it seems
that there is an interplay between 11β-HSD2 and hCG. Ni et al. [2009] and Shu
et al. [2014] demonstrated that treatment of syncytiotrophoblast with exogenous
hCG leads to an upregulation of 11β-HSD2 expression. However, in contrast to
my experiments they investigated the effect of hCG on expression of 11β-HSD2.
Ni et al. [2009] used an hCG antibody to neutralize hCG secretion which leads to
a reduced expression of 11β-HSD2 in primary syncytiotrophoblast. In addition,
treatment of the primary syncytiotrophoblast with exogenous hCG increases 11β-
HSD2 expression. Shu et al. [2014] further explored the hCG effect on upregulating
11β-HSD2 mRNA and protein expression and could demonstrate that p38 signalling
is involved in this process. As these two studies were different in the experimental
setup, a direct comparison with my results is not appropriate. Nevertheless, it is
noteworthy that there might be feedback mechanism between 11β-HSD2 and hCG
maintaining the expression of both molecules.
As mentioned previously, hCG promotes fusion of trophoblast cells [Dhar
et al., 2004]. Thus, it might be possible that the above mentioned role of 11β-HSD2
in promoting BeWo cell fusion might be associated with hCG secretion.
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Sun et al. [1998] identified an inhibitory effect of progesterone on 11β-HSD2
mRNA expression and activity in primary syncytiotrophoblast. Again, this experi-
mental setup is substantially different compared to my study. Jeschke et al. [2005]
and Yang et al. [2006] showed that CRH reduces progesterone secretion in primary
syncytiotrophoblasts and Gao et al. [2012] showed that inhibition of CRH or its
receptor leads to an increased progesterone production. In the BeWo cell model,
the 11β-HSD2 knockdown led to an increase in CRH mRNA expression in un- and
differentiated BeWo cells suggesting the possibility that this increased expression of
CRH reduces P4 secretion.
To highlight the importance of these findings, both hormones hCG and pro-
gesterone fulfill various roles in the placenta in order to maintain a successful preg-
nancy (Chapter 1.2.7.2). For example, both hormones are involved in maintaining
uterine quiescence [Eta et al., 1994; Ruddock et al., 2008]. Deregulation of hCG
and P4 hormones could have adverse effects on the development of the fetus with
a possible risk of pre-term labour. In several placental diseases, the expression and
activity of the enzyme 11β-HSD2 is reduced [Causevic and Mohaupt, 2007; Dy et al.,
2008] and this might lead to an abnormal hormonal milieu of the placenta. Based
on the BeWo cell results above, the reduced 11β-HSD2 expression could potentially
alter the endocrine function of the placenta in vivo.
Regarding cell turnover of BeWo cells, 11β-HSD2 seems to promote cell vi-
ability and protects against apoptosis. Reduced viability might be a result of de-
creased proliferation or increased apoptotic or necrotic processes. Theoretically, the
expression of 11β-HSD2 might have a pro-proliferation effect as it inactivates the
release of anti-proliferative cortisol. In other cellular models, Rabbitt et al. [2002]
transfected 11β-HSD2 in rat osteosarcoma cells and observed a pro-proliferative
effect. Koyama and Krozowski [2001] showed that use of glycyrrhetinic acid (in-
hibitor of the 11β-HSD enzymes) in Ishikawa endometrial cancer cells (express only
11β-HSD2 and no 11β-HSD1) decreases the cell number as determined by counting
cells after trypsinization. My result of a reduction in BeWo cell number (possibly
because of less proliferation) after 11β-HSD2 knockdown would be in agreement
with the observation by Koyama and Krozowski [2001]. Another explanation of the
lower cell number after 11β-HSD2 knockdown might also be related to decreased
hCG production. As discussed, downregulation of 11β-HSD2 led to a fall in hCG
secretion in BeWo cells. Hamada et al. [2005] showed that downregulation of hCG
in JAR cells leads to a decreased proliferation.
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The modulation of apoptosis by 11β-HSD2 is often observed in tumor cells.
Several groups showed that inactivation of 11β-HSD2 with simultaneous treatment
with cortisol provokes apoptosis in different cell types. Tao et al. [2013] showed
that Jurkat leukemia T cells display more apoptosis after cortisol treatment (An-
nexin V/PI assay) when 11β-HSD2 was inactivated with an inhibitor as well as with
a 11β-HSD2 shRNA. Inhibition of 11β-HSD2 with carbenoxolone in MOLT4F cells
leads to more apoptotic cells after prednisolone treatment as assessed by caspase-3/7
assay [Sai et al., 2011]. Also, carbenoxolone used in murine corticotroph tumor cells
induces apoptosis after cortisol treatment demonstrated with a TUNEL-staining [Ni-
gawara et al., 2006]. In agreement with these observation, knockdown of 11β-HSD2
for 24 h led to an increased activation of caspase-3/7 in BeWo cells. Demonstrating
the same effect with a different approach, O’Brien et al. [2004] transfected cell-
specifically osteoblast/osteocyte cells in an in vivo mice model with an 11β-HSD2
expressing vector which protects the cells against glucocorticoid-induced apoptosis.
Interestingly, during differentiation of trophoblast cells, the apoptotic cas-
cade is activated (Chapter 1.2.6.3). Therefore, upregulation of 11β-HSD2 in the
syncytiotrophoblast might be a mechanism of the placenta to control and protect
the developing syncytiotrophoblast against pursuing the whole apoptotic process.
As discussed above, knockdown of 11β-HSD2 led to a decrease in hCG and
progesterone production. It was shown by Jasinska et al. [2006], Kajihara et al.
[2011a] and Kajihara et al. [2011b] that hCG treatment leads to an increased ex-
pression of the anti-apoptotic Bcl-2 in endometrial stromal cells. Furthermore, Liu
et al. [2007] showed that progesterone treatment in HTR-8/SV cells (model system
of extravillous trophoblast cells) leads to less apoptosis characterized by decreased
Fas, FasL, caspase-8, caspase-3 and PARP expression and by increased Bcl-2 expres-
sion. Similarly to that, it might be possible that hCG and progesterone are involved
in regulating apoptosis in BeWo cells and that 11β-HSD2 protects against apoptosis
via a mechanism involving the sufficient expression of hCG and progesterone.
Taken together, my result revealed a role of 11β-HSD2 in protecting against
apoptosis in trophoblast cells as it has been shown before in other cell types.
My experiments identified an interesting relationship between 11β-HSD2 and
the molecular machinery controlling CRH expression. In undifferentiated BeWo
cells, downregulation of 11β-HSD2 led to a significant increase in CRH and both
its receptor (CRH-R1 and CRH-R2) mRNA after 24 h (Figure 5.13). This result
suggests that in the trophoblast 11β-HSD2 might limit the CRH production and is
thereby potentially preventing an overactivation of the cortisol-CRH positive feed-
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back loop. In the placenta, cortisol stimulates CRH expression [Robinson et al.,
1988] resulting in a positive feedback loop. Moreover, it has been shown that corti-
sol leads to an increase of placental CRH expression, whereas progesterone had the
opposite effect [Jones et al., 1989]. However, the positive effect of cortisol on pla-
cental CRH expression requires simultaneous presence of progesterone since Karalis
et al. [1996] could show in a primary trophoblast model that cortisol also had an
inhibitory effect on CRH mRNA expression when the cells were cultured in serum-
free media which guaranteed a progesterone-free milieu. In further experiments,
they revealed that progesterone inhibits CRH expression to a greater extend than
cortisol. According to this, cortisol and progesterone compete for binding to the
GR (progesterone binds to the GR [Ojasoo et al., 1988]) and higher levels of cortisol
block progesterone binding to the GR and consequently block the inhibitory effect of
progesterone on CRH expression [Karalis and Majzoub, 1995]. As 11β-HSD2 inacti-
vates cortisol, more progesterone could bind to the GR due to less competition with
active cortisol and as a consequence reduced levels of CRH are produced. Depletion
of 11β-HSD2 by siHSD2 might result in more cortisol available in the BeWo cells
for binding to GR leading to a higher CRH production as shown in my experiments
in undifferentiated BeWo cells (only treated with siHSD2).
The regulation of CRH and CRH-R2 seems to be similar regarding effects of
11β-HSD2 knockdown and forskolin and cortisol treatment. In the absence of cor-
tisol, siHSD2 and forskolin display effects on CRH and CRH-R2 mRNA expression
in a synergistic manner. When performing the same experiment in the presence of
cortisol, the siHSD2-induced upregulation of CRH and CRH-R2 mRNA expression
was abrogated in undifferentiated BeWo cells. This result is surprising because glu-
cocorticoids upregulate CRH in the placenta [Jones et al., 1989]. A combination of
exogenous cortisol and knockdown of 11β-HSD2 would be expected to lead to the
highest CRH mRNA expression because all of the exogenous cortisol could exert its
action and thereby lead to upregulation of CRH. As this was not the case, the re-
sult suggests that the siHSD2-induced upregulation of CRH and CRH-R2 mRNA (in
the absence of cortisol) is independent of the role of 11β-HSD2 to inactivate cortisol.
As BeWo cells might be quite insensitive to glucocorticoids as shown before
[Mark and Waddell, 2006], the responsiveness of our BeWo cells to cortisol after
11β-HSD2 knockdown was tested. Neither siHSD2 nor cortisol treatment had an
effect on the gluco- and mineralocorticoid responsive genes Dusp1, Per1, SGK1, and
ATP1A1. However, forskolin treatment led to an mRNA upregulation of all of these
genes suggesting that the cAMP signalling pathway might be involved in the GC
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regulation of gluco- and mineralocorticoid-responsive genes in BeWo cells. In order
to investigate this phenomenom further, several experiments have been performed
which are presented in chapter 6.
This insensitivity to cortisol strengthens the conclusion that the observable
effects of 11β-HSD2 downregulation in BeWo cells regarding differentiation, en-
docrine function, viability, apoptosis, and stress regulation is independent of cortisol
and suggests that the enzyme 11β-HSD2 might fulfill roles other than just regulation
of cortisol activity.
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Chapter 6
Glucocorticoid Action via GR
and its Effects on BeWo Cell
Biology
My previous results provided strong, albeit indirect, support for a lack of glucocorti-
coid effects in BeWo cells. To characterize this further, the responsiveness of BeWo
cells to glucocorticoids was tested using a reporter-gene-assay approach as well as
expression studies of glucocorticoid-responsive genes. Additionally, the involvement
of cAMP signalling in glucocorticoid signalling was also investigated.
Moreover, glucocorticoid effects on BeWo cell turnover, differentiation and
expression of molecules involved in the stress response and glucocorticoid action
molecular machinery was investigated. This was driven by the fact that in several
in vivo conditions such as psychological stress or chronic diseases, e.g. asthma,
which are treated with glucocorticoids, excess of glucocorticoids reach placental tis-
sue. The enzyme 11β-HSD2 controls the cellular amount of active cortisol available
for receptor activation within the tissue and its reduced expression of 11β-HSD2 in
placental diseases such pre-eclampsia and IUGR might lead to increased amounts of
active cortisol. Elevated levels of cortisol can pass through the placenta to induce
effects in the fetus, but it is also possible that active cortisol binds to the placen-
tal gluco- or mineralocorticoid receptor leading to an altered glucocorticoid action
within the placenta. Taken together, several physiological and pathological situa-
tions might cause increased levels of cortisol/glucocorticoids reaching the placental
tissue, which highlights the importance to investigate this mechanism.
186
6.1 Comparison of GRα Expression in BeWo and HeLa
Cells
It was previously shown that BeWo cells express GRα mRNA whose expression
was not affected by forskolin treatment or by 11β-HSD2 depletion (Figure 4.13 and
5.15).
The expression of GRα mRNA in BeWo cells was compared with HeLa
cells which are highly responsive to glucocorticoids [Melnykovych and Bishop, 1969,
1971]. Using qRT-PCR my results showed that HeLa cells expressed 10.7-fold more
GRα than BeWo cells (Figure 6.1 A) which might be a reason why BeWo cells are
less or non-responsive to glucocorticoids.
Furthermore, the feedback regulation of GRα by dexamethasone (a highly
potent synthetic glucocorticoid) and/or forskolin was determined. HeLa cells down-
regulated their GRα expression after dexamethasone (=Dex) treatment by 41-42%
(in the presence and absence of forskolin) indicating the presence of a negative
feedback mechanism (Figure 6.1 B). Forskolin showed no effects on GRα mRNA
expression in HeLa cells. In contrast, GRα mRNA expression in BeWo cells was not
affected by Dex or by forskolin treatment (Figure 6.1 C) suggesting the absence of
any GR feedback mechanisms in BeWo cells.
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Figure 6.1: mRNA expression of GRα in BeWo and HeLa cells. (A) mRNA
was extracted from BeWo and HeLa cells after 3 days of basal culture and a qRT-
PCR for GRα was performed. (B) HeLa and (C) BeWo cells were treated with
10−6M dexamethasone (=Dex) and/or 100 µM forskolin (=fsk) for 24 h before
extracting mRNA and performing qRT-PCR for GRα. Normalisation to 18S rRNA,
n=4, data are expressed as mean values ± SEM, fold above control = fold above
control cells which were not treated with Dex nor fsk, ns = non-significant, p<0.001
(=***), (A) t-test, (B, C) 2-way ANOVA with Bonferroni post-test.
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GRα Expression in BeWo Cells after Transfection with a GRα-vector
In order to adjust the low expression of GRα in BeWo cells, the human GRα gene
expressed in a suitable vector (pRShGRα-vector, see chapter 2.2.2.2 for details) was
transfected. Transfection efficiency was confirmed by qRT-PCR in BeWo cells. Fig-
ure 6.2 shows that the transfection of GRα led to a 736-fold higher GRα mRNA
expression compared with the non-transfected BeWo cells.
Figure 6.2: mRNA expression of GRα in BeWo cells after GRα trans-
fection. BeWo cells were transfected with 2 µg GRα (pRShGRα-vector) for 4 h,
mRNA was extracted 24 h after transfection and a qRT-PCR for GRα was per-
formed. Normalisation to 18S rRNA, n=4, data are expressed as mean values ±
SEM, p<0.001 (=***), t-test.
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6.2 Effects of Glucocorticoids on GRE-dependent Lu-
ciferase Transcription
Following overexpression of GRα in BeWo cells, I investigated potential changes in
cell responsiveness to glucocorticoids. To quantify this, a reporter-gene-assay was
used which consisted of a GRE-containing luciferase DNA-vector (= MMTV-luc,
(Chapter 2.2.2.2)). As a control cell line, HeLa cells which are highly responsive
to glucocorticoids [Melnykovych and Bishop, 1969, 1971] were used. Furthermore,
HEK 293 cells were also tested for their glucocorticoid response since they only ex-
press low amounts of GR (personal communication with Dr. Kino).
6.2.1 DNA-vector Transfection in BeWo, HEK 293 and HeLa Cells
A GFP-containing DNA-vector was transfected into BeWo, HEK 293 and HeLa
cells to determine their transfection efficiency characteristics. Figure 6.3 shows that
all cell lines could be transfected with the GFP-DNA-vector. HeLa cells seem to
display the highest transfection efficiency compared to HEK 293 and BeWo cells.
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Figure 6.3: GFP-vector transfection in BeWo, HEK 293 and HeLa cells.
BeWo, HeLa and HEK 293 cells were transfected with 2 µg of a GFP-containing
DNA-vector for 24 h before fluorescent and brightfield microscopy was performed.
Left: GFP (= green), right: brightfield. Representative images are shown, n = 3,
bar = 75 µm.
191
6.2.2 GC Responsiveness of BeWo, HEK 293 and HeLa Cells
Glucocorticoids cross the cell membrane due to their lipophilicity and in the cyto-
plasm they bind to the GRα receptor, which homodimerizes and translocates to the
nucleus where it acts as a transcription factor (Chapter 1.1.3.1). Most of the target
genes have glucocorticoid responsive elements (GREs) in their promoter region that
enable GR binding, which leads to either up- or downregulation of target genes [Tsai
et al., 1988; Wrange et al., 1989].
To test responsiveness of BeWo cells to glucocorticoids, we transfected BeWo
cells as well as HeLa and HEK 293 cells (as control cell lines) with the MMTV-
luc vector containing GRE elements and encoding the firefly-luciferase with and
without co-transfection of GRα (pRShGRα-vector) and stimulated them with 1
µM dexamethasone before measuring signal generation (for treatment protocol see
Figure 2.3 (2) in chapter Material and Methods, Chapter 2.2.2.2 for experimental
details).
HeLa cells expressed a functional GR as they showed a significant response
to dexamethasone (Dex) after MMTV-luc transfection (190-fold) (Figure 6.4 A).
Co-transfection of GRα and MMTV-luc led to a higher response to Dex (434-fold)
compared to control cells (Figure 6.4 B).
HEK 293 cells also expressed a functional GR, but cell responsiveness was
considerably lower after dexamethasone treatment (4.8-fold) compared to HeLa cells
(Figure 6.4 C). Co-transfection with the GRα-vector increased the responsiveness
to dexamethasone to 705-fold when comparing with control cells (Figure 6.4 D).
BeWo cells did not respond to dexamethasone in the absence of the exogenous
GRα-vector (Figure 6.4 E). However, co-transfection of the GRα-vector restored
the responsiveness to dexamethasone. BeWo cells transfected with the MMTV-luc
and the GRα vectors showed a 322-fold induction of luciferase activity after Dex
treatment compared to control cells suggesting that transfection of exogenous GRα
restored glucocorticoid sensitivity.
192
Figure 6.4: HeLa, HEK 293, BeWo cell responsiveness to dexamethasone.
HeLa (A, B), HEK 293 (C, D), and BeWo cells (E, F) were co-transfected with
the MMTV-luc- and pGL4.73-Rluc-vector with (B, D, F) and without (A, C,
E) pRShGRα-vector for 4 h and subsequently treated with 10−6M dexamethasone
(=Dex) for 20 h before relative light units were determined. (A, B) n=4, (C-F)
n=3, samples were normalized to renilla-luciferase activity, data are expressed as
mean values ± SEM, ns = non-significant, p<0.01 (=**), p<0.001 (=***), t-test.
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6.3 Effects of Glucocorticoids and Forskolin on Steroid-
dependent Transcription
6.3.1 Effects of Dexamethasone and Forskolin on GC-responsive
Genes via GR
Previous experiments raised the strong possibility that BeWo cells do not express
endogenous functional GR, and therefore transfection of the GRα expression vec-
tor was introduced into the experimental protocol in order to determine the effects
of glucocorticoids and forskolin on steroid-dependent transcription. My previous
results suggested that in BeWo cells forskolin and the cAMP pathway was driv-
ing regulation of glucocorticoid-responsive genes in BeWo cells. These experiments
used native BeWo cells without transfection of exogenous GRα and the less potent
naturally occuring glucocorticoid cortisol compared with the highly potent synthetic
glucocorticoid dexamethasone. To further test this experimental system, BeWo cells
were treated with dexamethasone with and without co-treatment of forskolin in the
absence and presence of exogenous GRα and either mRNA was extracted to perform
qRT-PCRs for glucocorticoid-responsive genes or the cells were co-transfected with
the MMTV-luc vector to perform reporter-gene-assays.
6.3.1.1 Effects of Dexamethasone and Forskolin on GC-responsive Genes
in HeLa Cells
HeLa cells were used as a control cell line because of their high responsiveness
to glucocorticoids to confirm glucocorticoid-induced upregulation of the specific
glucocorticoid-responsive genes (Dusp1, Per1, Gilz). According to my experimen-
tal protocol, HeLa cells were treated with dexamethasone and/or forskolin for 24 h
before determining mRNA expression levels of Dusp1, Per1 and Gilz.
Dexamethasone treatment led to a significant increase of Dusp1, Per1, and
Gilz mRNA by 5.2-, 6.7-, and 14.7-fold, respectively, compared to control cells (Fig-
ure 6.5 A, B, C). Forskolin treatment significantly induced Dusp1 and Gilz mRNA
expression by 2.1- and 1.8-fold (Figure 6.5 A, C), respectively, whereas mRNA ex-
pression of Per1 was not affected by forskolin treatment (Figure 6.5 B). Co-treatment
of dexamethasone and forskolin did not change Per1 mRNA level compared to Dex
treatment alone (Figure 6.5 B), whereas it significantly upregulated Dusp1 and Gilz
mRNA expression by a furter 30% and 24%, respectively, compared to dexametha-
sone treatment alone (Figure 6.5 A, C). This result confirms responsiveness of HeLa
194
cells to glucocorticoids and suggests that some glucocorticoid-responsive genes are
synergistically regulated by dexamethasone and forskolin.
Figure 6.5: Effect of dexamethasone and forskolin on GC-responsive gene
expression in HeLa cells. HeLa cells were treated with 10−6M dexamethasone
and/or 100 µM forskolin for 24 h before extracting the mRNA and performing qRT-
PCR for Dusp1 (A), Per1 (B), and Gilz (C). (A) Normalisation to 18S rRNA,
(B, C) normalisation to GAPDH mRNA, n=4, data are expressed as mean values
± SEM, p<0.05 (=*), p<0.001 (=***), ns=non-significant, 2-way ANOVA with
Bonferroni post-test.
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6.3.1.2 Effects of Dexamethasone and Forskolin on GC-responsive Genes
in BeWo Cells
Native and GRα-overexpressing BeWo cells were treated with dexamethasone and/or
forskolin for 24 h before determining the mRNA expression levels of glucocorticoid-
responsive genes. In native BeWo cells, dexamethasone did not have an effect on
the mRNA expression of Dusp1, Per1 nor Gilz (Figure 6.6 A, C, E). Forskolin sig-
nificantly increased the mRNA expression of Dusp1, Per1, and Gilz by 5.6-, 2.1-,
and 1.8-fold, respectively, compared to control cells (Figure 6.6 A, C, E).
In BeWo-GRα cells (= BeWo cells overexpressing GRα), dexamethasone sig-
nificantly increased the mRNA expression of Dusp1, Per1, and Gilz by 1.9-, 1.5-, and
83.5-fold, respectively, compared to control cells (Figure 6.6 B, D, F). Forskolin led
to a significant increase of Dusp1 and Per1 by 3.7- and 2.2-fold, respectively, (Figure
6.6 B, D) which is comparable to the situation in native BeWo cells. Co-treatment
of dexamethasone and forskolin in BeWo-GRα cells led to the highest induction of
Dusp1 and Per1 by 5.9- and 3.3-, respectively, (Figure 6.6 B, D) indicating syner-
gistic pathways. In case of Gilz, forskolin treatment did not affect the Gilz mRNA
level, nor did it further increase the dexamethasone-induced Gilz mRNA upregula-
tion which suggests that Gilz is exclusively regulated through glucocorticoid-induced
GRα pathways (Figure 6.6 F).
This result suggests that in the absence of exogenous GRα in BeWo cells,
forskolin regulates GC-responsive genes. In the presence of functional exogenous
GRα, Dusp1 and Per1 are regulated by dexamethasone and forskolin synergisti-
cally, whereas Gilz appears to be strongly regulated by glucocorticoids only.
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Figure 6.6: Effect of dexamethasone and forskolin on GC-responsive gene
expression in BeWo cells. In the absence (left graphs) or presence (right
graphs) of exogenous GRα, BeWo cells were treated with 10−6M dexamethasone
and/or 100 µM forskolin for 24 h before extracting the mRNA and performing qRT-
PCR for Dusp1 (A, B), Per1 (C, D), and Gilz (E, F). (A, B) Normalisation
to 18S rRNA, (C-F) normalisation to RPLP0 mRNA, n=4, data are expressed
as mean values ± SEM, p<0.01 (=**), p<0.001 (=***), ns=non-significant, 2-way
ANOVA with Bonferroni post-test.
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6.3.2 Effects of Dexamethasone and Forskolin on GRE-dependent
Luciferase Transcription
Since the previous result suggested that in BeWo cells specific glucocorticoid-respon-
sive genes were under the transcriptional control of forskolin and cAMP pathways,
this hypothesis was further tested by performing a reporter-gene-assay with the
MMTV-luc vector in BeWo (with and without GRα transfection) and HeLa cells
after dexamethasone and/or forskolin treatment.
In HeLa cells, dexamethasone significantly increased luciferase activity by
58-fold compared to basal condition, whereas forskolin exerted a modest effect (4.3-
fold increase) (Figure 6.7 A). Co-treatment with Dex and forskolin led to a further
52% increase compared to Dex treatment alone. This result suggested that in HeLa
cells dexamethasone was the main driver of GR activation and cAMP pathways
could further augment this effect exerting a synergistic action.
In native BeWo cells, dexamethasone did not induce a signal in the reporter-
gene assay (Figure 6.7 B). Forskolin, however, significantly increased luciferase ac-
tivity by 56-fold compared to control cells. In BeWo-GRα cells, dexamethasone
significantly increased luciferase activity compared to control (Figure 6.7 C) and
augmented forskolin-induced GR transactivation by 207% compared to forskolin
treatment alone. Forskolin treatment significantly increased luciferase activity by
38-fold compared to control cells. This result suggested that in BeWo cells the ab-
sence of exogenous functional GR allows forskolin to control GC-responsive targets.
Restoration of the GR levels then promotes a synergistic interaction between the
two pathways.
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Figure 6.7: Effect of dexamethasone and forskolin on GRE-dependent lu-
ciferase transcription. HeLa cells were transfected with the MMTV-luc vector
for 4 h (A) and treated with 10−6M dexamethasone and/or 100 µM forskolin for 4
h before luciferase activity was determined. BeWo cells were transfected with the
MMTV-vector with (C) and without GRα (B) for 4 h and treated with 10−6M
dexamethasone and/or 100 µM forskolin for 4 h before luciferase activity was de-
termined. Samples were normalized to renilla-luciferase activity, n=3, data are ex-
pressed as mean values ± SEM, ns=non-significant, p<0.01 (=**), p<0.001 (=***),
2-way ANOVA with Bonferroni post-test.
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6.4 Effects of Glucocorticoids in BeWo Cell Biology
Previous data showed that overexpression of GRα receptors in BeWo cells (= BeWo-
GRα cells) restores cell responsiveness to glucocorticoids. Therefore, in my following
experiments this modification was carried out.
6.4.1 Effects of Glucocorticoids on BeWo Cell Turnover and Dif-
ferentiation
Glucocorticoids play an important role in differentiation processes of many different
cell types [Ballard, 1979]. Thus, I investigated whether glucocorticoids can alter cell
turnover including viability, apoptosis, and differentiation of BeWo-GRα cells.
6.4.1.1 Effects of Glucocorticoids on BeWo Cell Viability
BeWo-GRα cells were treated with dexamethasone for 24 and 48 h before assessing
viability. Dexamethasone treatment did not lead to any changes in cell viability in
BeWo-GRα cells (Figure 6.8).
Figure 6.8: Effect of glucocorticoids on BeWo-GRα cell viability. BeWo cells
were transfected with the GRα vector for 4 h and treated with 10−6 M dexametha-
sone for (A) 24 h or (B) 48 h before performing the MTT assay. n=3, data are
expressed as mean values ± SEM, ns = non-significant, t-test.
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6.4.1.2 Effects of Glucocorticoids on Apoptosis in BeWo Cells
BeWo-GRα cells were treated with dexamethasone for 24 and 48 h before assessing
apoptosis. Figure 6.9 shows that dexamethasone did not influence the activation of
caspase-3/7 in BeWo cells.
Figure 6.9: Effect of glucocorticoids on BeWo-GRα cell apoptosis. BeWo
cells were transfected with the GRα vector for 4 h and treated with 10−6 M dex-
amethasone for (A) 24 h or (B) 48 h before measuring the activated caspase-3/7
with the ApoONE assay. (A) n=4, (B) n=3, data are expressed as mean values ±
SEM, ns = non-significant, t-test.
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6.4.1.3 Effects of Glucocorticoids on Differentiation of BeWo Cells
Effects of Glucocorticoids on Sync-1 and -2 Expression
BeWo-GRα cells were treated with dexamethasone and/or forskolin for 24 h before
assessing Sync-1, -2, and their receptor expression. The previously observed (Figure
4.4 and 4.5) upregulating effect of forskolin on Sync-1, -2, and MFSD2 mRNA ex-
pression as well as the inhibitory effect of forskolin on ASCT2 mRNA was detected
again (Figure 6.10 A-D). Dexamethasone treatment did not change Sync-1 mRNA
expression (Figure 6.10 A). Dexamethasone minimally increased ASCT2 mRNA
expression in differentiated cells (forskolin-treated for 24 h) (Figure 6.10 C). Inter-
estingly, expression of Sync-2 and its receptor MFSD2 was slightly downregulated
in undifferentiated BeWo cells by dexamethasone (Figure 6.10 B, D).
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Figure 6.10: Effect of dexamethasone and forskolin on Syncytins and their
receptors in BeWo-GRα cells. BeWo cells were transfected with the GRα vector
for 4 h and treated with 10−6 M dexamethasone and/or 100 µM forskolin for 24 h
before mRNA was extracted and qRT-PCR for (A) Syncytin-1, (B) Syncytin-2,
(C) ASCT2, and (D) MFSD2 was performed. qRT-PCRs for Syncytin-1 and -2
were normalized to 18S rRNA, qRT-PCRs for ASCT2 and MFSD2 were normalized
to RPLP0 mRNA, n=4, data are expressed as mean values ± SEM, p<0.05 (=*),
p<0.01 (=**), ns=non-significant, 2-way ANOVA with Bonferroni post-test.
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Effects of Glucocorticoids on hCG Secretion
BeWo-GRα cells were treated with dexamethasone (or cortisol) and/or forskolin for
24 h before measuring hCG secretion. As expected, the previously observed (Figure
4.8) forskolin-dependent induction in hCG secretion was confirmed (Figure 6.11). A
small significant decrease of hCG secretion was observed in undifferentiated BeWo
cells after Dex but not cortisol treatment, whereas no other effects in hCG secretion
in differentiated BeWo cells could be detected.
Figure 6.11: Effect of glucocorticoids on hCG production in BeWo-GRα.
BeWo cells were transfected with the GRα vector for 4 h and treated with 10−6M
dexamethasone or 500 nM cortisol ± 100 µM forskolin for 24 h before measuring
hCG in the supernatent. Samples were normalized to protein concentration, n=4,
data are expressed as mean values ± SEM, p<0.05 (=*), ns=non-significant, 2-way
ANOVA with Bonferroni post-test.
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6.4.2 Effects of Glucocorticoids on Expression of Molecules involved
in Stress Response and Glucocorticoid Action
BeWo-GRα cells offer a potentially useful model to investigate interactions between
glucocorticoids and the placental CRH/CRH-R system.
The previously observed (Figure 4.11) forskolin-induced upregulation of CRH,
CRH-R1 and CRH-R2 was again present in BeWo-GRα cells (Figure 6.12 A, B and
C). The increased responsiveness of BeWo-GRα to Dex resulted in significant ef-
fects on CRH and CRH-R2 mRRNA expression: dexamethasone treatment led to a
significant increase in CRH by 2-fold, and in CRH-R2 mRNA expression by 1.9-fold
compared with control cells (Figure 6.12 A and C). The combination of dexametha-
sone and forskolin treatment did not lead to a further increase than the treatments
carried out alone. CRH-R1 mRNA expression was not affected by dexamethasone
treatment (Figure 6.12 B).
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Figure 6.12: Effect of dexamethasone and forskolin on CRH and its re-
ceptors in BeWo-GRα cells. BeWo cells were transfected with the GRα-vector
for 4 h and treated with 10−6 M dexamethasone and/or 100 µM forskolin for 24 h
before mRNA was extracted and qRT-PCR for (A) CRH, (B) CRH-R1 and (C)
CRH-R2 was performed. qRT-PCRs were normalized to RPLP0 mRNA expression,
n=4, data are expressed as mean values ± SEM, p<0.05 (=*), ns=non-significant,
2-way ANOVA with Bonferroni post-test.
206
The previously observed (Figure 4.14, 4.17 and 4.13) forskolin-induced upreg-
ulation of 11β-HSD2 and BCRP mRNA expression as well as the forskolin-induced
downregulation of MR mRNA was confirmed in BeWo-GRα cells (Figure 6.13 A,
B and C). Dexamethasone treatment led to a small downregulation of 11β-HSD2
mRNA by 20% in undifferentiated BeWo-GRα cells, whereas there was no effect in
differentiated cells (Figure 6.13 A). BCRP mRNA expression was not affected by
dexamethasone treatment (Figure 6.13 B). MR mRNA expression was minimally,
but significantly, upregulated in un- and differentiated BeWo-GRα cells (Figure
6.13 C). These results suggest that despite increased responsiveness to glucocorti-
coids these genes are not significantly regulated by glucocorticoids.
Figure 6.13: Effect of dexamethasone and forskolin on 11β-HSD2, MR and
BCRP in BeWo-GRα. BeWo cells were transfected with the GRα-vector for 4 h
and treated with 10−6 M dexamethasone and/or 100 µM forskolin for 24 h before
mRNA was extracted and qRT-PCR for (A) 11β-HSD2, (B) BCRP and (C) MR
was performed. qRT-PCRs were normalized to 18S rRNA expression, n=4, data are
expressed as mean values± SEM, p<0.05 (=*), p<0.001 (=***), ns=non-significant,
2-way ANOVA with Bonferroni post-test.
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6.5 Discussion of Chapter 6
This chapter investigated the characteristics of BeWo cell responsiveness to gluco-
corticoids. My previous results (Chapter 5) raised the possibility that BeWo cells
might be resistant to glucocorticoids. Furthermore, there was strong suggestion
that the cAMP pathway appeared to be involved in the regulation of glucocorticoid-
responsive genes. In order to investigate this, a reporter-gene-assay measuring bind-
ing of GRα to GRE-elements and transcription studies of several glucocorticoid-
responsive genes were developed.
It has been shown that the placenta expresses the glucocorticoid receptor and
that it is a glucocorticoid-responsive tissue, e.g. genes such as CRH, hCG, PAI-1,
intergrins and GLUT1 are regulated by glucocortiocids in the placenta [Driver et al.,
2001; Patel et al., 2003; Chan et al., 2003; Jones et al., 1989; Ringler et al., 1989a;
Ma et al., 2002; Ryu et al., 1999; Hahn et al., 1999]. Previous experiments identified
glucocorticoid sensitivity of term placental explants since dexamethasone treatment
led to an increase of 11β-HSD2 and P-gp mRNA as well as FKBP5 protein expres-
sion (Chapter 3.4.1 and 3.4.3). However, it might be possible that cells other than
trophoblasts are more responsive to glucocorticoids as Lee et al. [2005] showed only
little expression of GR in syncytiotrophoblast and moderate expression of GR in
cytotrophoblasts compared to the high GR expression in placental fibroblasts. Fur-
thermore, they showed a higher phosphorylation status (at Ser203 and Ser211) of
the endogenous GR when comparing placental fibroblasts with trophoblasts which
might suggest presence of a more transcriptionally active GR in fibroblasts. More-
over, GR expression in placental cell lines such as BeWo and JEG-3 cells has been
shown to be minimal [Chen et al., 1998; Stejskalova et al., 2013; Mark and Waddell,
2006] suggesting that immortalized trophoblast cell lines might be less responsive
to glucocorticoids than primary placental tissue.
The GRα form of the glucocorticoid receptor is the predominant form in the
term placenta [Johnson et al., 2008; Mparmpakas et al., 2014] and therefore this
isoform was being analyzed in this study. Indeed, the expression of GRα in BeWo
cells was only 10% of the GRα expression in HeLa cells which are highly responsive
to glucocorticoids. Speeg and Harrison [1979] detected even lower amounts (2%) of
GRα in BeWo cells compared with HeLa cells. Therefore, I studied the hypothesis
that an increase in the GRα amount could restore BeWo cell responsiveness to
glucocorticoids.
In HeLa cells, dexamethasone treatment led to a downregulation of GRα
mRNA by 41% which is in agreement with the findings from Cidlowski and Cid-
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lowski [1981], Burnstein et al. [1990], Burnstein et al. [1994] and Webster et al. [1997].
For example, Webster et al. [1997] detected a downregulation of GRα mRNA of 60%
after 100 nM dexamthasone treatment in COS-1 cells. Some studies suggest that in
placental explants, treatment with dexamethasone also leads to a decrease of GRα
mRNA [Johnson et al., 2008]. However, in BeWo cells, endogenous GRα mRNA
expression was not regulated by dexamethasone. This finding is in agreement with
Mparmpakas et al. [2014] who showed that cortisol (10 - 1000 nM) does not change
the GRα mRNA expression in BeWo cells. Studies in glucocorticoid resistant cells
also showed that mRNA expression of GRα is not regulated by glucocorticoids [Sai
et al., 2011; Tao et al., 2013] suggesting a correlation between glucocorticoid sen-
sitivity and the regulation of GRα expression. Interestingly, Webster et al. [1997]
observed that mouse GR which is mutated at several phosphorylation sites abol-
ishes the dexamethasone-induced downregulation of the GR. Possibly, mutations at
phosphorylation sites of the GRα might be a reason for the impaired glucocorticoid
dependent suppression of endogenous GRα in BeWo cells and could be investigated
in future studies.
The initial reporter-gene-assay experiments tested the capacity of the GRα
receptor to bind to GRE elements encoded on the MMTV-luc vector. Treatment of
HeLa cells with dexamethasone led to a strong binding of their endogenous GR to
the MMTV-luc vector confirming their high responsiveness to glucocorticoids which
has been shown by Nader et al. [2009]. This strong response could be enhanced with
overexpression of exogenous GRα, but as the endogenous GR already produced a
strong signal, this co-transfection was not necessary in the subsequent experiments.
The endogenous GR of the HEK 293 cells also gave a response to dexamethasone
treatment, however the intensity was only 2% of the HeLa cell signal confirming the
relative low sensitivity of HEK 293 cells to glucocorticoids. Co-transfection of GRα
into HEK 293 cells rendered them highly responsive to glucocorticoids, this strategy
was also undertaken by several other groups [Kratschmar et al., 2012]. In contrast
to these two cell lines, no increase in MMTV-luc activity could be detected after
dexamethasone treatment in BeWo cells confirming the previous result that BeWo
cells might be glucocorticoid resistant. Because overexpression of GRα in BeWo
cells led to a strong signal after dexamethasone treatment (322-fold increase), it
was concluded that transfection of exogenous GRα into BeWo cells restored their
sensitivity to glucocorticoids. Similarly, transfection of GRα restores the glucocor-
ticoid signalling in a SCLC (small cell lung carcinoma) cell line which is resistant
to glucocorticoids and expresses an aberrant GR [Ray et al., 1994]. This approach
(transfection of a GRα expression vector) has been previously used in studies in pla-
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cental cell lines such a JEG-3 and BeWo cells [Chen et al., 1998; Stejskalova et al.,
2013; Mark and Waddell, 2006].
Pathways controlling GC-responsive gene expression and roles of cAMP-
driven pathways were investigated in BeWo and HeLa cells. In HeLa cells, re-
sults for Dusp1, Per1 and Gilz mRNA expression demonstrated their specificity of
GC effects since regulation of these genes by the cAMP pathway seems to play
an insignificant role compared to the strong regulation by dexamethasone. In con-
trast, the endogenous GR of the BeWo cells did not upregulate these genes after
dexamethasone treatment which is consistent with their unresponsiveness in the
reporter-gene-assay to dexamethasone. However, forskolin treatment led to a signif-
icant induction of those genes which suggests that the cAMP pathway controls the
regulation of glucocorticoid-responsive genes in glucocorticoid resistant BeWo cells.
Rendering the BeWo cells sensitive to glucocorticoids by transfection of exogenous
GRα resulted in distinct and gene-specific effects. The gene Gilz was exclusively
regulated by dexamethasone, confirming the complete restoration of glucocortiocoid
sensitivity by transfection of exogenous GRα. In contrast, Dusp1 and Per1 gluco-
corticoid sensitivity seems to be only partially restored by transfection of GRα. This
result suggests that the glucocorticoid and the cAMP signalling act independently
but synergistically on the expression of some glucocorticoid-responsive genes. It
might be possible that the GC regulation of these genes differs from each other, e.g.
the promoter regions might contain different response elements such as simple GRE,
composite GRE, competitive GRE or tethering mechanisms, which might explain
the inconsistent effects of this experiment.
I investigated this phenomenon of signalling pathway cross-talk further using
the reporter-gene-assay since the MMTV-luc reporter contains a well characterized
composite GRE [Guido et al., 1996] (Figure 2.2). As expected, native BeWo cells
did not respond to dexamethasone treatment, whereas HeLa exhibited a strong re-
sponse signal. Similar to the gene transcription studies, forskolin only minimally
transactivated GR in HeLa cells, whereas a strong effect of forskolin on GR trans-
activation was observable in BeWo cells in the absence as well as in the presence
of exogenous GRα. The finding that the cAMP pathway is involved in the reg-
ulation of glucocorticoid-responsive genes has been identified by several groups.
In many cellular systems, the cAMP/PKA pathway appears to enhance GR sig-
nalling. In particular, this synergistic action is well documented in neuronal models
of disease. For example, Pace et al. [2011] showed that forskolin treatment aug-
ments the dexamethasone-induced MMTV-luc activity in HT22 mouse neuronal
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cells, while inhibition of the PKA pathway with the antagonist H89 attenuates the
dexamethasone-induced MMTV-luc activity. Also, Lim-Tio and Fuller [1998] de-
tected an enhancing effect of 8-Br-cAMP on cortisol-induced MMTV-luc activity in
renal LLC-PK1 cells. And Doucas et al. [2000] demonstrated a complex assembly
of GR involving the catalytic subunit of PKA (=PKAc) in HEK 293 and HeLa cells
as well as that an overexpression of PKAc in the monkey kidney CV-1 cell line en-
hances GR activation further in the presence of dexamethasone. They also observed
a decrease in dexamethasone-induced MMTV-luc activity in the presence of a PKA
inhibitor (H89) in CV-1 cells. In agreement with these findings, HeLa as well as
BeWo cells (in the presence of exogenous GRα) showed a synergistic activity of
dexamethasone and forskolin on MMTV-luc expression in my studies. Miller et al.
[2002] investigated the effect of the PDE type 4 inhibitor rolipram which inhibits
the breakdown of cAMP by phosphodiesterase (PDE) type 4 on GR function: they
observed that rolipram treatment leads to a higher MMTV-luc activity without and
with dexamethasone treatment in mouse fibroblast and rat glioma cells suggesting
a possible action on GR in the absence of ligand. Also other groups observed a
ligand independent transactivation of GR. For example, Eickelberg et al. [1999] ob-
served an activation of GR after treatment with dibutyryl- and 8-bromo-cAMP in
lung fibroblasts. Comparable to those studies is the result of the BeWo and HeLa
cells which showed a forskolin-induced transactivation of the GRα in the absence of
dexamethasone.
There are a number of potential interactions that might explain how the
cAMP/PKA pathway is involved in the GR function. For example, PKA can phos-
phorylate the GR [Haske et al., 1994] leading to increased GR functionality, PKA
leads to increased binding of GR to DNA [Rangarajan et al., 1992], or PKA can lead
to a more stable mRNA transcript and a higher expression of GR [Dong et al., 1989;
Pen˜uelas et al., 1998]. The latter explanation might not be relevant for BeWo and
Hela cells as forskolin treatment did not lead to a change in GR mRNA expression
in BeWo and HeLa cells unlike the observation by Dong et al. [1989]. This different
result might be explained by the different cell lines used. However, it might be pos-
sible that phosphorylation processes of GR by PKA render the GR transcriptionally
more active in BeWo and HeLa cells. Investigation of the phosphorylation status
of the endogenous as well as transfected exogenous GRα after forskolin with or
without dexamethasone treatment in BeWo cells could be a possible future research
direction. Due to the lack of a CRE element in the MMTV-luc vector [Mulhol-
land et al., 2003], CRE-induced transcription by cAMP is excluded as the cause
for the observed stimulation of MMTV-luc transcription in BeWo cells. Mulholland
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et al. [2003] also showed that the cAMP-induced MMTV-luc transcription is PKA-
dependent, but CREB-independent. In order to test whether the forskolin-induced
MMTV-luc transcription is independent of GRα, future experiments could use a
GR antagonist (e.g. RU486) in BeWo cells with and without transfected exogenous
GRα.
In conclusion, native BeWo cells seem to be resistant to glucocorticoids,
but the overexpression of GRα (= BeWo-GRα cells) can restore the GC sensitiv-
ity. However, cAMP signalling appears to exert stronger effects on GRE-dependent
transcription than glucocorticoids in BeWo-GRα cells. It is a common mechanism
that cAMP signalling acts synergistically on GR activation, but in case of resistant
cells to GC it seems that the relatively weak effect of the cAMP pathway (as seen in
the HeLa cells) on the GC regulation of GC-responsive genes and GRE-dependent
transcription events (possibly by GR activation) becomes stronger. A future study
in primary placental tissue and primary trophoblast cells from different trimesters
regarding cAMP signalling involvement in regulation of glucocorticoid-responsive
genes would determine whether placental tissue is differently sensitive to GC de-
pending on their developmental stage and whether this phenomenon is caused by a
cAMP synergistic mechanism.
One reason for the glucocorticoid resistance in native BeWo cells besides the
low expression of the GRα could be a mechanism upstream of the GR receptor that
involves the enzyme 11β-HSD2 or transporter molecules such as P-glycoprotein and
BCRP. All of these molecules are able to influence binding of active cortisol to its
receptor, i.e. 11β-HSD2 by inactivating cortisol into cortisone and P-gp as well as
BCRP by exporting active cortisol out of the cells. However, although 11β-HSD2
is highly expressed in the BeWo cells (Chapter 4.2.3), this option is unlikely since
my previous results showed that downregulation of 11β-HSD2 did not alter the
mRNA expression of glucocorticoid-responsive genes after cortisol treatment. Fur-
thermore, dexamethasone is not being metabolized by 11β-HSD2 [Diederich et al.,
2002]. Moreover, BeWo cells express only minimal amounts of P-gp, which makes
it unlikely that this transporter can successfully export all exogenously added cor-
tisol or dexamethasone molecules. As the BCRP is highly expressed in the BeWo
cell line [Ceckova et al., 2006], eﬄux studies of cortisol and dexamethasone after
manipulating BCRP expression might be of interest for future experiments.
The complex and extensive machinery of GR-associated proteins such as
coactivators which are necessary for the active GR machinery such as p300/CBP
as well as p/CAF and p160 family molecules (Figure 1.4) might exhibit defects in
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expression in BeWo cells and this might explain GR insensitivity. For example,
Grenier et al. [2004] showed in mouse Schwann cells that inhibition of the coactiva-
tors SRC-1 and SRC-2 by siRNA leads to an inhibition of dexamethasone-induced
MMTV-luc expression by 60% and 40%, respectively. Waters et al. [2004] showed
that overexpression of the repressor NCoR (nuclear co-repressor) leads to an attenu-
ation of dexamethasone-induced GR transactivation in the A549 lung cancer cell line
and they reveal that a GR resistant SCLS cell line expresses high levels of NCoR. In
future experiments, expression levels of several coactivators and repressors could be
characterized on mRNA and protein level in BeWo cells. Furthermore, chaperone
molecules such as Hsp70, Hsp90 and immunophilins which are important for the
maturation and translocation of the GR into the nucleus as well as for rendering
the GR hormone-activatable [Japiassu´ et al., 2009] might have defects or might be
low expressed in the BeWo cells.
Phosphorylation processes play an important role in the activation of the
GR [Ismaili and Garabedian, 2004]. One or more of these phosphorylation sites
could be mutated leading to an ineffective GR response of the BeWo cells. Mason
and Housley [1993] showed that mutation of phosphorylation sites in the mouse GR
changes the GR transcriptional activity. As mentioned above, in future experiments
use of antibodies recognizing different phosphorylated GR forms could character-
ize the phosphorylation status of the endogenous GRα in BeWo cells (possibly in
comparison with the phosphorylation status of transfected exogenous GRα).
Mutations at other sites of the GR might also explain the BeWo cell GC
resistance. It might be possible that a mutation in the GR abrogates its ability to
translocate to the nucleus. For example, Jewell et al. [1995] showed that transfected
human GR which has a deletion of the hinge region containing the nuclear local-
isation signal exhibits a cytoplasmic distribution of the GR after dexamethasone
binding in COS-1 cells. Immunocytochemical staining of the GR with and without
dexamethasone treatment could test this possibility of an abolished translocation of
the GR to the nucleus in the BeWo cells in future experiments.
Another possibility to explain the BeWo cell GC resistance is that BeWo cells
might express high amounts of GRβ. GRβ has been shown to inhibit the transcrip-
tional activity of GRα [Bamberger et al., 1995]. Transfection of GRβ into mouse
hybridoma cells renders them insensitive to the action of glucocorticoids [Hauk et al.,
2002]. Interestingly, it has been shown that the gender of the fetus has an influence
on the resistance and sensitivity of the placenta to cortisol with male fetuses to be
more resistant against cortisol programming effects. Saif et al. [2014] showed that
there is an increased localisation of GRβ to the nucleus in male placentae which
213
might be the cause of their increased resistance to glucocorticoids. As the BeWo
cells are male gender, this mechanism might play a role in the BeWo cell GC resis-
tance. Indeed, Mparmpakas et al. [2014] showed that in term placentas the GRβ
mRNA expression is only 2.5% of the GRα expression, whereas in BeWo cells the
expression ratio from GRα to GRβ is approximitely 1:1. So, in future experiments,
it is very important to perform quantitative PCR and westernblot experiments to
compare the mRNA and protein levels of GRα and GRβ in BeWo cells (possibly in
comparison to their levels in HeLa cells).
As the first reporter-gene-assay demonstrated the restoration of BeWo cell
glucocorticoid sensitivity, transfection of exogenous GRα (= BeWo-GRα cells) was
introduced in the experimental protocol to investigate effects of glucocortiocoids on
BeWo cell turnover, differentiation and expression of molecules involved in the stress
and glucocorticoid action molecular machinery.
This study did not find any effect of dexamethasone on BeWo-GRα cell
turnover (specifically cell viability and activation of caspase-3/7). Regarding cell
differentiation, a decrease of Syncytin-2 and its receptor was detected after dexam-
ethasone treatment in undifferentiated cells, however in differentiated cells was no
difference which suggests that the morphological fusion process initiated by forskolin
treatment might probably not be affected by dexamethasone.
Several studies revealed a stimulating effect of glucocorticoids on hCG se-
cretion of placental cells. In particular, Ringler et al. [1989a] showed that dexam-
ethasone increases primary trophoblast hCG secretion and augments cAMP-induced
hCG secretion after 48 and 72 h. Also, Ho¨cker et al. [2004] showed that 48 h of
prednisolone (a synthetic glucocorticoid) treatment leads to higher hCG secretion
in primary trophoblast cells. And Ni et al. [2009] showed that 24 h of cortisol
treatment increases mRNA levels of both α- and β-hCG as well as increases hCG
protein secretion. In this study, no inducing glucocorticoid effect on hCG secretion
was observed in the BeWo-GRα cells. This difference might be because of the fact
that all of the before mentioned studies isolated primary trophoblasts from term
placentae. It might be possible that glucocorticoid sensitivity of placental tissue
increases during pregnancy as Speeg and Harrison [1979] detected a 27-fold increase
of GR expression in term compared with first trimester placenta. Also, Hodyl et al.
[2010] has shown that increased cortisol levels (observed in asthma patients) are
associated with increased GR activity in placentae. As the cortisol concentration in
fetal serum increases towards the end of pregnancy [Murphy, 1982], term placentae
is potentially the condition of the highest glucocorticoid sensitivity and therefore,
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effects of glucocorticoids in primary trophoblasts isolated from term placentae were
observed in the above mentioned studies, but not in BeWo-GRα cells.
In the placenta, CRH is upregulated by glucocorticoids [Jones et al., 1989]
and it appears that these two molecules are linked via a positive feedback loop mech-
anism. In BeWo-GRα cells, dexamethasone increased CRH mRNA expression which
is similar to the observation of Wang et al. [2014b] who demonstrated that cortisol
increases CRH mRNA levels in primary trophoblasts. Similar effects were observed
for CRH-R2 mRNA expression in BeWo-GRα cells, in particular both dexametha-
sone and forskolin treatment led to an increase of CRH-R2. Interestingly, Wang et al.
[2012] showed that in the placenta the CRH gene is constitutively regulated by an
NFκB enhancer element which is driven by the RelB/NFκB2 transcription factor.
They also showed that dexamethasone can stimulate the synthesis of RelB/NFκB2
and its nuclear translocation which might explain the positive regulation of CRH
by glucocorticoids in the placenta. This finding suggests that the observed upreg-
ulation of CRH mRNA in BeWo-GRα cells by dexamethasone might be mediated
by activation of NFκB signalling (which is in contrast to the first part of the stud-
ies presented in this chapter which concentrated on the GRE-dependent signalling
pathways). Also, the fact that forskolin and dexamethasone did not exert syner-
gistic effects on CRH mRNA expression in BeWo-GRα cells are in agreement with
this explanation model because probably the CREB-induced and the NFκB-induced
transcription machinery can not bind to the promoter region of the CRH gene at
the same time. This result suggests that under specific experimental conditions the
unique regulation of CRH by glucocorticoids in the placenta can be reproduced in
the BeWo cells.
Regulation of components of the glucocorticoid action (11β-HSD2, BCRP,
MR) in BeWo-GRα cells was only minimally influenced by dexamethasone. Several
studies showed that glucocorticoids upregulate the expression and activity of 11β-
HSD2 [Ni et al., 2009; Audette et al., 2010; Tzschoppe et al., 2011], whereas this
effect was not detected in the BeWo-GRα cells. Again, these studies were carried
out in primary term trophoblasts or in placental term explants which might repre-
sent a more sensitive system to the actions of GCs than BeWo-GRα cells.
In summary, HeLa cells showed a strong response to dexamethasone in the
reporter-gene-assay as well as in the qRT-PCRs for glucocorticoid-responsive genes.
In contrast to that, native BeWo cells were unresponsive to dexamethasone on
reporter-gene and qRT-PCR level. However, after overexpression of GRα, BeWo
cells produced a strong signal in the reporter-gene-assay after Dex treatment. A
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modest upregulation of Dusp1, Per1, and a strong upregulation of Gilz was observed
in BeWo-GRα cells after Dex treatment. Both results suggest that transfection of
exogenous GRα can at least partially restore the BeWo cell capacity to respond
to glucocorticoids. In BeWo-GRα cells, cell turnover and differentiation were not
or only slightly affected by dexamethasone treatment, the expression of CRH and
CRH-R2, but not CRH-R1, were upregulated by Dex, other components of the
glucocorticoid action molecular machinery were not or only slightly affected.
An interplay of different signalling pathways in the regulation of the glu-
cocorticoid response appears to be present in BeWo as well as in HeLa cells. In
both types of cells, cAMP stimulation can activate glucocorticoid-responsive genes
and can induce expression of a GRE-containing reporter-gene-vector, although this
interaction is much weaker in HeLa cells.
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Chapter 7
Summary and Conclusion
The understanding of placental biology and the placentation process are very im-
portant as alterations in these processes can lead to abnormal fetal development
and affect long-term health. Pathological conditions associated with adaptation
processes in response to physical as well as psychological stress responses can exert
profound effects on placental biological mechanisms. These placental adaptation
processes can impair placental efficacy and can cause placental insufficiency. Pla-
cental diseases such as pre-eclampsia and IUGR (Chapter 1.3.1) are examples of
diseases associated with abnormal placentation processes. In addition, pre-existing
maternal pathologies such as diabetes and obesity can also induce placental adap-
tation responses (Chapter 1.3.2). Thus, a detailed understanding of the placental
dysfunction might help identify molecules or signalling pathways which could be
targeted by future therapeutic investigations. The aim of this study was to explore
the molecules involved in stress mechanisms, specifically the roles of CRH, glucocor-
ticoids and 11β-HSD2 on some key basic cell biology processes of trophoblast cells.
During placentation and also during the course of pregnancy, fundamental
cell biology processes such as proliferation, differentiation and apoptosis are acti-
vated in a coordinated manner to maintain trophoblast cell homeostasis (Chapter
1.2.5). In a finely tuned process, cytotrophoblast cells proliferate, differentiate and
fuse with the adjacent syncytiotrophoblast cell layer. In the normal cell turnover
of trophoblast cells, apoptosis occurs as shedding of syncytial knots from the syn-
cytiotrophoblast. However, these processes seem to be altered in placental diseases
as decreased differentiation and increased apoptosis are some of the hallmarks of
placental pathologies [Langbein et al., 2008; Sharp et al., 2010; Heazell et al., 2011].
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The syncytiotrophoblast fulfills several important functions such as nutri-
ent transfer, hormone production and acts as a barrier to protect the fetus. The
endocrine function of the placenta, especially secretion of human chorionic go-
nadotropin (hCG), progesterone and estradiol, is essential for a successful pregnancy
(Chapter 1.2.7.2). The fetus and the placenta signal their demands via hormones
to the mother and also maternal, fetal and placental hormones regulate placental
and fetal development and growth (Figure 1.15). Endocrine activity might poten-
tially be affected in placental pathologies. The syncytiotrophoblast also acts as a
glucocorticoid barrier of which the enzyme 11β-HSD2 is the main component. 11β-
HSD2 expression and activity which inactivates active cortisol into cortisone has
been shown to be reduced in placental diseases such as pre-eclampsia and IUGR
[Causevic and Mohaupt, 2007; Shams et al., 1998; McTernan et al., 2001; Dy et al.,
2008; Bo¨rzso¨nyi et al., 2012]. As a result, excess glucocorticoids might reach the
fetus which has detrimental effects on fetal development, but might also predispose
the individuals to develop metabolic, cardiovascular and psychiatric disorders in
later life (Chapter 1.3.3).
Important for the coordination of stress responses are the hormone CRH and
its receptors CRH-R1 and -R2. As part of the HPA axis, CRH is the master regu-
lator in controlling biological mechanisms to stress signals. In higher primates and
humans, many regulatory roles for placental CRH have been proposed in placental
biology (Chapter 1.1.2.2) and its levels rise towards the end of pregnancy. During
all trimesters of pregnancy, glucocorticoids from the maternal circulation cross the
placenta, but most of the molecules are inactivated by the enzyme 11β-HSD2. Near
term cortisol produced by the fetus can reach the placenta and the activity of the
placental 11β-HSD2 is decreased, both leading to higher cortisol levels towards the
end of pregnancy which might be a the cause for the increasing CRH levels because
of the positive-feedback mechanism of cortisol and CRH in the placenta. Alteration
in the CRH expression as well as in the expression of the CRH receptors and the
gluco- and mineralocarticoid receptor (GR and MR) might change the dynamics
of the placental stress systems with possible changes in glucocorticoid action and
potentially this might evoke placental adaptation or dysfunction.
In this thesis, the potential alterations of basic placental cell biology pro-
cesses such as cell turnover (cell proliferation, viability, apoptosis), differentiation
(expression of Syncytins and their receptors) and endocrine function (secretion of
hCG, P4, E2) in placental explants and BeWo cells were investigated in several
potential adverse conditions (in the presence of CRH, LPS and glucocorticoids).
Moreover, the interplay of these processes with the enzyme 11β-HSD2 was explored
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in BeWo cells. As the placental CRH system is possibly involved in regulatory pla-
cental adaptation processes under challenging conditions, the CRH responsiveness
(expression of CRH and its receptors CRH-R1 and -2) was also investigated as well
as the components which are involved in glucocorticoid action (GR, MR, 11β-HSD2,
BCRP).
CRH levels have been shown to be increased in placental diseases [Laatikainen
et al., 1991; Goland et al., 1993; Warren et al., 1992]. This feature might therefore be
involved in the pathologies of the various placental diseases. Chapter 3 focused on
investigating the effects of CRH on placental cell turnover and on endocrine function
using the placental explant model. In addition, LPS was used to stimulate the
TLR4 receptor of the placental cells which evokes an inflammatory response. Many
placental diseases (pre-eclampsia, placental infection) as well as maternal pathologies
(diabetes, obesity) are characterized by an exaggerated inflammatory response or a
low-grade inflammatory milieu. Furthermore, also physiological processes such as
the parturition process have been shown to involve activation of TLRs and induction
of pro-inflammatory cytokines (Figure 1.17).
My studies showed that hCG hormone secretion of placental explants is in-
fluenced by the molecules CRH and LPS. In detail, in high hCG responders CRH
has an inducing effect on hCG secretion by placental explants which is abrogated in
the presence of LPS. This result suggests that CRH overexpression observed in pla-
cental diseases might be a mechanism of the placenta to augment reduced hormone
secretion to a sufficient level. In contrast, in low hCG responders placental explant
tissue seems to be hyperresponsive to stimuli as both CRH and LPS increased hCG
secretion. No effect of CRH and LPS on placental explant cell turnover could be
observed. Unfortunately, methodological complications of the placental explant led
to the decision to focus subsequent research on the BeWo cell line.
The characterization of BeWo cells (Chapter 4) confirmed that the cAMP
stimulator forskolin successfully induced cell fusion in this cell line to generate a
syncytium-like state. Biochemical differentiation is characterized by upregulation
of many molecules including hormones. Indeed, hCG and progesterone secretion
were stimulated by forskolin which revealed the substantial endocrine function of
syncytialized BeWo cells. Regarding the stress response molecular machinery, BeWo
cell expression of CRH and its receptors was increased by forskolin suggesting an
activation of placental stress regulatory function of fused BeWo cells. Furthermore,
GR and MR were expressed in BeWo cells and MR expression was downregulated
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by forskolin possibly protecting against glucocorticoid-induced MR effects. Compo-
nents of the glucocorticoid barrier such as the enzyme 11β-HSD2 and transporter
molecules which export cortisol were upregulated during BeWo cell differentiation
suggesting a limitation of local glucocorticoid action.
The high expression of 11β-HSD2 in BeWo cells and their insensitivity to
glucocorticoids offered the possibility to study additional roles of 11β-HSD2 that do
not involve inactivation of cortisol to cortisone (Chapter 5). 11β-HSD2 appeared to
have a pro-differentiating effect and might promote cell fusion in BeWo cells as 11β-
HSD2 knockdown reduced mRNA levels of the Syncytin receptors which are involved
in the fusion process. Moreover, 11β-HSD2 might also promote endocrine function
as depletion of 11β-HSD2 decreased levels of secreted hCG and progesterone. Dur-
ing differentiation of trophoblast cells in the placenta, the apoptotic process is being
activated, however possibly through a high expression of Bcl-2 the apoptotic cas-
cade is arrested to allow formation of the syncytiotrophoblast (Chapter 1.2.6.3). As
both hCG and progesterone have been shown to increase the anti-apoptotic Bcl-2
[Jasinska et al., 2006; Kajihara et al., 2011a,b; Liu et al., 2007], the study (in BeWo
cells) might suggest a role of 11β-HSD2 in protecting against apoptosis through its
role in the maintenance of sufficient hCG and progesterone production and might
represent a possible mechanism of apoptosis prevention in the syncytiotrophoblast.
Another role of 11β-HSD2 might involve the limitation of CRH production and sen-
sitivity in BeWo cells as knockdown of 11β-HSD2 increased the expression of CRH
and its receptor CRH-R2. Also over this pathway, apoptotic processes might be
altered as CRH has been shown to limit progesterone secretion [Jeschke et al., 2005;
Yang et al., 2006; Gao et al., 2012].
The regulation of glucocorticoid-dependent processes in the BeWo cells were
explored as previous results demonstrated insensitivity of BeWo cells to cortisol, i.e.
gluco- and mineralocorticoid-responsive genes seemed to be regulated by the cAMP
pathway only (Figure 5.16 and 5.17 in chapter 5.5.2.2). Results of chapter 6 showed
that native BeWo cells were unresponsive to glucocorticoids, but overexpression of
exogenous GRα (= BeWo-GRα cells) restored their glucocorticoid sensitivity. As
native BeWo cells were used in the studies of potential roles of 11β-HSD2 (Chapter
5), this strengthens the notion that the observed roles of 11β-HSD2 in cell turnover,
differentiation and regulation of hormone secretion are independent of cortisol.
Possibly, increased local concentration of glucocorticoids might alter pla-
cental biology which could lead to placental adaptations as observed in placental
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diseases. However, no influence of glucocorticoids on glucocorticoid-sensitive BeWo-
GRα cell turnover, differentiation and endocrine function was detected. A potential
increase in CRH sensitivity was observed as CRH and CRH-R2 mRNA expression
was upregulated by dexamethasone in BeWo-GRα cells. The upregulation of CRH
by dexamethasone might be due to a stimulated NFκB signalling.
Several potential causes of the glucocorticoid insensitivity of BeWo cells in
addition to the relative low expression of GRα in native BeWo cells might be altered
expression of coactivators, repressors and chaperones of the GR, potential alterations
in the phosphorylation processes of the GR which activates its transcriptional action
and a possible high expression of the GRα action inhibiting receptor GRβ. These
options could be explored in future experiments.
In the absence of exogenous GRα, again regulation of glucocorticoid-depen-
dent processes by the cAMP pathway was observed. In BeWo-GRα cells, a syner-
gistic action of glucocorticoids and forskolin on glucocorticoid-dependent processes
could be demonstrated, however the cAMP pathway appeared to be the stronger
regulator. Whether this phenomenon might be a mechanism of trophoblast cells to
become insensitive to glucocorticoids could be investigated in future studies.
Results of this thesis might suggest that CRH could play an important role
as a potential regulatory hormone during placental adaptation to adverse stimuli as
during BeWo cell differentiation, expression of CRH and cell responsiveness to CRH
increases suggesting a higher sensitivity to CRH-induced regulatory processes and
also the other conditions investigated (depletion of 11β-HSD2, increased sensitivity
to GC action) revealed an increase of CRH and its receptor CRH-R2. Also a central
role for the enzyme 11β-HSD2 in BeWo cells could be shown as results suggest that
this enzyme is involved in many functions such as differentiation, hormone produc-
tion and maintenance of cell viability. However, the effects of alterations in hormone
production such as CRH, hCG and progesterone possibly evoked by modulation of
11β-HSD2 expression regarding basic cell biology processes such as cell differentia-
tion and apoptosis seem to be diverse und further exploration is required.
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